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Abstract 
Sialic Acid (Sia) plays a significant role in a number of essential processes in living 
organisms ranging from simple charged molecule interactions, stabilization of 
glycoconjugate conformations, recognition in pathogen invasion and determination of 
glycoprotein half life. Furthermore, the degree of sialylation of glycoproteins that are used as 
therapeutics is crucial for their activity and efficacy. Therefore, the requirement for a robust, 
rapid, specific and sensitive method for Sia quantification has become an important 
challenge. The goal of this study was to develop a novel lectin-based method for Sia 
detection and quantification that is: (i) more specific and less prone to interference by other 
substances than existing colorimetric and enzymatic assays and (ii) more rapid than existing 
HPLC methods. 
This project describes the cloning, expression and purification of Sia binding proteins that 
were subsequently immobilised onto a number of analytical platforms. A prokaryotic 
expression system was used and optimized for production of these Sia binding proteins. 
Firstly, a terminal sialic acid specific hemagglutinin from Influenza virus was successfully 
cloned and expressed in Escherichia coli and purified by affinity chromatography. Studies on 
this protein involved procedures aimed at solubilisation of aggregated proteins as well as 
various solubility-promoting genetic engineering techniques. 
Another Sia specific protein, namely SiaP, from Haemophilus influenzae was His-tagged and 
expressed in the KRX strain of E. coli and purified using immobilized metal ion affinity 
chromatography. The activity of this protein was confirmed by Mass Spectrometry (MS) 
analysis. This MS platform was subsequently used for assay development for free Sia 
quantification. A positive correlation was found between free Sia concentration and the 
amount of SiaP molecules that were saturated with the sugar in the sample. 
In an alternative approach the SiaP protein was tested using surface plasmon resonance 
(SPR). A method for stable and orientation-specific immobilization of the recombinant SiaP 
protein on a Biacore CM5 chip was established. A correlation between free Sia concentration 
and mass of the immobilized components was established and an operational range for the 
potential test was successfully identified. This indicates the possibility of application of the 
SiaP based method for rapid and specific sialic acid detection and quantification. 
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 2 
1 Introduction 
1.1 Sialic acid, the unusual sugar 
Sialic acid, also known as N-acetyl-neuraminic acid, was discovered in the 1930s by Klenk 
and Blix (Blix et al., 1957). The terms “sialic acid” and “neuraminic acid” both bear the 
hallmarks of their original discoveries:  Blix isolated sialic acid from submaxillary mucin 
(sialos = saliva in Greek) and Klenk isolated neuraminic acid derivative from brain 
glycolipids (neuro- + amine + acid). Some features of sialic acids cause them to be 
described as “unusual” molecules. Unlike most monosacharides in vertebrate 
glycoconjugates, which are five- or six-carbon residues, the sialic acids have a nine-carbon 
backbone. In nature, aside from sialic acid, only pseudaminic and legionaminic acids of 
bacteria are nine carbon keto-sugars (reviewed in Angata and Varki, 2002). They typically 
occupy the terminal position in the glycan chain, which makes them suitable for interaction 
with numerous agents (Varki, 1999). The sialic acids are not ubiquitous in nature and their 
distribution in various forms of life is irregular (Table 1.1). They are predominantly found 
in vertebrates, echinoderms and some bacteria but are almost completely absent in lower 
animals and plants, as opposed to other vertebrate monosacharides (Traving and Schauer, 
1998). Their synthesis is also different from other monosacharides as they are produced via 
condensation of a neutral six-carbon unit with the three-carbon molecule pyruvate (Tanner, 
2005). Finally, sialic acids are unusual in the nature of their high-energy nucleotide sugar 
donor form. While all the other vertebrate monosaccharides are activated in the form of 
guanine or uridine dinucleotides, e.g., GDP-Man and -Fuc, UDP-Glc, -Gal, -GlcNAc, -
GalNAc, -GlcUA, and -Xyl, sialic acids are activated as cytidine mononucleotides, i.e., 
CMP-Sia molecules (reviewed in Angata and Varki, 2002). 
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Figure 1.1. Structure of N-Acetylneuraminic acid 
(Sialic acid). 
1.1.1 Structure of sialic acid  
Sialic acids are common name for a family of over 50 naturally occurring nine-carbon keto 
sugars derived from the parent compound 2-keto-3-deoxy-5-acetamido-D-glycero-D-
galacto-nonulosonic acid (N-acetylneuraminic acid [Neu5Ac]), (Figure 1.1), (Vimr et al., 
2004; Lehmann et al., 2006). 
As the complete chemical names of 
sialic acids are too cumbersome for 
routine use a uniform and simple 
nomenclature system is being 
increasingly used, in which the 
abbreviation Neu denotes the core 
structure neuraminic acid, and Kdn 
denotes the core structure 2-keto-3-
deoxynononic acid. Various 
substitutions are then designated by 
letter codes (Ac = acetyl, Gc = 
glycolyl, Me = methyl, Lt = lactyl, S = sulfate), and these are listed along with numbers 
indicating their location relative to the carbon positions. For example, N-
glycolylneuraminic acid is Neu5Gc, 9-O-acetyl-8-O-methyl-N-acetylneuraminic acid is 
Neu5,9Ac28Me, and 7,8,9-tri-O-acetyl-N-glycolylneuraminic acid is Neu5Gc7,8,9Ac3. If 
there is no certainty what type of sialic acid is present at a particular location, the generic 
abbreviation Sia should be used. If other partial information is available, this can be 
incorporated, for example, a Sia of otherwise unknown type with an acetyl substitution at 
the C9 position could be written as Sia9Ac (Varki, 1999). 
The Sias’ specific structural features are the substitution of either an N-acetyl group (in 
Neu5Ac) or a hydroxyl group (in Kdn)  at position 5 and the carboxyl group at position 1 
that confers a negative charge on the molecule under physiological conditions and 
characterizes it as a strong organic acid (Angata and Varki, 2002). The unsubstituted form, 
neuraminic acid, does not exist in nature. Sia molecules can be substituted in more than one 
position with acetyl, methyl, hydroxyl and other groups resulting in their broad diversity 
(Table 1.1). The variability of Sia is further extended by their location on cells and 
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molecules. They usually represent the terminal sugar residue of a glycan chain, i.e. they are 
linked via C2 to position 3 or 6 of the penultimate sugar (most commonly galactose) or to 
position 8 of another Sia molecule, respectively. The α(2→8) linked homopolymers are 
known as polysialic acid (Lehmann et al., 2006).  
 
Table 1.1. Sialic Acids:  Occurrence and Structural Divergence. Table from Angata and Varki (2002). 
a
 Abbreviations used:  V, vertebrates; E, echinoderms; Ps, protostomes (insects and molluscs); Pz, protozoa; 
F, fungi; B, bacteria.b Present only as bound form.c Biosynthetic intermediate.d Present only as free form. 
Compound name Abbreviation Occurrencea  
neuraminic acid  Neu  Vb  
neuraminic acid 1,5-lactam  Neu1,5lactam  V  
5-N-acetylneuraminic acid  Neu5Ac  V, E, Ps, Pz, F, B  
5-N-acetyl-4-O-acetylneuraminic acid  Neu4,5Ac2  V  
5-N-acetyl-7-O-acetylneuraminic acid  Neu5,7Ac2  V, Pz, B  
5-N-acetyl-8-O-acetylneuraminic acid  Neu5,8Ac2  V, B  
5-N-acetyl-9-O-acetylneuraminic acid  Neu5,9Ac2  V, E, Pz, F, B  
5-N-acetyl-4,9-di-O-acetylneuraminic acid  Neu4,5,9Ac3  V   
5-N-acetyl-7,9-di-O-acetylneuraminic acid  Neu5,7,9Ac3  V, B  
5-N-acetyl-8,9-di-O-acetylneuraminic acid  Neu5,8,9Ac3  V  
5-N-acetyl-4,7,9-tri-O-acetylneuraminic acid  Neu4,5,7,9Ac4  V  
5-N-acetyl-7,8,9-tri-O-acetylneuraminic acid  Neu5,7,8,9Ac4  V  
5-N-acetyl-4,7,8,9-tetra-O-acetylneuraminic acid  Neu4,5,7,8,9Ac5  V  
5-N-acetyl-9-O-lactylneuraminic acid  Neu5Ac9Lt  V  
5-N-acetyl-4-O-acetyl-9-O-lactylneuraminic acid  Neu4,5Ac29Lt  V  
5-N-acetyl-7-O-acetyl-9-O-lactylneuraminic acid  Neu5,7Ac29Lt  V  
5-N-acetyl-8-O-methylneuraminic acid  Neu5Ac8Me  V, E  
5-N-acetyl-9-O-acetyl-8-O-methylneuraminic acid  Neu5,9Ac28Me  V, E  
5-N-acetyl-8-O-sulfoneuraminic acid  Neu5Ac8S  V, E  
5-N-acetyl-4-O-acetyl-8-O-sulfoneuraminic acid  Neu4,5Ac28S  V, E  
5-N-acetyl-9-O-phosphoneuraminic acid  Neu5Ac9P  Vc,d  
5-N-acetyl-2-deoxy-2,3-didehydroneuraminic acid  Neu2en5Ac  Vd  
5-N-acetyl-9-O-acetyl-2-deoxy-2,3-didehydroneuraminic acid  Neu2en5,9Ac2  Vd  
5-N-acetyl-2-deoxy-2,3-didehydro-9-O-lactylneuraminic acid  Neu2en5Ac9Lt  Vd  
5-N-acetyl-2,7-anhydroneuraminic acid  Neu2,7an5Ac  Vd  
5-N-acetylneuraminic acid 1,7-lactone  Neu5Ac1,7lactone  V  
5-N-acetyl-9-O-acetylneuraminic acid 1,7-lactone  Neu5,9Ac21,7lactone  V  
5-N-acetyl-4,9-di-O-acetylneuraminic acid 1,7-lactone  Neu4,5,9Ac31,7lactone  V  
5-N-glycolylneuraminic acid  Neu5Gc  V, Pz, F  
4-O-acetyl-5-N-glycolylneuraminic acid  Neu4Ac5Gc  V  
 5 
Compound name Abbreviation Occurrencea  
7-O-acetyl-5-N-glycolylneuraminic acid  Neu7Ac5Gc  V  
8-O-acetyl-5-N-glycolylneuraminic acid  Neu8Ac5Gc  V  
9-O-acetyl-5-N-glycolylneuraminic acid  Neu9Ac5Gc  V, E  
4,7-di-O-acetyl-5-N-glycolylneuraminic acid  Neu4,7Ac25Gc  V  
4,9-di-O-acetyl-5-N-glycolylneuraminic acid  Neu4,9Ac25Gc  V  
7,9-di-O-acetyl-5-N-glycolylneuraminic acid  Neu7,9Ac25Gc  V  
8,9-di-O-acetyl-5-N-glycolylneuraminic acid  Neu8,9Ac25Gc  V  
7,8,9-tri-O-acetyl-5-N-glycolylneuraminic acid  Neu7,8,9Ac35Gc  V  
5-N-glycolyl-9-O-lactylneuraminic acid  Neu5Gc9Lt  V  
4-O-acetyl-5-N-glycolyl-9-O-lactylneuraminic acid  Neu4Ac5Gc9Lt  V  
8-O-acetyl-5-N-glycolyl-9-O-lactylneuraminic acid  Neu8Ac5Gc9Lt  V  
4,7-di-O-acetyl-5-N-glycolyl-9-O-lactylneuraminic acid  Neu4,7Ac25Gc9Lt  V  
7,8-di-O-acetyl-5-N-glycolyl-9-O-lactylneuraminic acid  Neu7,8Ac25Gc9Lt  V  
5-N-glycolyl-8-O-methylneuraminic acid  Neu5Gc8Me  E  
9-O-acetyl-5-N-glycolyl-8-O-methylneuraminic acid  Neu9Ac5Gc8Me  E  
7,9-di-O-acetyl-5-N-glycolyl-8-O-methylneuraminic acid  Neu7,9Ac25Gc8Me  E  
5-N-glycolyl-8-O-sulfoneuraminic acid  Neu5Gc8S  V, E  
5-N-glycolyl-9-O-sulfoneuraminic acid  Neu5Gc9S  E  
5-N-(O-acetyl)glycolylneuraminic acid  Neu5GcAc  V  
5-N-(O-methyl)glycolylneuraminic acid  Neu5GcMe  E  
2-deoxy-2,3-didehydro-5-N-glycolylneuraminic acid  Neu2en5Gc  Vd  
9-O-acetyl-2-deoxy-2,3-didehydro-5-N-glycolylneuraminic acid  Neu2en9Ac5Gc  Vd  
2-deoxy-2,3-didehydro-5-N-glycolyl-9-O-lactylneuraminic acid  Neu2en5Gc9Lt  Vd  
2-deoxy-2,3-didehydro-5-N-glycolyl-8-O-methylneuraminic acid  Neu2en5Gc8Me  Ed  
2,7-anhydro-5-N-glycolylneuraminic acid  Neu2,7an5Gc  Vd  
2,7-anhydro-5-N-glycolyl-8-O-methylneuraminic acid  Neu2,7an5Gc8Me  Ed  
5-N-glycolylneuraminic acid 1,7-lactone  Neu5Gc1,7lactone  V  
2-keto-3-deoxynononic acid  KDN  V, B  
5-O-acetyl-2-keto-3-deoxynononic acid  KDN5Ac  V  
7-O-acetyl-2-keto-3-deoxynononic acid  KDN7Ac  V  
9-O-acetyl-2-keto-3-deoxynononic acid  KDN9Ac  V  
4,5-di-O-acetyl-2-keto-3-deoxynononic acid  KDN4,5Ac2  V  
4,7-di-O-acetyl-2-keto-3-deoxynononic acid  KDN4,7Ac2  V  
5,9-di-O-acetyl-2-keto-3-deoxynononic acid  KDN5,9Ac2  V  
7,9-di-O-acetyl-2-keto-3-deoxynononic acid  KDN7,9Ac2  V  
8,9-di-O-acetyl-2-keto-3-deoxynononic acid  KDN8,9Ac2  V  
2-keto-3-deoxy-5-O-methylnononic acid  KDN5Me  B  
2-keto-3-deoxy-9-O-phosphonononic acid  KDN9P  Vc,d 
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Sias autonomously form a pyranose (six-membered) ring in solution via intramolecular 
hemiketal condensation and adopt a 2C5 chair conformation (Figure 1.2). In natural 
glycoconjugates, Sias exist only in the α-configuration, except in the high-energy donor 
form CMP-Sias, where the anomeric carbon is in the β-configuration (α and β 
configurations refer to the C7 carbon and C1 carboxyl groups being in a trans and cis 
orientation, respectively) (Angata and Varki, 2002). 
 
 
 
 
 
 
 
 
1.1.2 Natural functions of sialic acid 
Sialic acid as a small, hydrophilic and negatively charged molecule has a simple 
physicochemical impact on its environment. Involvement of Sias in such processes as 
binding and transport of positively charged molecules is attributed to their negative charge 
(reviewed in Traving and Schauer, 1998). Similarly attraction and repulsion phenomena 
between cells and molecules are often driven by highly charged Sias (reviewed in Traving 
and Schauer, 1998 and in Vimr et al., 2004). Furthermore, the negative charge of Sias 
present on glycoconjugates stabilizes their correct conformation (reviewed in            
Traving and Schauer, 1998; Vimr et al., 2004 and in Matsuno et al., 2008). However, its 
main function is that of specific phenomena related to cellular and molecular recognition. 
As a very diverse group, Sias participate in various recognition processes between cells and 
molecules. They are antigenic determinants, for example, of blood groups and as such 
enable the immune system to distinguish between self and non-self structures according to 
their Sia pattern. They serve as ligands for lectins and antibodies and in this way play a 
regulatory role in many physiological processes. Nevertheless, many pathogenic agents 
Figure 1.2. Structures of sialic acids:  (A) Neuraminic acid (Neu, R = H), N-acetylneuraminic acid 
(Neu5Ac, R = CH3CO−) and N-glycolylneuraminic acid (Neu5Gc, R = HOCH2CO−). Figure from (Angata 
and Varki, 2002). 
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such as toxins (e.g. cholera toxin), viruses (e.g. influenza), bacteria (e.g. Escherichia coli, 
Helicobacter pylori) and protozoa (e.g. Trypanosoma cruzi) also bind to host cells via Sia-
containing receptors (reviewed in Lehmann et al., 2006). 
Another important feature of Sias, that seems to be in direct contrast to their recognition 
function, is the masking of cells and molecules. The Sia rich mucous layer of the 
respiratory epithelium serves as a protective shield against pathogens. This thick glycan 
coating efficiently insulates receptors on the surface of the host cells from bacteria and 
viruses (reviewed in Traving and Schauer, 1998). The density of Sia structures [more than 
10 million molecules per human erythrocyte, (Varki, 1999)] on the surface of erythrocytes 
determines their lifespan. Red blood cells that have lost certain numbers of terminal Sias, 
from their surface glycans, over time, have penultimate galactoses of the glycan chains 
exposed to the environment (Aminoff et al., 1977). This serves as a signal for macrophages 
to phagocytose such cells as aged (Bratosin et al., 1995) (Figure 1.3). 
 
Likewise, various serum glycoproteins are removed from the bloodstream by hepatocytes 
after losing terminal Sias and exposure of subterminal galactoses (Egrie et al., 2001; 
Fernandes et al., 2001). Similarly, masking of endogenous structures by Sias protects 
cancer cells and some pathogens from being recognized by immune system cells (Traving 
et al., 1998). In terms of cancer, the higher degree of sialylation has an immunosuppressive 
effect and corresponds to higher sialyltransferase activities often seen in tumour tissues. 
Figure 1.3. The masking function of sialic acids: mechanism of binding (b) and phagocytosis (c) of 
sialidase-treated erythrocytes (a) by macrophages. Sialylation enables these cells to have a long lifetime in 
circulation. 
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Thus, terminal galactose residues that would otherwise inhibit further cell growth and 
spreading are masked. This might be one reason for the loss of growth and division 
inhibition of cancer cells (Wieser et al., 1995; Traving and Schauer., 1998). 
Sia was also found to be a potent defence molecule against oxidative damage being able to 
detoxify hydrogen peroxide. Equimolar amounts of Sia and H2O2 react with each other 
resulting in the production of non-toxic 4-(acetylamino)-2,4-dideoxy-D-glycero-D-galacto-
octonic acid (ADOA) (Iijima et al., 2004). 
Thus, as Sias display such a diverse functionality, the changes in their abundance as well as 
the sialylation pattern of glycoconjugates is seen during many important physiological and 
pathological processes. 
 
1.1.3 Sialic acids in human physiology and pathology 
The very diverse group of Sias play significant roles in human physiology. The defined 
level of Sia expression and its quality in the body as well as the sialylation pattern of 
various entities are crucial for the correct functioning of the organism. Uncontrolled 
alterations in any of them results in serious disorders. Increased serum concentrations of 
Sias have been detected in a number of cancerous states, such as pancreatic cancer, skin 
squamous cell carcinoma, lung, prostate, breast, ovary, colon, and thyroid cancers 
(Diamantopoulou et al., 1999; Paszkowska et al., 2000; Wongkham et al., 2003; Marzouk 
et al., 2007). Sia levels have been correlated with the tumour size, positive lymph nodes 
metastasis, and advanced clinical stage in patients with head and neck squamous cell 
carcinoma. Moreover, Sia concentrations are strongly associated with the patient survival 
rate (Marzouk et al., 2007). Enhanced expression of α(2→6)-linked Sias on N-glycans 
often correlates with human cancer progression, metastatic spread, and poor prognosis. The 
changes of sialylation pattern are often a reflection of gene expression aberrations. Up-
regulation of the ST6GALI gene encoding the enzyme β-galactoside: α(2→6)-
sialyltransferase (ST6Gal-I) leads to increased Sia α(2→3)Gal β(1→4)GlcNAc 
(Sia6LacNAc) production, that is found on the surface of many cancer cells (Hedlund et al., 
2008). 
Sia increased expression is reported in carcinomas of the colon, breast and cervix, 
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choriocarcinomas, acute myeloid leukemia, and in some brain tumours (Marzouk et al., 
2007; Hedlund et al., 2008). Elevated plasma Sia concentration is strongly related to the 
presence of microvascular complications in type I diabetes (Crook et al., 2001) and 
cardiovascular morbidity in the general population (Lindberg et al., 1991; Crook, 1993). 
Sia level of low-density lipoprotein LDL is also elevated in coronary atherosclerotic 
patients in comparison to healthy subjects (Orekhov et al., 1989). The overproduction of 
Sia and its elevated excretion in the urine is observed in the patients with the rare genetic 
disease sialuria (Wang and Brand-Miller, 2003). 
Changes in Sia level in the human organism can be observed during some physiological 
states such as pregnancy. An increase in concentration of Sia in maternal saliva and plasma 
is associated with pregnancy. Sia increases from about 50 mg/l at 10 weeks gestation to 
over 150 mg/l at 21–40 weeks gestation in saliva corresponding to the period of rapid Sia 
accumulation in the fetal brain (Salvolini et al., 1998). 
A definite sialylation level is also crucial for activity and stability of glycoprotein hormones 
and enzymes such as erythropoietin (EPO) (Egrie et al., 2001) and asparaginase (Fernandes 
and Gregoriadis, 2001; Egrie and Browne, 2001). EPO is a glycoprotein hormone produced 
in kidneys with the main function of the stimulating red bloo cells production (Fried, 2009). 
Furthermore, EPO has been used as a drug since 1988 primarily for the clinical treatment of 
anemia, especially anemia caused by renal failure. The number of the Sia residues on the 
glycans’ terminal positions was found to affect the speed of catabolism and biologic activity 
of EPO (Egrie and Browne, 2001; Marzouk et al., 2007). It was found that the removal of 
terminal Sia from carbohydrate chains of EPO increased their in vitro activity but abolished 
the in vivo activity completely (Marzouk et al., 2007). 
Sia has become increasingly interesting for the biopharmaceutical industry producing 
protein-based drugs because of its unique features that increase activity and stability of 
sialylated drugs in vivo. Furthermore, sialyation and hypersialylation (Fernandes and 
Gregoriadis, 2001) of heterogeneous glycoproteins in humans efficiently decreases their 
immunogenic potential in comparison to non-sialylated forms Egrie and Browne, 2001). 
Therefore, a growing number of glycosylated pharmaceutical products are being studied 
with regards to their sialylation and the effects of it (Byrne et al., 2007).  
Sias have a high potential to serve as a diagnostic marker for many diseases and 
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physiological states. By monitoring their levels in the organism it may be possible to 
determine and monitor pathological disorders of such importance as cancer. Furthermore, 
accurate estimation of Sia level in glycoprotein-based drugs as well as determination of 
their sialylation pattern enables production of more efficient compounds. This lowers the 
costs of production as less substance is needed to achieve certain action, which is certainly 
beneficial for the pharma industry. The concentration of Sias in the bio-processors during 
the production is of great importance for the quality of the final product and should also be 
monitored. 
Since the discovery of Sia almost a century ago many methods for its analysis have been 
developed. The requirement for reliable and sensitive assays for Sia detection and 
quantification has been addressed with various approaches applied in biochemistry, 
medicine and the pharma industry. Furthermore, many potential methods are under scrutiny 
and may be developed into useful tools in the near future.  
 
1.1.4 Sialic acid detection and quantification methods 
 
1.1.4.1 Colorimetric methods for sialic acid quantification 
The first Sia detection methods were modifications of assays which had been previously 
used for the measurement of other carbohydrates. They involved orcinol, resorcinol, 
diphenylamine, direct Ehrlich, tryptophan-perchloric acid, hydrochloric acid, and sulfuric-
acetic acid procedures (Warren, 1959).  
The two most common colorimetric methods for the measurement of Sia levels are the 
thiobarbituric acid (TBA) assay of Warren, (1959) and the resorcinol method of 
Svennerholm (Svennerholm, 1956, 1957). These colorimetric methods are based on the 
conversion of Sia into chromophores that can be monitored spectrophotometrically. 
 
1.1.4.2 Thiobarbituric acid (TBA assay, Warren’s assay) 
In this method the Sia is oxidized in strong acid solution by treatment with periodic acid. 
The periodate oxidation product is subsequently coupled with 2-thiobarbituric acid and 
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Sialylated glycan → free sialic acid + glycan 
Free sialic acid → N-acetyl-D-mannosamine + pyruvic acid 
 
forms a red chromophore with λmax = 549 nm (Warren, 1959). This method is suitable for 
free Sia only. Color production varies linearly with the concentration of N-acetylneuraminic 
acid over the range of 0.01 to 0.06 µmole. In terms of sensitivity, the molar extinction 
coefficient is 57,000 (Warren, 1959) and also described as 3-300 µM (Chaplin and 
Kennedy, 1994). The procedure takes about one hour and suffers from malondialdehyde 
(MDA) interference in the sample (Sobenin et al., 1998). 
 
1.1.4.3 Resorcinol method of Svennerholm 
The resorcinol method described in 1957 by Svennerhold is similar to the above 
thiobarbituric acid method (Svennerhold, 1957). The Sia after periodate oxidation in acidic 
conditions is coupled with resorcinol to form a chromophore with λmax = 630 nm (Jourdian 
et al., 1971). The chromogens formed from free and glycosidically bound Sia by periodate 
oxidation show marked differences in stability. Therefore by suitable variation of time and 
temperature, it is possible to convert the assay procedure to a differential method for 
determining total, glycosidically bound and, by calculation, also free Sia (Jourdian et al., 
1971). This method is however less sensitive then the thiobarbituric acid method with the 
molar extinction coefficient of 27,900 (Jourdian et al., 1971). 
 
1.1.4.4 Enzymatic methods for sialic acid quantification 
All the enzymatic reactions involve initial enzymatic release of Sia from sialylated glycans 
by neuraminidase. The free Sia is than subjected to N-acetylneuraminic acid aldolase to 
generate N-acetyl-D-mannosamine and pyruvic acid. One of the Sia cleavage products is 
subsequently enzymatically converted into a chromophore that can be accurately measured 
spectrophotometrically (Figure 1.4). 
 
 
 
 
 
 
Figure 1.4. Common reactions in the enzymatic measurement of sialic acid 
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Free sialic acid → N-acetyl-D-mannosamine + pyruvic acid 
N-acetyl-D-mannosamine →N-acetyl-D-glucosamine 
N-acetyl-D-glucosamine → N-acetyl glucosaminic acid + H2O2 
H2O2 + 4-aminoantipyrine + ESPDMA → quinine imine dye (λmax, 590 nm) 
Detection methods involving pyruvate 
In the method by Sugahara (1980) the oxidation of pyruvate by pyruvate oxidase produces 
hydrogen peroxide which is used as a substrate for peroxidase to produce 4-amino-
antipyrine, a colorimetry measured dye. 
The pyruvic acid can be also reduced in the presence of reduced form of nicotinamide 
adenine dinucleotide (NADH) by lactate dehydrogenase. Then the concentration of 
nicotinamide adenine dinucleotide (NADH) is measured spectrophotometrically at 349 nm 
(Kolisis, 1986). 
Both of these methods suffer from interference, mostly by pyruvic acid which is normally 
present e.g. in the serum (Teshima et al., 1988). 
 
Detection methods based on N-acetyl-D-mannosamine 
The assay developed by Teshima in 1988 was based on conversion of N-acetyl-D-
mannosamine into N-acetyl-D-glucosamine by acylglucosamine 2-epimerase. Then N-
acetyl glucosaminic acid and hydrogen peroxide are produced by N-acetylhexosamine 
oxidase. Ultimately, hydrogen peroxide is detected using peroxidase, 4-aminoantipyrine 
and N-ethyl-N-(3-sulfopropyl)-3,5-dimethoxy aniline (Figure 1.5) (Teshima et al., 1988). 
This method is affected by ascorbic acid; however, its interference could be prevented by 
adding ascorbate oxidase (Teshima et al., 1988). The procedure takes about 10 minutes. 
 
 
 
 
 
 
1.1.4.5 Chromatographic methods 
A fluorometric detection following High-performance liquid chromatography (HPLC) 
separation of previously labelled Sia has been successfully applied to determine 13 
members of the Sia family in tissues samples from rats and mice (Morimoto et al., 2001). 
Figure 1.5. Teshima method of sialic acid detection and quantification. ESPDMA = N-ethyl-N-(3-
sulfopropyl)-3,5-dimethoxy aniline. 
 13 
The HPLC method is sensitive and specific with a detection limit of 25 fmol (Hara et al., 
1989; Matsuno and Suzuki, 2008). However it requires long analysis time, expensive 
equipment, columns and may be subjected to interference by contaminants in the sample 
(Matsuno and Suzuki, 2008). 
 
1.1.4.6 Amperometric biosensor based method 
The Sia amperometric biosensor operation is based on the sequential action of two enzymes 
(N-acetylneuraminic acid aldolase and pyruvate oxidase) that ultimately produce hydrogen 
peroxide, which is then detected by anodic amperometry at the platinum electrode. The 
biosensor presents several advantages such as simple preparation, low cost, high sensitivity 
and selectivity, reasonable operational stability (at least 8 days), and successful 
applicability in biological samples. The limit of detection is 10 µM, and the response is 
linear to 3.5 mM (Marzouk et al., 2007). This type of assay is not commercially available 
nor has it has been widely used for Sia detection and hence it will not be further discussed.  
 
1.1.4.7 Conclusions 
Several methods for colorimetric analysis of Sias developed to date have been found to be 
not specific or sensitive enough to get an accurate determination of Sias in biological 
materials, which usually contain very low Sia concentrations and large amounts of 
substances that may interfere with the colorimetric tests (Romero et al., 1997). These 
assays are not only relatively insensitive, but in general have a low specificity and cannot 
be applied to the direct measurement of Sias in tissues and in other unpurified biological 
materials (Warren, 1959). The increased specificity and sensitivity of chromatographic 
methods are at the price of extended time of analysis and requirement for expensive 
equipment and highly skilled personnel. This clearly indicates that the currently available 
methods of specific Sias detection and quantification are not rapid and easy to use while the 
more robous methods suffer from unspecificity and interference. Presently there are no 
universal methods that would be specific, precise, sensitive, reliable, quick, uncomplicated 
and, preferably, inexpensive. However, as it has been presented, the role of Sia in living 
organisms is of great significance and thus the regulation of its metabolism and precise 
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estimation of its level is also critical. Therefore, unsurprisingly, mechanisms with the 
capacity to maintain Sia exist in nature and Sia turnover is, indeed, closely and precisely 
monitored by living organisms. In these mechanisms crucial functions are played by 
proteins that can bind Sia with high specificity and high affinity. The aim of this study was 
to explore the potential of such proteins in order to develop a novel Sia detection and 
quantification method that would fulfil a niche left unfulfilled (specific and quick method) 
by the already existing methods. A method that would be specific, precise, sensitive, 
reliable, quick, uncomplicated and also inexpensive. 
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1.2 Sialic acid binding proteins 
The great importance of Sia in various biological processes is reflected in the abundance of 
natural Sia binders present in living organisms. Sia binding proteins play a significant role 
in cell recognition (Lasky, 1995; Bevilacqua et al., 1991), pathogen infection (Spackman, 
2008; Guo et al., 2009), Sia acquisition (Johnston et al., 2007; Severi et al., 2007) and 
detachment from the host cell and spread of viruses (Spackman, 2008; Lee and Saif, 2009). 
These proteins, although from distinct organisms often share some similarity (Johnston et 
al., 2007; Lehmann et al., 2006). 
 
1.2.1 Viral sialic acid binding proteins 
Many viruses utilize Sias to facilitate attachment to host cells (Angata and Varki, 2002; 
Lehmann et al., 2006), although their degree of dependence on Sias for this purpose varies. 
Haemagglutinins of influenza viruses (A, B, and C) (Harms et al., 1996; Xu et al., 1996; Ito 
et al., 1997), Newcastle disease virus [NDV, an avian pathogen (Suzuki et al., 1985)], 
mouse polyoma virus (Cahan et al., 1983), Sendai virus [a rodent pathogen (Suzuki et al., 
1985)], mouse hepatitis virus (Regl et al., 1999), and many others ( Angata and Varki, 
2002) have been isolated and shown to bind Sias. Viruses often possess two Sia binding 
proteins of “contradictory” functions: haemagglutinins, that facilitate cell entry by 
recognizing and binding to specific receptors containing terminal Sia on the host cell 
surface and neuraminidases, that cleave off terminal Sia of the human receptors which 
enables the virus to detach from the cell surface at the end of one cycle (Figure 1.6) 
(Spackman, 2008). 
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1.2.2 Bacterial adhesins 
Many bacterial pathogens also utilize Sia receptors on the surface of host cells. Prokaryotic 
proteins involved in cell attachment are collectively known as adhesins. Bacterial adhesins 
are often expressed in a strain-specific way and can influence the range of tissues the strain 
can infect or colonise (Ofek and Sharon, 1990; Kline et al., 2009). Strains shown to use 
sialoglycoconjugates as attachment sites express either S-fimbriae, K99-fimbriae, the F41 
adhesin or one of the colonization factor antigens (CFA) (Lehmann et al., 2006). Such 
examples include Helicobacter pylori (Miller-Podraza et al., 1996) and E. coli strain K99 
(Ono et al., 1989). The former is an etiological agent of peptic ulcers in humans, and the 
latter causes lethal dysentery among piglets and calves. H. pylori express two different 
adhesins (in an environment-dependent manner) which can recognize Sias (Miller-Podraza 
Figure 1.6. Mechanism of Action of Neuraminidase Inhibitors. Panel A shows the action of neuraminidase in the 
continued replication of virions in influenza infection. The replication is blocked by neuraminidase inhibitors 
(Panel B), which prevent virions from being released from the surface of infected cells. Figure from Moscona 
(2005). 
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et al., 1997). SabA recognizes all terminal α(2→3)-linked Sia regardless of the underlying 
glycan structure. The neutrophil-activating protein, HPNAP, binds solely 
Neu5Acα(2→3)Galβ(1→4)GlcNAcβ(1→3)Galβ(1→4)GlcNAc structures (Teneberg et al., 
1997). The recognition is mediated solely by the SabA adhesion     (Unemo et al., 2005). 
The adhesins expressed by E. coli K99 strain shows high specificity toward 
Neu5Gcα(2→3)Galβ(1→4)Glc structure on glycolipids, which is abundantly expressed in 
the gastrointestinal tract of piglets (Yuyama et al., 1993; Angata and Varki, 2002). The 
binding site of K99-fimbriae adhesin is found in the major subunit. The presence of a 
hydrophobic region close to the binding site seems to enhance Sia binding affinity, which 
favours Neu5Gc over Neu5Ac. The specific recognition of Neu5GcLacCer by K99-
fimbriated E. coli might contribute to host specificity, since humans and animals that lack 
Neu5Gc cannot be infected (Lehmann et al., 2006). 
S-fimbriae of E. coli were found to preferentially bind to gangliosides carrying 
Neu5Gcα(2→3)Gal and Neu5Acα(2→8)Neu5Ac structures, with the C-8 and C-9 hydroxyl 
groups on Sia being required for recognition (Hanisch et al., 1993). The adhesion protein, 
SFaS, is a minor component of the multi-subunit S-fimbriae (Hacker et al., 1993). 
Another example of Sia-specific adhesin found in E. coli is F41. This 28 kDA protein is 
specific for glycophorin A with a clear selectivity for the M blood type (Brooks et al., 
1989). 
Of the CFA the most extensively studied are CFAI, CFAII and CFAIV. Whereas CFAI is a 
single fimbrial antigen, CFAII and CFAIV are composed of antigenically distinct structures 
called coli surface antigens (Lehmann et al., 2006). 
The Sia specific adhesisns are also utilized by protozoan pathogens.  They were found in 
Tritrichomonas foetus (Babal et al., 1999), Entamoeba histolytica (Feingold et al., 1984) 
and Plasmodium falciparum (the protozoan which causes the most virulent form of malaria 
[Orlandi et al., 1992]). 
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1.2.3 Bacterial toxins 
A separate group of Sia-specific proteins found in bacteria are toxins. The toxicity of these 
soluble lectins results from their ability to catalytically modify macromolecules that are 
required for essential cellular functions such as vesicular trafficking, cytoskeletal assembly, 
signalling or protein synthesis. To reach their targets, these proteins bind specific surface 
receptors before endocytosis and translocation across the internal membrane can occur. 
These toxins classically bind to oligosaccharide receptors on host cell surfaces, and many 
of them show high specificity toward Sia, generally located on gangliosides (reviewed in 
Lehmann et al., 2006). One of the best examples of a Sia-binding soluble lectin is cholera 
toxin, belonging to the AB5 family, produced by Vibrio cholerae (Richards et al., 1979). It 
is composed of five B subunits and an A subunit (Figure 1.7). The B subunits show specific 
binding to a sialylated glycolipid (ganglioside GM1), delivering the A subunit to the 
cytosol. This in turn causes overactivation of an intracellular signaling pathway (adenylate 
cyclase, producing cyclic AMP) in gastrointestinal epithelial cells, causing severe diarrhea 
and electrolyte imbalance (Vanden Broeck et al., 2007; Sanchez and Holmgren, 2008). 
Other notable examples of Sia-dependent toxins are those from Clostridium tetani (Bizzini, 
1979; Eisel et al., 1986) and Clostridium botulinum (Dolly and Aoki, 2006), causing 
tetanus and botulism, respectively (Angata and Varki, 2002). 
 
 
Figure 1.7. Crystal structure of cholera toxin B-subunit pentamer with bound GM1 pentasaccharide shown 
from the bottom (a) and from the side (b). Figure from Varki (1999). 
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1.2.4 Animal endogenous sialic acid-specific lectins 
It is obvious that binding of Sia receptors on the surface of the cells by pathogens is often 
detrimental for the host. However, expression of such receptors and their specific 
recognition by “self” proteins is necessary for many physiological processes. The great 
variety of such proteins has already been identified and characterized (Angata and Varki, 
2002) and others are yet to be found. The majority of the identified animal, endogenous, 
lectins were found in the immune system. The first reported example of a vertebrate Sia-
recognizing lectin was a part of the alternative pathway of complement, one of the earliest 
response components of the innate immune system (Ram et al., 1998). The protein consists 
of 20 short consensus repeats (approximately 60 amino acids per repeat unit, also called 
“sushi” domains). Some of the repeat units are involved in Sia recognition and require an 
intact unsubstituted Sia side chain (Ripoche et al., 1988). Factor H is a regulatory 
(inhibitory) factor, and binding of it to cell surface glycoconjugates containing Sias 
prevents the alternative complement pathway from inadvertently attacking “self” cells 
(Nilsson and Mueller-Eberhard, 1965). Foreign cells which are not covered with Sias will 
not be protected by factor H and are hence exposed to the attack by complement (Ram et 
al., 1998; Whaley et al., 1976). 
Particular carbohydrate structures present on human cells containing Sias and fucose called 
sialyl Lewis x (Lex) and sialyl Lewis a (Lea) are recognized by a group of lectins called 
selectins. The family of three C-type lectins is defined by a shared structural motif and 
calcium requirement for carbohydrate recognition (revied in Varki, 1999). These cell 
adhesion molecules are critically involved in the regulation of leukocyte traffic (Cambia 
and Figdor, 2003) . The selectins are typical type I proteins composed of a tandem array of 
discrete protein domains. These include an amino terminal C-type lectin domain, a single 
epidermal growth factor (EGF)-like domain, from two to nine short consensus repeat (SCR) 
domains, a single membrane spanning region, and a cytoplasmic tail (Kansas, 1996) 
(Figure 1.8). 
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Another group of mammalian Sia recognizing lectins are siglecs (Sia-binding Ig 
superfamily lectins) (Crocker and Varki, 2001). Siglecs share a common domain structure 
with an amino-terminal V-set Ig-like domain, variable numbers (1-16) of C2-set Ig-like 
domains, a single-pass transmembrane domain, and a cytosolic tail (Figure 1.9),       
(Angata et al., 2004). An essential arginine (Arg97) on the F strand (conserved in the other 
siglecs) forms a salt bridge with the carboxylate of Sia and two tryptophans (Trp2 and 
Trp106) on the A and G strands form hydrophobic contacts with the N-acetyl and glycerol 
side groups of Neu5Ac respectively (Crocker et al., 2001). Biological functions of the 
siglecs involve regulation of B-cell activation, siglec-2/ CD22 (O'Keefe et al., 1996) and 
maintenance of myelin sheath structure, siglec-4a/MAG (Schachner et al., 2000). 
Figure 1.8. Structure of L-selectin. All the selectins have similar extracellular domains. L-selectin is the only 
selectin that carries a defined extracellular cleavage site that is close to the cell membrane. Leucocyte 
stimulation can often lead to rapid cleavage at this site. Figure from Ivetic et al. (2004). 
 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Schematic representation of Siglecs in primates and rodents. Siglecs have one V-set domain (a 
domain similar to Ig's variable region) and 1–16 C2-set domains (domains similar to Ig's constant region), 
followed by transmembrane and cytoplasmic domains. Genes for Sialoadhesin/Siglec-1, CD22/Siglec-2, and 
myelin-associated glycoprotein/Siglec-4 are located outside of the Siglec gene cluster in both primates and 
rodents. CD33rSiglecs are further classified into five subgroups (V1C1, V1C2, V1C3, V1C4, and V2C2), based on 
the number of V- and C2-set Ig-like domains. Figure from Angata et al. (2004). 
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1.2.5 Fungal lectins 
Sia specific lectins have been isolated and characterized from the fruiting bodies of various 
mushroom species (reviewed in Lehmann et al., 2006). Their natural function, in many 
cases, is not clearly understood. However, the identification and isolation of Sia-specific 
lectins from pathogenic fungi, particularly airborne species that cause severe infections in 
immunocompromized individuals, has raised the possibility that the initial stages of 
infection, particularly fungal spore (conidia) binding to the lung epithelial cells, may be 
mediated through Sia receptors. The first human pathogenic fungal species thought to 
possess a Sia-specific lectin were Chrysosporium keratinophilum and Anixiopsis 
stercoraria (synonym of Aphanoascus fulvescens) (Chabasse and Robert, 1986), which 
cause skin and nail infections in humans (Chabasse and Robert, 1986; Lehmann et al., 
2006). 
Histoplasma capsulatum is the causative agent of histoplasmosis, a severe pulmonary 
infection that is most commonly found in tropical areas. Early studies showed that a 50-
kDa cell wall protein from H. capsulatum yeast was able to bind laminin of extracellular 
matrix with high affinity, a process thought to be important in the initial stages of infection 
(McMahon et al., 1995). 
In developed countries, Aspergillus fumigatus is now regarded as the most important 
airborne fungal human pathogen. The inhaled conidia adhere and germinate in the lung. 
The preferential receptor for A. fumigatus lectin is Neu5Ac-α(2→6)-GalNAc (Lehmann et 
al., 2006). 
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1.2.6 Plant lectins 
Although only a few Sia specific plant lectins have been isolated, their historical 
importance in investigating the expression and biology of Sia is unquestioned. The function 
of Sia-specific lectin in these organisms is unclear as the presence of Sia in plants is 
questionable. The expression of Sia was reported (Shah et al., 2003), however, this research 
was subsequently questioned (Seveno et al., 2004). It was then concluded that it is not 
possible to demonstrate unequivocally that plants synthesize Sias because the amounts of 
these sugars detected in plant cells and tissues are so small that they may originate from 
extraneous contaminants (Zeleny et al., 2006). According to the most popular theory the 
Sia-binding lectins are involved in defense mechanisms (Peumans et al., 1995). The highly 
sialylated epithelial cells of animal digestive tracts provide numerous ligands for Sia 
specific lectins. Presumably, it is this binding of Sia-specific lectins from elderberry 
(Sambucus nigra) bark and wheat germ agglutinin that initiates the severe toxicity 
symptoms observed upon ingestion of plant lectins in higher organisms. The consequence 
of this is that elderberry, for example, is virtually never attacked in the wild. Moreover, Sia-
specific plant lectins, like other plant lectins, are predominantly localized in regions of the 
plant that are most susceptible to attack, and thus require an adequate protection strategy 
(Peumans et al., 1995; Lehmann et al., 2006). 
Sambucus nigra bark lectin (SNA) is a 140 kDa glycoprotein consisting of two different 
subunits 34.5 kDa and 37.5 kDa respectively, held together by intramolecular disulphide 
bridges (Broekaert et al., 1984). SNA requires the presence of terminal Neu5Ac-
Gal/GalNAc sequences for high affinity binding (Shibuya et al., 1987) 
Another plant lectin, widely regarded as Sia-specific, is wheat germ agglutinin (WGA). The 
18 kDa WGA monomer is composed of four conserved 43 amino acid residue segments, 
which are folded into spatially distinct domains (A,B,C and D) of similar sequence. 
Monomers associate into dimers in a head-to-tail fashion, such that domains in contact 
across the dimer interface (A1-D2, B1-C2, C1-B2, D1-A2) are quasi-2-fold related. The 
domains are stabilized by four disulfide bonds and have an aromatic amino acid residue 
rich region for sugar binding (Wright et al., 1993) 
Although wheat germ lectin is known to bind Sia, this lectin binds more preferably to N-
acetyl-D-glucosamine and its p-1,4-linked oligomers. The interaction of wheat germ 
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agglutinin with Sia is based on its structural similarity to N-acetyl-D-glucosamine, namely, 
the superimposable configuration of amino and hydroxyl groups at C-5 and C-4 of the 
pyranose ring of Sia with the C-2 and C-3 of N-acetyl-D-glucosamine (Shibuya et al., 
1987). 
Maackia amurensis express two Sia-specific lectins, haemagglutinin (MAH) and 
leukoagglutinin (MAL) (Imberty et al., 2000). The MAL lectin was shown to bind strongly 
to carbohydrate chains containing NeuAc-α(2→3)-Galβ-(1→4)GlcNAc/Glc structure 
whereas the MAH lectin has highest affinity and is directed toward the NeuAc-α(2→3) 
Gal-β(1→3)[αNeuAc(2→6)]αGalNAc tetrasaccharide (Knibbs et al., 1991; Imberty et al., 
2000). 
The 258 amino acid MAL lectin is composed of two asymmetric subunits named A and 
B. Each monomer folds into two large β-pleated sheets. Two monomers associate to form 
the so-called "canonical legume lectin dimer" characterised by a large 12-stranded β-sheet, 
resulting from the abutment of the two back sheets (Figure 1.10) (Imberty et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Crystal structure of the leukoagglutinin 
(MAL) from Maackia amurensis in complex with 
sialyllactose. The two independent monomers are 
shown with different colors. The Ca2+ and Mn2+ ions 
are displayed as green and magenta spheres, 
respectively. Figure form Imberty et al. (2000). 
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1.2.7 Current application of sialic acid specific lectins 
In the light of the importance and versatility of Sia, the high specificity of Sia binding 
lectins has made them useful tools for a variety of applications. Initially the Sia specific 
lectins were used for detection of sialylated viruses, such as the plant rhabdoviruses potato 
yellow dwarf virus and eggplant mottled dwarf virus, propagated in plants of Nicotiana 
rustica (Slifkin and Doyle, 1990). They enabled development of rapid methods for 
pathogen identification in the field of medical microbiology (Wagner, 1982) as well as 
characterisation of sialylated viral envelopes ( Slifkin and Doyle, 1990). Sia binding lectins 
were also applied in studying the specific Sia receptors on the surface of eukaryotic cells 
(Welty et al., 2006) as well as sialylation of glycoproteins (Pinto da Silva et al., 1981). In 
histology, lectins are used for detection of Sia receptors, e.g. on epithelial cells of the 
human airway (Nicholls et al., 2007). Cancer research benefited from new cancer 
biomarkers’ analysis methods based on lectins (Taylor et al., 2009) and the biomedical 
industry in new purification and separation protocols based on Sia-specific lectins (Madera 
et al., 2005). 
 
1.2.8 Sia-specific proteins utilized in this project 
Two Sia-specific lectins were chosen for the purpose of this project, namely 
haemagglutinin of influenza virus and SiaP of Haemophilus influenzae. They have different 
specificity for particular forms of Sia. One specifically binds glycans’ terminal Sias and the 
second naturally targets free Sia. They come from different organisms and have different 
structures; however, both are relatively small proteins and uncomplicated molecules which 
should be advantageous in some aspects of the study, e.g. expression in a bacterial host or 
orientated immobilisation. 
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1.2.8.1 Haemagglutinin of Influenza Virus 
Influenza virus, with thogovirus, belongs to the Orthomyxoviridae family. Three different 
types (A, B, and C) of influenza viruses are known and were classified on the basis of 
antigenic differences among their nucleocapsid and matrix proteins. Influenza A viruses 
were found to inhabit different animal species including humans, horses, swine, and a wide 
variety of domesticated and wild birds (Lee and Saif, 2009). Influenza type B viruses were 
isolated from humans and seals whereas influenza type C viruses have been isolated from 
humans and from swine (Ha et al., 2002). Influenza A viruses are further divided into 
subtypes based on the antigenic relationships of their haemagglutinin (HA) and 
neuraminidase (NA) surface glycoproteins ( Lee and Saif, 2009). The HA and NA genes are 
extremely variable in sequence, and less than 30% of the amino acids are conserved among 
all the virus subtypes. A total number of 16 different HA subtypes (H1-H16) and 9 different 
NA subtypes (N1-N9) have been identified (Fouchier et al., 2005). Only three subtypes of  
HAs (H1, H2, H3) and two NAs (N1, N2) serotypes have adapted to humans, although 
some are very notable as the pandemic strains: H1N1 in 1918, H2N2 in 1957, H3N2 in 
1968 (Stevens et al., 2007) and H5N1 in 2005 (Michaelis et al., 2009). 
Ten viral proteins are encoded in eight segments of single stranded, negative sense RNA 
molecules, contained within the viral envelope in tight association with the nucleocapsid 
and the three polymerase proteins (PB2, PB1, PA), (Figure 1.11). Together they form the 
ribonucleoprotein (RNP), this complex being the minimal functional unit of replication 
(Nakajima, 1997). The matrix protein (M1), which lies inside the lipid envelope, is 
associated with both the RNP and the viral envelope. It is thought to play a fundamental 
role in virus assembly. The M2 protein decorates the surface of the envelope and acts as an 
ion channel, playing a role in triggering the viral uncoating in the endosome. The NS2 
protein, also known as the nuclear export protein (NEP), mediates the export of newly 
synthesized RNPs from the nucleus (Lee and Saif, 2009). The NS1 protein is a regulatory 
protein with numerous functions that is not packed into the virion (Krug et al., 2003). The 
most prominent feature of the virus envelope is tightly packed projections of two types of 
glycoproteins: rod-shaped trimers of HA and mushroom-shaped tetramers of NA. Virions 
can exhibit a variety of shapes and sizes ranging from spherical particles to elongated 
filamentous forms depending on the virus strain and passage history (Lee and Saif, 2009). 
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1.2.8.2 Structure of haemagglutinin 
The haemagglutinin is a major component of the virus envelope and accounts for 
approximately 30% of the total virus protein (Wrigley, 1979). The trimeric, transmembrane 
glycoprotein has a molecular weight of about 210,000 Da. Each subunit comprises two 
domains, HA1 (58,000 Da) and HA2 (26,000 Da), linked together via two disulfide bonds 
(Skehel et al., 1975; Doms et al., 1986). The two subunits are formed during virus 
assembly at the plasma membrane of the infected cell as the result of proteolytic cleavage 
of a glycosylated precursor polypeptide HA0 (Hay, 1974). The precursor has a molecular 
mass of approximately 80,000 and is approximately 550 amino acids long with an N-
terminal signal sequence, a transmembrane domain near the C-terminus and a short 
cytoplasmic tail (Skehel et al., 1975; Stevens et al., 2007). 
Figure 1.11.  A schematic diagram of the structure of the influenza A virus.  Figure from Kaiser (2006). 
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The first X-ray structure of haemagglutinin from influenza virus was published by Wilson 
et al. (1981). Since that time over 25 structures have been reported for the HA, including 
three principal molecular conformations assumed by the protein during the virus life cycle: 
the precursor structure, the structure of the cleaved native HA present on the surface of 
infectious virions, and the structure of HA following the conformational changes involved 
in membrane fusion (Figure 1.12) (Stevens et al., 2007).  
 
The mature HA homotrimer is ~135 Å in length with two distinct domains (Figure 1.13). 
The cylindrical protein is composed of a globular head, containing the receptor binding 
domain (HA1 residues 52 to 275 in H3 numbering), and an intertwined ‘stem’ domain at its 
membrane proximal base, composed of both HA1 residues (11 to 51 and 276 to 329) and 
Figure 1.12. X-ray crystallographic models for the 3 principal molecular conformations assumed by the HA 
protein during the virus life cycle. The precursor structure (A), and the structure of the cleaved native HA (B) 
present on the surface of infectious virions are virtually identical to each other except for the HA1/HA2 cleavage 
site (marked by an *). After uptake of the virus through the endocytotic pathway, the HA undergoes a dramatic 
molecular rearrangement (C) that enable, the HA to expose the fusion peptide for subsequent membrane fusion. 
Figure from Stevens et al. (2007). 
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HA2 (1 to 176). From each monomer, long parallel α-helices of approximately 50 amino 
acids in length dominate this region and associate to form a triple stranded coiled-coil. 
Glycosylation is essential for the proper refolding and cellular processing of HA and can 
vary between strains with respect to the number and positioning of glycosylation sites. For 
example, the H3 haemagglutinin of the 1968 pandemic virus has seven glycosylation sites 
whereas the 1918 H1 HA has only four. Acquisition of glycosylation sites that change the 
antigenic properties of the protein can be directly related to escape from the host immune 
response (Stevens et al., 2007). 
 
 
 
 
 
 
Figure 1.13.  The structure of hemaglutinin. A - Globular and fibrous domain of a single subunit. B - 
Structure of the homotrimer. Figure from Lodish et al. (1999). 
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1.2.8.3 Priming of haemaggutinin 
To gain full activity the HA protein requires a posttranslational alteration, consisting of 
HA0 cleavage, which takes place before the virion leaves the host cell. The cleavage results 
in the formation of the two disulfide-linked subunits HA1 and HA2, eliminating an arginine 
residue, R329, that separates them in the precursor. The cleavage takes place in the loop 
comprising residues 323–328 of HA1, and 1–12 of HA2.  The loop projects the eight 
residues at the cleavage site, HA1 327 to HA2 5, away from the surface of the molecule 
(Figure 1.12). The newly created amino terminus (Kapatral et al., 2002, 2003; Johnston et 
al., 2007) of HA2 is a nonpolar sequence called the fusion peptide (Chen et al., 1998). A 
negatively charged cavity is found adjacent to the loop, into which HA2 residues 1–10, the 
fusion peptide, inserts after HA0 cleavage, possibly guided by an electrostatic force 
generated when the positively charged amino terminus of HA2 is formed (Chen et al., 
1998). 
 
1.2.8.4 Haemagglutinin’s receptor-binding site (RBS) structure and function 
One of the primary functions of HA protein, receptor binding, is mediated by the HA2 
domain. A shallow depression at the top of the HA molecule binds terminal Sias of animal 
glycoproteins and glycolipids with millimolar affinity (Sauter et al., 1992a). The receptor-
binding site is composed of residues conserved in all subtypes of influenza (Skehel et al., 
2000; Ha et al., 2001; Ha et al., 2003) and comprises three structural elements, namely an 
-helix (190-helix, HA1 188 to 190) and two loops, 130-loop and 220-loop. The lower left 
and right edges of the site are formed by two surface loops; residues 225-228, the 220 loop 
and 135-138, the 130 loop, respectively (Figure 1.14) (Ha et al., 2003). One side of the 
Sia’s pyranose ring faces the base of the site, and the axial carboxylate, the acetamido 
nitrogen, and the 8- and 9-hydroxyl groups face into the site and form hydrogen bonds with 
conserved side-chain or main-chain polar atoms. Serine 136 forms a hydrogen bond with 
the carboxylate, which is also hydrogen bonded to the amide of the peptide bond 137; 
histidine 183 and glutamic acid 190 form hydrogen bonds with the 9-hydroxyl group, and 
tyrosine 98 forms hydrogen bonds with the 8-hydroxyl group. The 5-acetamido nitrogen 
forms a hydrogen bond with the carbonyl of peptide 
 31 
substituent is in van der Waals contact with the six-membered ring of tryptophan 153. The 
7-hydroxyl group and acetamido carbonyl hydrogen bond to each other and the N-acetyl 
methyl group forms van der Waals contacts with leucine 194 (Skehel et al., 2000).  
 
 
 
 
 
 
 
 
 
 
Although the Sia receptor is bound in almost identical orientation in both avian and human 
H3 proteins there is a significant difference between these two binding sites at positions 
226 and 228. The positions 226 and 228 are occupied by leucine (occasionally other non-
polar residues) and serine in the human H3 protein or by glutamine and glycine in the avian 
H3 protein (Ha et al., 2003). In human H3 the L226 side chain D-methyl group points 
downward into the binding site where it contacts conserved Y98 and A138, resulting in a 
slightly different geometry for adjacent residues. The 130 loop is shifted away from the 220 
loop and thus the human H3 binding site is 0.5 Å wider than the avian H3 one. In the 
absence of this methyl group, the avian HA site can collapse inward, with the ring of Y98 
rotating about 20° and the side chains of W153, H183, and the backbone of the 190 α-helix 
also changing slightly (Figure 1.15) (Ha et al., 2003). The residue number 228 in human 
H3 is serine of which the OH-group contacts the Sia 9-OH whereas in avian H3 glycine 
hydrogen-bonds via a water molecule to the 8- and 9-OH of the Sia. This residue, along 
with residue 226, significantly influences the geometry of the binding site and, thus, the 
specificity of the protein (Ha et al., 2001). 
Figure 1.14. Haemagglutinin receptor binding. Schematic 
diagram of the receptor-binding site of a HA-receptor 
analog complex, showing the positions of the residues and 
hydrogen bonds that they form with sialic acid (dashed 
lines). Figure from Skehel et al. (2000). 
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Interestingly, H2N2 viruses isolated from humans during the first year of the 1957 
pandemic contain 228G (as do most avian viruses), whereas some avian H3 viruses contain 
“human” 228S (Matrosovich et al., 2000). Similarly, in the H1 subtype haemagglutinin, 
isolated from humans, the avian specific Gln-226/Gly-228 pair was present (Ha et al., 
2003). It is possible that the mechanism directing the specificity of H1 subtype viruses is 
different than in H3 viruses.  In H1 subtype the HA residues at positions 190 and 225 were 
found to dictate the specificity (Matrosovich et al., 2000) while position 226 is occupied by 
glutamine in both human and avian viruses. The receptor-binding properties of such 
atypical avian and human viruses have not been characterized (Matrosovich et al., 2000). 
 
1.2.8.5 Specificity of the Receptor Binding Site 
The sialylated gicans on the surface of human respiratory tract cells and avian intestinal 
cells have identical composition with regards to the three terminal monosaccharides: Sia, 
Gal, GlcAc. There is, however, a major difference between them with regards to the 
linkages between these monosaccharides. Human terminal glycans adopt a “folded” 
conformation imposed by the Siaα(2→6)Gal linkage and Galβ(1→4)GlcNAc linkage 
Figure 1.15. Conformational differences in the 
receptor-binding sites of the H3 avian and H3 
human HAs. Side-chain and main-chain shifts are 
indicated by dashed arrows. Figure from Ha et al. 
(2003). 
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which position the GlcNAc directly over the Sia. The folded conformation is mainly 
stabilized by hydrogen bonds between GlcNAc 3-OH and the ring oxygen of either the Sia 
or Gal. Alternatively, GlcNAc 3-OH forms a hydrogen bond with the Sia gliosidic oxygen. 
The avian glycans adopt an “extended” form imposed by the Siaα(2→3)Gal linkage and 
Galβ(1→3)GlcNAc linkage (Eisen et al., 1997) (Figure 1.16 and Figure 1.17). The NeuAc 
group on the third saccharide appears to be crucial for stabilizing the folded conformation 
as α(2→6)-sialyllactose, identical to the first three saccharides of lactoseries 
pentasaccharide c (LSTc) but lacking the Neu5Ac group on the third Glc residue, and exerts 
an extended conformation (Skehel et al., 2000). Accommodation of such different receptors 
by human and avian influenza viruses’ haemaggluinins dictates the different structures of 
their binding sites. The receptor-binding site of the human HA is wider than avian to 
accommodate glycans in folded conformation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16. Lactoseries pentasaccharide c (LSTc). An oligosaccharide containing the three terminal 
monosaccharides present on the surface of human respiratory tract cells. Sequence of sugar residues and 
linkages are: NeuAcα (2-6)Galβ (1-4)GlcNAcβ (1-3)Galβ (1-4)Glc. Figure from Ha et al. (2001). 
Figure 1.17. Lactoseries pentasaccharide a (LSTa). An oligosaccharide containing the three terminal 
monosaccharides present on the surface of human respiratory tract cells. Sequence of sugar residues and 
linkages are: NeuAcα (2-3)Galβ (1-3)GlcNAcβ (1-3)Galβ (1-4)Glc. Figure from Ha et al. (2001). 
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As the structures of the LSTc (human) and LSTa (avian) saccharides are different, they both 
exit the HA binding site in opposite directions. The human receptor exits the human HA 
binding site pointing outwards from the trimer threefold symmetry axis whereas the avian 
receptor exits the binding site near the interface between two HA monomers and the 
carbohydrate part of the HA glycoprotein (Figure 1.18) (Eisen et al., 1997). This difference 
imposes the receptor linkage specificity, as for a given (avian or human) H3 one version of 
the saccharide is energetically preferred and thus the natural receptor for human influenza 
H3 virus is terminal Siaα(2→6)Gal which for avian H3 virus it is terminal Siaα(2→3)Gal 
(Connor et al., 1994). 
Figure 1.18. Conformations of LSTa (red) and LSTc (green) and HA monomers (white and gold). The 
molecular surface of HA viewed along the threefold molecular symmetry axis. Ligand models are from one 
binding site, least-squares fitted onto the other binding sites. Figure from Eisen et al. (1997). 
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1.2.8.6 Biological Significance of Receptor-Binding Specificity  
The influenza viruses infect mainly respiratory tract cells of humans, horses and pigs as 
well as the intestinal epithelial cells of birds. The preference of influenza viruses for these 
cells is driven by the presence of specific receptors on the surface of the above cells, 
namely by an abundance of Siaα(2→6)Gal receptors on airway ephitelial cells in humans 
and Siaα(2→3)Gal receptors in avian intestines (Ha et al., 2003). This explains why avian 
viruses are specific for birds and human viruses for humans. Furthermore the presence of 
Siaα(2→3)Gal rich mucins in the human lungs (Couceiro et al., 1993) may impose 
additional selective pressure on the Siaα(2→6)Gal specific human influenza viruses and 
prevent binding of avian viruses. Similarly, Siaα(2→6)Gal rich equine fluids (Matrosovich 
et al., 1998) inhibit the human viruses in birds. The nature of the Sia linkage on cells, the 
action of these soluble inhibitors, or both, appear to be involved in selecting HAs with 
different linkage recognition specificity. 
Another factor dictating the influenza virus tissue tropism is the distribution of specific host 
proteases in the organism that are necessary for haemagglutin in activation. The protein is 
synthesized as a single-chain precursor (HA0) in the endoplasmic reticulum, where it is 
assembled as a trimer, glycosylated by the host glycosylation machinery in the Golgi 
apparatus and subsequently exported to the cell surface (Stevens et al., 2006). The HA0 is 
then cleaved by specific host proteases into HA1 and HA2, required for membrane fusion 
activity and infectivity (Skehel et al., 2000). The HA1 and HA2 polypeptide chains are 
usually separated by a single arginine residue, which is eliminated from the C terminus of 
HA1 by a virion-associated carboxypeptidase after cleavage (Garten et al., 1983). The 
cleavage may be mediated by the serine protease, tryptase Clara, produced by Clara cells of 
the bronchiolar epithelium (Kido et al., 1992). This enzyme shows recognition specificity 
for the sequence Q/E-X-R found at the cleavage sites of these HAs, which in conjunction 
with the narrow tissue distribution of the enzyme, restricts infection to the lung in 
mammals. In some HAs of the H5 and H7 subtypes there are polybasic sequences inserted 
at the cleavage site, separating the HA1 and HA2 polypeptide chains. In these cases, 
cleavage is intracellular and involves subtilisin-like enzymes that are active in the post-
translational processing of hormone and growth factor precursors. The furin recognition 
sequence R-X-R/K-R is a common feature of the inserted polybasic sequences. The wide 
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tissue distribution of furin-like enzymes and the efficiency of intracellular compared with 
extracellular cleavage appear to be related to the widespread systemic and virulent 
infections caused by the H5 and H7 viruses in birds and the localized outbreak in Hong 
Kong, in 1997, of severe respiratory infection by an H5 virus in humans (Skehel et al., 
2000). 
 
1.2.8.7 A Second Ligand Binding Site in HA 
A second receptor binding site was identified between subunits of the HA trimer in an 
interface where two HA1 domains and an HA2 domain make close contact and are known 
to dissociate when the molecule changes conformation to affect membrane fusion (Sauter et 
al., 1992b). A study of ligand binding to the second site suggested that a substituent that is 
larger than methyl is required at position 2 but that α(2→6)-sialyllactose does not fit. The 
affinity of α(2→3)-sialyllactose for the second site was estimated, by collecting X-ray 
diffraction data at various ligand concentrations, to be at least fourfold weaker than its 
affinity for the primary site. As the ligands from the second site can extend up toward the 
first site, it was suggested to construct a bridging ligand as an inhibitor of virus-cell binding 
that could take advantage of both sites. There is, however, no evidence that the second site 
is physiologically important (Sauter et al., 1992b). 
 
1.2.8.8 Membrane fusion as a second function of haemagglutinin 
The second function of the HA protein after adhesion to the Sias containing receptors on 
the cell surface is the fusion of the membrane of the endocytosed virus particle with the 
endosomal membrane. This promotes the release of the viral nucleocapsids into the 
cytoplasm (Lee et al., 2009; Stevens et al., 2007). The membrane fusion and viral entry is 
mediated by the HA2 subunit. Comparison of the HA1 and HA2
 
sequences among 
influenza virus subtypes reveals that the HA2
 
sequence is well conserved, suggesting a 
highly conserved membrane fusion mechanism (Guo et al., 2009). 
Following interaction with a receptor at the cell surface the virus is rapidly internalized via 
endocytosis. Viruses are trafficked through the endocytic pathway and, ultimately, reach a 
low-pH compartment (approx pH 5.5). At this pH, the viral fusion machinery is triggered 
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and HA undergoes an irreversible conformational change (Stevens et al., 2007). The change 
exposes the HA2 N-terminal fusion peptide, while preserving the structure of the HA1 
receptor binding domain. The exposed fusion peptide inserts into the cellular membrane, 
anchoring HA into both prefusion membranes; by its N terminal in the endosomal 
membrane and by its C terminal in the virus membrane (Skehel et al., 2000). 
The refolding process involves three steps. Initially the fusion peptide, which at neutral pH 
is buried in the trimer interface only 30 Å from the virus membrane, is extruded at fusion 
pH to the N-terminal tip of the 100 Å trimeric coiled coil that is newly formed at this low 
pH; its formation involves relocation of a short α helix and refolding of a segment of the 
extended chain into an α helix (Bullough et al., 1994). Then the middle of the long α  helix 
of native HA2 unfolds to form a reverse turn, and the second half of the long α  helix 
jackknifes back to lie antiparallel against the first half, also relocating C-terminal residues 
by >100 Å in relation to coiled-coil residues 76–105, which form a common structure in 
both conformations. Subsequently, residues 141–175, located C terminal to a small β sheet 
hairpin that accompanied the jackknifed α helix, appeared to be extruded from their 
compact association in HA2 to become a mostly extended structure that reached back up 
the central coiled-coil, packing antiparallel within the groove between adjacent α helices. 
The overall effect of this refolding is apparently to deliver the fusion peptide toward the 
target membrane and to bend the molecule in half so that the fusion peptide and the viral 
membrane anchor are near the same end of the rod-shaped molecule (Figure 1.19) (Skehel 
et al., 2000). 
 
 
 
 
 
 
 
 
Figure 1.19. Hypothetical mechanism for membrane fusion by virus glycoproteins. (a) The entire HA molecule. 
(b–d) The HA2 subnunits alone, in which the termini of the proteins come into relative proximity, thereby 
inducing membrane fusion. Figure from Skehel et al., (2000). 
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1.2.8.9 Haemagglutinin targeting influenza treatment approaches 
Currently, a number of steps in the influenza virus replication cycle have been identified for 
therapeutic intervention and drug design such as viral uncoating that can be inhibited by 
amantadine or the release of newly formed virus particles that can be blocked by 
neuraminidase inhibitors (De Clercq, 2006). Their effect is to reduce the yield of viable 
virus progeny, thus reducing morbidity, allowing time for the host immune system to mount 
an effective response and decreasing community transmission.  
Drugs oriented at haemaggutinin inhibition can truly block the entrance of the pathogen 
into the host cell and thus efficiently prevent the infection and/or spread of the virus. 
Monomeric Sias or methyl sialosides have been proposed as potential treatments (reviewed 
in Carlescu et al., 2008). However, due to rapid clearance by enzymatic breakdown and low 
binding affinity, high concentrations are required for effective inhibition and this results in 
unwanted toxicity issues. The main obstacle from a drug development perspective 
associated with all receptor-haemagglutinin interactions is their relatively low binding 
affinity. An effective HA antiviral must have improved binding compared to the natural 
receptor, and ideally be independent of Sia-linkage. The most potent HA inhibitors reported 
are based on polyvalent constructs (reviewed in Carlescu et al., 2008). Use of such 
polymers with multivalent ligands overcomes the problem of low affinity. The simplest 
form reported for influenza has been polymers such as polyglutamic acid with Sia bound 
through neuraminidase-resistant linkages (Stevens et al., 2007). Such compounds by 
mimicking the natural sialylated animal cell receptors bind to both HA and NA on the virus 
surface. Tests of Sia-polyacrylamide conjugates, also termed sialylglycopolymers in mouse 
models resulted in 100% survival rate with lethal doses of mouse-adapted, different 
influenza A strains (H3N2, H1N1) (De Clercq, 2006). This suggests such compounds as 
potentially valuable broad spectrum reagents. 
Another approach focused on the blocking of viral attachment has recently been studied. In 
the system investigated by Malakhov et al., (2006) the haemagglutinin binding was 
inhibited by the removal of the receptor from the susceptible cells. A recombinant fusion 
protein composed of the sialidase (neuraminidase) catalytic domain derived from 
Actinomyces viscosus fused with a cell-surface-anchoring sequence was used to remove the 
influenza-virus receptors from the airway epithelium. A sialidase fusion construct, DAS181 
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(Fludase), was shown to effectively cleave the receptors used by both human and avian 
influenza viruses. Significant in vivo efficacy of the sialidase fusion construct was noted in 
both prophylactic and therapeutic approaches (Malakhov et al., 2006). 
It was recently demonstrated that a 20-amino-acid peptide (EB, for entry blocker) derived 
from the signal sequence of fibroblast growth factor 4 exhibits broad-spectrum antiviral 
activity against influenza viruses including the H5N1 subtype in vitro. The EB peptide was 
protective in vivo, even when administered postinfection. Mechanistically, the EB peptide 
inhibits the attachment to the cellular receptor, preventing infection (Jones et al., 2006). 
Further studies demonstrated that the EB peptide specifically binds to the viral 
haemagglutinin protein. The mechanism of action of this peptide needs further investigation 
which may confer benefit by a completely new approach to antiviral therapy. 
The entry of influenza virus to the host cell, driven by haemagglutinin molecules on the 
surface of the virion, is dependent on the conformational change of the HA. An inhibitor of 
viral growth, (Deshpande et al., 2001) BMY-27709 (4-amino-5-chloro-2-hydroxy-N-
9AαH-octahydro-6β-methyl-2H-quinolizin-2α-benzamide), was found to prevent the low 
pH-induced conformational rearrangement of HA into its fusogenic state (Luo et al., 1996; 
Luo et al., 1997; Deshpande et al., 2001). This was found to be active against all H1 and 
H2 subtype viruses; it is however, inefficient as of yet against H3 subtype viruses (Luo et 
al., 1997). 
 
1.2.8.10 Summary of the haemagglutinin from influenza virus 
Haemagglutin’s HA1 domain containing the receptor binding site is relatively small and 
thus is useful for large scale production and application on various analytical platforms. 
The specificity of the HA towards either α(2→3) and α(2→6) linked Sia can be altered by 
changing only three amino acids (in H3 subtype) while the overall structure remains the 
same. This would be clearly advantageous for production of proteins with different 
specificities where the expression, purification and other procedures are the same.  The 
specificity of such proteins towards terminal Sia may be explored for development of 
sialylated glycan analysis method. 
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1.2.8.11  SiaP protein of Haemophilus influenzae 
The bacterial pathogen, Haemophilus influenzae, is exclusively adapted to infect or 
colonize humans. Strains can be encapsulated or nonencapsulated (nontypeable). 
Nontypeable Haemophilus influenzae (NTHi) is a frequent colonizer of the nasopharynx. 
When the airway is compromised, NTHi can cause local infections such as otitis media 
(Leibovitz et al., 2003), chronic bronchitis and pneumonia (Murphy, 2003). 
The bacterium evades the innate immune response of the host by sialylation of its 
lipooligosaccharides (LOS) (Mandrell et al., 1992) and thus appears as self for the host’s 
defence system. The acceptors for Sia are LOS terminal lactose, N-acetyllactosamine, and 
possibly N-acetylgalactosamine (Mansson et al., 2001; Jones et al., 2002). It was also 
found that Sia can be utilized by H. influenzae as a carbon and nitrogen source (Vimr et al., 
2000). 
Interestingly, although the Sia is crucial for the pathogen survival inside the host, the NTHi 
is incapable of synthesizing Sia, and thus requires an exogenous source of Sia (Bouchet et 
al., 2003). It was found that Sia acquisition is mediated via a tripartite ATP-independent 
periplasmic (TRAP) transporter driven by an electrochemical gradient (Muller et al., 2006). 
TRAP transporters consist of three components: an extracytoplasmic solute receptor (ESR) 
and two distinct integral membrane components of unequal size which are sometimes fused 
(Kelly et al., 2001). In NTHi the two integral membrane components are fused and known 
as SiaT or SiaQM and the extracytoplasmic solute receptor is SiaP (Johnston et al., 2007) 
(Figure 1.20). The ESR protein (often also known as a periplasmic-binding protein) 
increases the uptake affinity of the transport system by binding Sia and delivering it to the 
inner membrane transporter (Allen et al., 2005). Such a high-affinity Sia uptake system 
may be important for the bacteria in their normal physiological environment. 
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Figure 1.20. Overview of the Sia utilization in Haemophilus influenzae. Sia gets into the periplasm via NanC 
pores (Severi et al., 2007) and is captured by SiaP which delivers it to the inner membrane SiaQM transporter. 
Sia is then transported into the cytoplasm and utilized either as a carbon and nitrogen source or for LOS 
sialylation. Sialylated LOS is later transported to the outer membrane. Dashed arrows indicate the path of Sia 
in the bacterium and solid blue lines indicate the cycle of the SiaP protein. 
 
1.2.8.12  Structure of the SiaP 
Structurally SiaP is a monomeric protein with a molecular weight of about 37 kDa. 
(Johnston et al., 2007). The 329 amino acid polypeptide secreted to the periplasmic space 
and during translocation through the inner membrane a 23 amino acid leader peptide is 
cleaved off (Johnston et al., 2007). SiaP has two α/β domains connected by three segments 
of the polypeptide and separated by a large cleft (Figure 1.21) (Muller et al., 2006). 
Domain I, encompassing residues 1-124 and 213-252, contains a 5-stranded β-sheet against 
which are packed six α-helices. The strand order is β2-β1-β3-β10-β4, with strand β10 
running anti-parallel to the other four strands (Figure 1.21 and Figure 1.22) (Muller et al., 
2006). Domain II contains residues 125-212 and 253-306 and has a 6-stranded β-sheet 
surrounded by 3 α-helices (Figure 1.21 and Figure 1.22) (Muller et al., 2006). Here the 
sheet topology is β7-β6-β8-β5-β9-β11 with strand β5 running anti-parallel to the other 
strands. Residues 280-306 at the C terminus of the molecule form a pair of α-helices that 
fold across the base of the molecule and pack against both domains. A striking feature of 
the structure is the long helix, α9, which spans the breadth of the molecule (Muller et al., 
2006). 
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1.2.8.13   SiaP ligand bindig site 
The binding of Neu5Ac, a natural ligand, by the SiaP protein is initiated through direct 
interactions between the highly charged carboxylate at the C1 position of the sugar with 
positively charged residues R127 and R147 (Figure 1.23) (Johnston et al., 2007). The 
primary role of R127 is electrostatic stabilization of the charge on the sugar. R127 δ-
guanido interacts with both the C1 carboxyl and the C2 hydroxyl of the sugar (forming a 
salt bridge). E186 interacts with R127 and appears to optimize its position. The guanidino 
group of R147 seems to be key to the binding interaction, both in terms of its charge 
interaction with the C1-carboxyl group as well as in the orientation of the ligand (Johnston 
et al., 2007). The orientation is also governed by an interaction between the glycol group 
hydroxyls and the carboxyl of E67. This interaction also induces the ligand specificity of 
Figure 1.21. Overall structure of the SiaP. 
Figure from Muller et al. (2006). 
 
Figure 1.22. Schematic diagram of the topology 
of SiaP. The N-terminal domain is in light gray, 
and the C-terminal domain is in black. Features 
that distinguish SiaP are in dark gray. Figure 
from Muller et al. (2006). 
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the binding site. N187 makes direct interactions with Neu5Ac at the C1 carboxyl and the 
C2 hydroxyl. D49 interacts with O7 and R70 probably stabilizing the position of the 
former. N10 makes two interactions with the acetyl oxygen, from the side chain and a water 
mediated interaction by the main chain amide. The N10 interactions are not crucial for the 
binding. Additionally Q214, interacts with the ligand through water molecules (Johnston et 
al., 2007).  
 
Quantitative comparison of the open and closed structures reveals a rotation of 28.7-34.7° 
about a hinge that runs close to the peptide bonds connecting residues Thr-127-Arg-128, 
Ile-211—Leu-212, and Glu-254—Lys-255 (Muller et al., 2006; Johnston et al., 2007). 
During the rotation about the hinge region the SiaP protein changes its conformation from 
“open” to “closed” (Figure 1.24).  
 
 
Figure 1.23. Structure of SiaP and the binding site. A ribbon diagram showing SiaP with Neu5Ac bound. 
The residues marked in red show no complementation; the ones in maroon show partial complementation, 
and those in green show complete complementation. Neu5Ac is shown as a ball-and-stick model. Figure 
from Johnston et al. (2007). 
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Figure 1.24. SiaP protein in an "open" (A) form before Neu5Ac accommodation and a "closed" (B) conformation after 
Neu5Ac accommodation. Image created using Protein Workshop software with PDB file 3b50 (Johnston et al. 2007). 
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The ligand is almost completely buried, with only 32 Å2 of its 435-Å2 surface area 
accessible to the solvent (Figure 1.25) (Muller et al., 2006), which probably influences the 
affinity. The affinity of SiaP for Neu5Ac was determined using isothermal titration 
calorimetry (ITC). The Kd of 28 nM was reported, which indicates a high affinity 
interaction between SiaP and Neu5Ac (Johnston et al., 2007).  
 
 
 
 
 
 
The carboxylate and N-acetyl groups of Neu5Ac are essential for high affinity binding to 
SiaP. A homologous ligand lacking the carboxylate group binds to SiaP with 2000-fold 
lower affinity then Neu5Ac (Muller et al., 2006) which proves the importance of it. 
However, 4-acetylaminocyclohexane carboxylic acid, containing both a carboxylate and an 
N-acetyl group in analogous positions to the natural ligand Neu5Ac and also adopting a 
chair conformation similar to Neu5Ac, does not bind to SiaP (Muller et al., 2006). This 
suggests that the carboxylate and N-acetyl groups are essential, but not sufficient, for the 
high affinity binding of Neu5Ac to SiaP. 
 
1.2.8.14   SiaP homologues 
The residues crucial for carboxylate coordination in SiaP, namely R127, R147 and N187 
are present in homologous sequences found in operons with genes for sialometabolism 
(Muller et al., 2006) (Figure 1.26). High conservation is also detected among residues D49 
and E67, responsible for glycerol moiety binding. The N-acetyl binding N10 residue is not 
conserved, being replaced by glutamine, valine, or threonine in the homologs of SiaP.  
Figure 1.25. Surface representation of the 
Neu5Ac2en (close homolog of Neu5Ac) structure 
viewed looking down into the binding cleft. The 
ligand is in blue, and domain I is on the left, whereas 
domain II is on the right. Figure from Muller et al. 
(2006). 
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Figure 1.26. Multiple sequence alignment of amino acid sequences of H. influenzae SiaP and 6 related TRAP 
ESR proteins that are likely to form components of a Sia transporter. The genes for all seven of these 
sequences are encoded in operons encoding sialometabolic genes. 
 
In most cases the Sia specificity is unconfirmed; however, initial studies on the SiaP 
homologue from V. cholerae indicates that it binds Neu5Ac with an affinity of about 300 
nM (Johnston et al., 2007). Furthermore, a TRAP ESR from F. nucleatum subsp. vincentii 
shares high homology with SiaP (Kapatral et al., 2002, 2003; Johnston et al., 2007). The 
Sia binding by the protein has not been characterized yet. However, the fact that the 
organism appears to lack a homolog of Neu5Ac synthase, yet incorporates Sia into its 
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lipopolysaccharide (LPS) (Kapatral et al., 2002, 2003; Johnston et al., 2007), indicates that 
it has a Sia acquisition system most probably homologous to the one in H. influenzae. 
Not homologous in terms of overall amino acid sequence, although bearing a similar 
feature of the ligand binding site, are some other Sia-specific proteins. A conserved arginine 
is a common theme among various proteins of diverse structures and biological functions 
that bind Sia. For example, enzymes that cleave at the terminal Sia of the glycans, 
neuraminidases, contain a characteristic arginine triad that coordinates the carboxylate 
group (Crennell et al., 1993; Taylor, 1996; Muller et al., 2006). SiaP is similar in using a 
triad of residues to coordinate the carboxylate group but achieves this using two arginine 
residues and one asparagine, a conserved structural motif that appears to be important for 
high affinity binding (Muller et al., 2006). 
 
1.2.8.15   Summary of the SiaP protein 
The relatively small size of the SiaP protein would be advantageous for its production and 
application for Sia detection. Free Sia specificity would enable development of analytical 
methods for free Sia analysis. The SiaP protein C-terminus is located on exactly the 
opposite side of the protein than the sugar binding site. This would be beneficial for 
applications requiring utilization of the protein in immobilised form, as a desired protein 
orientation would be achieved by specific C-terminal tagging. 
 
1.3    Aims 
The aim of this study was to develop a novel method for Sia detection and quantification 
based on Sia-binding proteins. A method, that would be specific, precise, sensitive, reliable, 
quick, uncomplicated and also inexpensive. As a cost effective way of the protein 
production prokaryotic expression system was selected. Additionally, the goals involved 
optimization of protein expression and purification, the methodology development for Sia-
free protein production and orientated immobilisation of the protein on a surface of the 
analytical device. The produced Sia-specific protein was envisaged to be characterise using 
various analytical platforms including ELLA, MS and surface plasmon resonance, and 
subsequently applied for Sia detection and quantification using these platforms. 
  
 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial Strains, Primer Sequences and Plasmids 
Bacterial strains, primer sequences and plasmids used in this thesis are presented in Table 
2.1, Table 2.2 and Table 2.3 respectively. The ha1 gene from pI.17 plasmid was cloned into 
the pCR2.1 derived pPCRHA1 plasmid and then subcloned into pJS102 expression vector 
(pLecB3 derived). In order to promote soluble production of the HA1 protein the ha1 gene 
was subsequently subcloned into the pJS103 (pQE50-PelB derived) and the pJS104 
(pMALp2E derived) plasmids. For the SiaP protein production the siaP gene was obtained 
on the pGTY2 plasmid and then the plasmid was modified by adding a 6xHis tag, creating 
the pJS201 plasmid. The pJS201 plasmid was subsequently modified by adding a C-
terminal 6xLys tag (pJS202 and pJS2021), Strep2 tag (pJS203 and pJS2031) and a (Gly Gly 
Gly Ser)2  linker (pJS2011, pJS2021 and pJS2031). 
 
Table 2.1. E. coli strains used in this thesis. 
Strain Genotype Features Source 
BL21 F′ dcm ompT hsdS(rB- mB-) gal Protease deficient Stratagene 
JM109 
F′ (traD36, proAB+ lacIq, D(lacZ)M15) endA1 
recA1 hsdR17(rk-, mk+) mcrA supE44 l- gyrA96 
relA1 D∆(lacproAB) thi-1 
General cloning strain Sigma 
KRX 
[F´, traD36, ∆ompP, proA+B+, lacIq, 
∆(lacZ)M15] ∆ompT, endA1, recA1, gyrA96 
(Nalr), thi-1, hsdR17 (rK–, mK+), e14– (McrA–), 
relA1, supE44, ∆(lac-proAB), ∆(rhaBAD)::T7 
RNA polymerase 
Cloning and expression 
strain. Provides tight 
control over expression. 
Promega 
Rossetta F′ ompT hsdSB(RB- mB-) gal dcm pRARE2 
Expression strain for 
eukaryotic proteins. 
Contains pRARE 
plasmid with genes for 
rare E. coli tRNAs. 
Chloramphenicol 
resistant. 
Novagen 
XL-10 
Gold 
Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F′ proAB lacIqZ ∆M15 Tn10 (Tetr) Amy Camr] 
General cloning and 
expression strain. Stratagene 
 
 
 
 
 
 
 50 
Table 2.2. Primers used in this thesis. 
Name Sequence (5′ – 3′) Tm (C°) 
HA1F1 CCATGGCAATGCAAAAACTTCCCGGAAATGACAACAGC 67 
HA1R1 AGATCTAGTTTGTTTCTCTGGTACATTCCGC 60 
1HA1NotI ATCGGCGGCCGCCATGCAAAAACTTCCCGGAAATGACAACAGC 72 
R1HA1BglII GAAGATCTAGTTTGTTTCTCTGGTACATTCCGC 62 
HA1KpnIF1 GACAGGTACCGATGCAAAAACTTCCCGGAAATGACAACAGC 69 
HA1BamHIR ACTGGATCCTTAAGTTTGTTTCTCTGGTACATTCCGC 64 
F1SiaPNdeI GGGAATTCCATATGATGAAATTGACAAAACTTTTCC 60 
R1SiaPXhoI CCGCTCGAGTGGATTGATTGCTTCAATTTGTTTTAAAGC 64 
FSiaLYS CTCCTCCTCTGAGATCCGGCTGCTAACAAAGCCC 69 
RSiaPLYS GAGGAGGAGGTGGTGGTGGTGGTGGTGCTCGAG 72 
FSiaPCS CCACAATTCGAGAAATGAGATCCGGCTGCTAACAAAGCCC 69 
RSiaPCS GTGAGACCAGTTACTGTGGTGGTGGTGGTGGTGCTCGAG 72 
JS2011F GGCGGAGGAAGTCTCGAGCACCACCACCACCACCAC 74 
JS2012R ACTTCCGCCACCTGGATTGATTGCTTCAATTTGTTTTA 63 
 
Table 2.3. Plasmids used in this thesis 
 Name Description Source 
pI.17 pUC-based plasmid carrying the gene for hemagglutinin. Johnson et al., (2000) 
pCR2.1 Linearized vector for TA cloning. AmpR, KanR, LacZα. Invitrogen 
pPCRHA1 pCR2.1 vector with ha1 gene This study 
pLecB3 pKK233-3 (Amersham) derived plasmid for LecB expression with 6His-tag. AmpR. Ptac. 
Creavin et al, (in 
prep) 
pJS102 pLecB3 derived, lecB replaced with ha1. AmpR. Ptac This study 
pQE60-PelB 
pQE60 (Qiagen) derived plasmid with PelB signal sequence for 
periplasmic expression of C-terminally 6His-tagged proteins. 
AmpR. T5 promoter. 
Ryan (Ph.D Thesis) 
pJS103 pQE60-PelB derived for HA1 periplasmic expression with 6His-tag. AmpR. T5 promoter. This study 
pMALp2E Vector containing malE gene for periplasmic expression of N-terminally MBP tagged proteins. AmpR. Ptac. NEB 
pMALp2Ef pMALp2E (NEB) derived with random ~1kb DNA fragment cloned in EcoRI site. AmpR. Ptac. This study 
pJS104 pMALp2E (NEB) derived for MBP fused HA1 periplasmic 
expression. AmpR. Ptac. This study 
pGTY3 pET21b (Novagen) derived plasmid containing siaP gene. Severi et al., (2005) 
pJS201 pGTY3 derived plasmid for C-terminally 6His-tagged SiaP 
expression. T7 promoter. AmpR. This study 
pJS201 derived plasmids:  
pJS202 Additional 6Lys-tag at C-terminus This study 
pJS203 Additional Strep2-tag at C-terminus This study 
pJS2011 (Gly Gly Gly Ser)2 linker introduced between SiaP and C-terminal 6His-tag This study 
pJS2021 (Gly Gly Gly Ser)2 linker introduced between SiaP and C-terminal 6His-tag. Additional 6Lys-tag at C-terminus This study 
pJS2031 (Gly Gly Gly Ser)2 linker introduced between SiaP and C-terminal 6His-tag. Additional Strep2-tag at C-terminus This study 
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2.1.2 DNA molecular marker and protein molecular weight markers 
• 1 Kb Molecular Marker (Invitrogen).  
 
 
 
 
 
 
 
 
 
 
 
 
• Protein molecular weight markers 
o Sigma Marker Wide Range (M.W. 6,500-200,000), S8445 
Constituent proteins: 
Myosin (porcine heart) 205 kDa  
β-Galactosidase (E. coli) 116 kDa  
Phosphorylase B (rabbit muscle) 97 kDa  
Glutamic dehydrogenase (bovine liver) 55 kDa 
Albumin (bovine serum) 66 kDa  
Ovalbumin  (chicken egg) 45 kDa  
Glyceraldehyde-3-phosphate dehydrogenase (rabbit muscle) 36 kDa 
Carbonic anhydrase (bovine erythrocytes) 29 kDa  
Trypsinogen (bovine pancreas) 24 kDa  
Trypsin inhibitor (soybean) 20 kDa  
α-Lactalbumin (bovine milk) 14.2 kDa 
Aprotinin (bovine lung) 6.5 kDa 
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o NEB ColorPlus Prestained Protein Marker, Broad Range (7-175 kDa), 
P7709L 
Constituent proteins: 
MBP-β-galactosidase (E. coli) 175 kDa 
MBP-truncated-β-galactosidase (E. coli) 80 kDa 
MBP-CBDE (E. coli) 58 kDa 
CBD-Mxe Intein-2CBDE (E. coli) 46 kDa 
CBD-Mxe (E. coli) 30 kDa 
CBD (E. coli) 23 kDa 
Lysozyme (chicken egg white) 17 kDa 
Aprotein (bovine lung) 7 kDa 
 
 
 
 
 
 
 
 
 
 
o Bio-Rad Precision Plus Protein All Blue Standard (161-0373): 
Constituent proteins: 
Myosin (rabbit muscle) 200 kDa 
β -Galactosidase (E. coli) 116 kDa 
Phosphorylase b (rabbit muscle) 97 kDa 
BSA 66 kDa 
Ovoalbumin (hen egg white) 45 kDa 
Carbonic anhydrase (bovine) 31 kDa 
Tripsin inhibitor (soyabean) 21 kDa 
Lysozyme (hen egg white) 14 kDa 
Aprotein (bovine pancreas) 6.5 kDa 
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2.1.3 Media, Solutions and Buffers 
Tryptone and Yeast extract were from Scharlau Chemie. Other chemicals were from Sigma 
Chemicals Co. Ltd and BDH Chemicals Ltd. All chemicals were Analar® grade. 
 
• Luria Bertani (LB) Broth  
Used for routine culturing of E. coli. 
  Tryptone    10 g 
  Yeast Extract    5 g 
  Sodium Chloride   10 g 
NaOH was used to adjust to pH 7.0 and the volume brought to 1 L with distilled water 
(dH2O). The solution was then sterilised by autoclaving at 121°C and 1.5 bar for 21 min. 
This medium was used for culturing of bacteria. 
 
• PBS Buffer 
  NaCl     8 g 
KCl     0.2 g 
Na2HPO4      1.44 g 
    KH2PO4    0.24 g 
Dissolved in 800 ml of distilled H2O.  Adjusted the pH to 7.4 with HCl. Added H2O to 1 l. 
Sterilized by autoclaving. 
 
 
• TE Buffer 
Tris – HCl    10 mM 
Na2-EDTA    1 mM 
pH     8.0 
 
• Solutions for the 1,2,3 Plasmid Preparation Method 
Solution 1: 
Glucose (0.5 M)   1 ml  
  EDTA (0.1 M)   1 ml 
  Tris – HCl (1 M)   0.25 ml  
  dH2O     7.75 ml 
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Solution 2: 
  NaOH (1 M)    2 ml  
  SDS (10%)    1 ml 
  dH2O     7 ml 
Solution 3: 
  Potassium Acetate   3 M 
  pH     4.8 
To 60 ml of 5 M potassium acetate 11.5 ml of glacial acetic acid was added and 28.5 ml of 
dH2O. The resulting solution was 3 M with respect to potassium and 5 M with respect to 
acetate. 
 
• 50X Tris Acetate EDTA (TAE) Buffer 
EDTA (0.5 M)   100 ml 
Glacial Acetic Acid   57.1 ml 
Tris – HCl    242 g 
pH     8.0  
dH2O     to 1 l 
The solution was diluted to 1x with dH2O before use. 
 
• Gel Loading Dye (6X) 
Bromophenol Blue   0.25% 
Xylene Cyanol   0.25% 
Ficoll (Type 400)   15% 
Made in dH2O and stored at 4°C. 
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• TFB1 Buffer for Competent Cells 
RbCl     100 mM 
MnCl2     50 mM  
Potassium Acetate   30 mM 
CaCl2     10 mM 
Glycerol    15% v/v 
pH     5.8 
The pH of the solution was adjusted with HCl before the MnCl2 was added. The solution 
was then sterilised through a 0.2 µm sterile filter and stored at 4oC. 
 
 
• TFB2 Buffer for Competent Cells 
MOPS     10 mM 
RbCl     10 mM 
CaCl2     75 mM 
Glycerol    15% v/v 
pH     6.8 
The pH of the solution was adjusted with KOH. The solution was then sterilised through a 
0.2 µm sterile filter and stored at 4oC. 
 
• Lysis Buffer: 
Na2HPO4    6.9 g 
NaCl     17.54 g 
Imidazole    0.68 g 
Adjusted to pH = 8.0 with NaOH and the volume brought to 1 L with dH2O. The solution 
was then sterilised by autoclaving and stored at room temperature. Before use the solution 
was filtered through a 0.45 µm filter. 
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• Running Buffer for SDS-PAGE (5x) 
Trizma Base    15 g 
Glycine    72 g 
SDS     5 g 
dH2O     to 1000 ml 
The solution was stored at 4°C. 
 
• Sample Buffer for SDS-PAGE (5x) 
Tris-HCl pH 6.8 [0.5 M]  1.25 ml 
Glycerol    5 ml 
SDS [10% w/v]    2 ml 
Bromophenol blue [0.5% w/v] 0.25 ml 
Beta-Mercaptoethanol  0.5 ml 
• Coomassie Blue stain for SDS-PAGE 
Coomassie Blue   1 g 
Methanol    180 ml 
dH2O     180 ml 
Acetic Acid    40 ml 
 
• Destain Solution for SDS-PAGE 
Methanol    180 ml 
dH2O     180 ml 
Acetic Acid    40 ml 
 
• Stop Solution: 
Trizma base    50 g 
Acetic Acid    2.5% (v/v) 
dH2O     up to 1000 ml 
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• Transfer Buffer for Western Blots 
Tris-HCl    25 mM 
Glycine    192 mM 
Methanol    20% (v/v) 
 
• Tris Buffered Saline (TBS) – Tween (10x) 
Tris-HCl    250 mM 
NaCl     1.5 M 
KCl     30 mM 
Tween-20 1% (added from 20% (v/v) stock) 
pH     8.0 
 
• Blocking Buffer for Western Blots 
Tris-HCl    25 mM 
NaCl     150 mM 
KCl     3 mM 
Tween-20 0.1% (added from 20% (v/v) stock) 
Milk powder    5% (w/v) 
pH     8.0 
 
• TBST: 
Tris-HCl    20 mM 
NaCl     150 mM 
Triton X-100    0.1% (v/v) 
CaCl2     1 mM 
MnCl2     1 mM 
MgCl2     1 mM 
pH = 7.6 
The buffer was prepared as a 5x stock (without Triton X-100 which was added directly 
before use) and kept at 4ºC. The MnCl2 was added after the pH was brought to 7.6 with 
HCl. 
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• TMB solution: 
Two mg of TMB (3,3´,5,5´-tetramethyl benzidine) were dissolved in 200 µl of DMSO and 
added to 9.8 ml of 50 mM citrate buffer pH 5.5. The solution was mixed thoroughly and 3 
µl of H2O2 were added directly before use. The fresh solution was prepared before each 
use. 
 
• HBS buffer: 
HEPES    10 mM 
EDTA     3 mM 
NaCl     150 mM 
Tween 20 0.005% (added from 20% (v/v) stock) 
pH 7.4 
Before Tween 20 addition the solution was filtered through a 0.2 µm filter. The fresh 
solution was prepared before each use. 
 
 
2.2 Methods 
2.2.1 Polymerase chain reaction (PCR) 
This technique was used to amplify genes in order to clone them into plasmids. 
 
• Standard PCR Reaction Mixtures 
o With Phusion DNA Polymerase (Sigma): 
dNTP [10 mM] mix       1µl 
5x Phusion Reaction Buffer containing 7.5 mM MgCl2  10 µl 
Template DNA (varying concentration)    1 µl 
Forward primer [10 µM]      1.5 µl 
Reverse primer [10 µM]      1.5 µl 
Phusion DNA polymerase [2 u/ µl]     0.3 µl 
Sterile dH2O         to 50 µl 
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o With Red Taq Polymerase (Sigma): 
dNTP [10mM] mix       1 µl 
10x Red Taq PCR Buffer containing 500mM MgCl2  5 µl 
Forward primer [10 µM]      1 µl 
Reverse primer [10 µM]      1µl 
Red Taq DNA polymerase [5 u/µl]     1 µl 
Sterile dH2O         to 50 µl 
 
• PCR Program Cycles 
o with Phusion DNA Polymerase: 
Stage 1:  Step 1: 95°C for 10 sec 
Stage 2:  Step 1: 95°C for 10 sec 
   Step 2: Annealing Temperature for 15 sec 
Step 3: 72°C for 0.5 minute for every Kb to be synthesized 
 Stage 2 was usually repeated for 30 cycles 
Stage 3:  Step 1: 72°C for 10 minutes. 
o with Red Taq DNA Polymerase: 
Stage 1:  Step 1: 95°C for 10 minutes 
Stage 2:  Step 1: 95°C for 1 minute 
   Step 2: Annealing Temperature for 30 sec 
Step 3: 72°C for 1 minute for every Kb to be synthesized. 
 Stage 2 was usually repeated for 30 cycles 
Stage 3:  Step 1: 72°C for 10 minutes. 
 
2.2.2 Plasmid Preparation by the 1,2,3 Method 
This method was used for the isolation of plasmids that were then used for analysis by 
agarose gel electrophoresis and restriction analysis. For ligation the gel extraction kit (RBC 
Bioscience). The principle of this method is selective alkaline denaturation of high 
molecular mass chromosomal DNA while covalently closed circular DNA remains double-
stranded (Birnboim et al., 1979). A 1.5 ml aliquot of a bacterial culture grown in selective 
media was pelleted by centrifugation at 12,000xg in a microfuge. The supernatant was 
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removed and the pellet was resuspended in 200 µl of solution 1 (section 2.3) by vortexing. 
Then 200 µl of solution 2 was added and mixed by inversion for several seconds. The tube 
was left at room temperature for 5 min. Then 200 µl of solution 3 was added and the tube 
was gently mixed by inversion for several seconds. The tube was then left for 10 min at 
room temperature. A clot of chromosomal DNA formed and was pelleted by centrifugation 
at 12,000xg for 10 min in a microfuge. The supernatant was transferred to a fresh tube and 
450 µl of phenol: chloroform: isoamylalcohol (25:24:1) was added and mixed by vortexing. 
After centrifugation at 12,000xg for 5 min the upper, aqueous layer was carefully 
transferred to a fresh tube. An equal volume of isopropanol was added. After mixing by 
inversion for several seconds, the tube was centrifuged at 12,000xg for 30 min to pellet the 
plasmid DNA. The isopropanol was removed and the pellet washed with 750 µl 70% (v/v) 
ethanol and centrifuged at 12,000xg for 4 min. The ethanol was removed and the plasmid 
DNA was dried in a vacuum dryer for 1 minute. The plasmid DNA was resuspended in 50 
µl of TE buffer and stored at 4oC. 
 
2.2.3 Agarose Gel Electrophoresis for DNA Characterization 
DNA was analysed by separation on agarose gels in a horizontal gel apparatus. Gels were 
prepared by dissolving agarose in 1xTAE buffer to the required concentration (typically 0.7 
– 1.2% [w/v]) and heating in the microwave oven until the agarose was fully melted. The 
1xTAE buffer was also used as the running buffer. A tracker dye (1kb Molecular Marker 
[Invitrogen]) was incorporated into DNA samples (2 µl to 7 µl of the sample) to facilitate 
loading. Gels were frequently run at 140 V for 20 minutes. Gels were stained by immersing 
in a bath with ethidium bromide for 10-20 minutes. Gels were then visualized on a UV 
transilluminator and photographed using a UV image analyser. 
 
2.2.4 Ethidium Bromide Stain 
A 10 mg/ml stock solution in dH2O was stored at 4ºC in the dark. For the staining of 
agarose gels, 100 µl of the stock solution was mixed with 1 l of dH2O. The staining solution 
was kept in a plastic tray and covered to protect against light. Used ethidium bromide stain 
was collected and disposed of according to manufacturer instruction. 
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2.2.5 Isolation of DNA from Agarose Gels 
The DNA sample was separated using agarose gel electrophoresis on a 0.7 % agarose gel 
containing SYBR Safe™ DNA gel stain (Invitrogen). HiYield Gel/PCR DNA Fragment 
Extraction Kit (RBC Bioscience) was used to extract relevant DNA fragments from the gel 
according to manufacturer’s instructions. 
 
2.2.6 DNA Restriction 
This technique was used on DNA after PCR and plasmid DNA to clone the PCR product 
into a plasmid or in order to degrade the template DNA after site directed mutagenesis (use 
of KpnI enzyme restricting methylated DNA). The enzymes and buffers were from New 
England Biolabs (NEB) and were used according to manufacturer’s instruction. 
 
2.2.7 Ligation 
This technique was used to ligate DNA fragments after DNA restriction with restriction 
enzymes. The DNA ligase and buffer were from NEB and were used according to 
manufacturer’s instructions. Typical ligation mix: 
Fresh PCR product/ DNA restriction fragment 2 µl 
Vector DNA      2 µl 
10X Ligation Buffer     1 µl     
T4 DNA Ligase     1 µl 
Sterile dH2O      to 10 µl 
The reaction was performed at room temperature overnight. 
 
2.2.8 TA Cloning of PCR Products 
Polymerase chain reaction (PCR) products, after amplification with Red Taq polymerase 
(Sigma), were cloned using the TA Cloning Kit from Invitrogen into the pCR2.1 vector 
supplied. The diagram below shows the concept behind the TA Cloning method (Figure 
2.1). 
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This method is based on the fact that thermostable polymerases like Red Taq lacks 3′ – 5′ 
exonuclease activity and because of that they leave 3′ A-overhangs. PCR products 
generated by Taq polymerases are subsequently ligated with the pCR2.1 vector which is 
linearized with 3′ T-overhangs. The ligation mix consisted of the following: 
Fresh PCR product   1µl 
pCR2.1 Vector (25 ng/ µl)  2 µl 
10x Ligation Buffer   1 µl 
Sterile dH2O    5 µl 
T4 DNA Ligase   1 µl 
The reaction was performed at room temperature overnight. The reaction mix was then 
used to transform the competent cells. 
 
2.2.9 Preparation of Competent Cells by RbCl Treatment 
A glycerol stock of an E. coli strain was streaked on LB agar and incubated at 37oC 
overnight. A 10 ml aliquot of LB broth was inoculated with a single colony from this fresh 
plate and incubated at 37oC overnight. One ml of the overnight culture was added to 250 ml 
of LB broth in a 500 ml flask and incubated at 37oC and 220 rpm until an OD600 of 0.5 was 
reached. The flask was then placed on ice for 10 min. The culture was transferred to a 
sterile, chilled 250 ml centrifuge tube and centrifuged at 3,500 rpm (Beckman TA-10-250 
Rotor) at 4oC for 5 min. The cell pellet was carefully resuspended in 75 ml of ice cold 
TFB1 buffer, placed on ice for 90 min and centrifuged as before. The cell pellet was gently 
resuspended in 10 ml of ice cold TFB2 buffer. The cell suspension was dispensed into 0.6 
ml aliquots in microfuge tubes, flash frozen and stored at -80oC. 
Figure 2.1. Principle of TA Cloning. 
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2.2.10 Transformation of Competent Cells Prepared by RbCl 
Treatment 
A 2 µl aliquot of a ligation mixture was added to 200 µl of competent cells that were 
thawed on ice and mixed by gentle flicking of the tube. The cells were then kept on ice for 
30 min and then heat shocked at 42oC for 60 s and immediately placed back on ice for 5 
min. An 800 µl aliquot of LB broth was added to the cells and then incubated in a 37oC 
water bath for 60 min. A 200 µl aliquot of the resulting transformation mixture was then 
aseptically spread on the LB agar plates containing an appropriate antibiotic and incubated 
at 37oC overnight. 
2.2.11 Determining cell efficiency 
Competent cell efficiency is defined in terms of the number of colony forming units (cfu) 
obtained per µg of transforming plasmid DNA. A 0.25 µg/µl stock of pBR322 plasmid 
DNA was diluted to 250 pg/µl, 25 pg/µl and 2.5 pg/µl. Then 2 µl of each of the dilutions 
(and a negative control – no DNA) were used to transform competent cells as described 
above. The cell efficiency was calculated from the number of colonies obtained, taking into 
account the dilution factor and the fraction of culture transferred to the spread plate. 
 
2.2.12 Bacterial storage 
Bacterial strains were stored as 40 % (v/v) glycerol stocks. A 750 µl aliquot of an overnight 
culture (37ºC in LB broth) was mixed with 750 µl of sterile 80 % (v/v) glycerol in a 
microfuge tube. If the bacterial strains contained plasmids, the selective antibiotic was 
included in the culture.  Duplicate stocks were stored at -20oC and -70oC. Working stocks 
streaked on LB agar plates, containing antibiotics where appropriate, were stored at 4oC. 
 
2.2.13 Antibiotic Preparation 
Antibiotics used were from Sigma. Antibiotic stocks were prepared to a concentration of 
100 mg/ml and stored at -20°C. 
• Ampicillin was prepared in dH2O and used at a final concentration of 100 µg/ml in 
both solid and liquid media. 
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• Tetracycline was prepared in 50% (v/v) ethanol and stored in the dark as it is light 
sensitive. It was used at a concentration of 10 µg/ml in both solid and liquid media. 
• Kanamycin was prepared in dH2O and used at a final concentration of 50 µg/ml in 
both solid and liquid media. 
 
2.2.14 Soluble protein isolation 
This technique was used for protein isolation from the soluble fraction of E. coli cells. A 
100 ml culture of E. coli cells was centrifuged for 10 min at 6,000xg and the pellet was 
resuspended in 10 ml of Lysis Buffer. The cells were disrupted on ice with a 3 mm micro-
tip sonicator (Sonics & Materials Inc) using 2.5 sec, 40 kHz pulses for 30 sec. The cell 
debris was removed by centrifugation at 13 000xg for 20 min at 4°C. The cell lysate was 
subsequently filtered through a 0.45 µm filter. 
 
2.2.15 Inclusion bodies isolation and preparation 
This technique was used for the isolation of inclusion bodies isolation from E. coli in order 
to analyse or solubilise HA1 protein. A 100 ml culture of E. coli cells was centrifuged for 
10 minutes at 6,000xg and the pellet was resuspended in 10 ml of Lysis Buffer (section 
2.1.3). The cells were disrupted on ice with a 3 mm micro-tip sonicator (Sonics & Materials 
Inc) using 2.5 sec, 40 kHz pulses for 30 sec. The sample was centrifuged at 13,000xg for 20 
minutes at 4°C. The supernatant was removed and the pellet was resuspended in 5 ml of 
Lysis Buffer (section 2.1.3) containing 1 % (v/v) Triton X-100. The sample was mixed for 
5 min at room temperature and centrifuged as previously. The washing step with 1 % (v/v) 
Triton X-100 was repeated once more and subsequently the inclusion bodies were washed 
with Lysis Buffer (section 2.1.3) but without Triton. The inclusion bodies were either 
solubilised straight after isolation or kept at -20°C. 
 
2.2.16 Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out as described by Laemmli (1970). Briefly, glass plates used for 
gel preparation were washed with detergent, rinsed with water and wiped with a tissue 
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soaked in 70% (v/v) ethanol. Two glass plates were put together, sealed with a gasket and 
kept together by two clamps. The matrix was prepared as follows: 
12% Resolving gel: 5% Stacking gel: 
Acrylamide/bis-acrylamide (30/0.8%) 3.96 ml  0.425 ml 
1 M Tris-HCl pH 8.8    1.945 ml  - 
1 M Tris-HCl pH 6.8    -   0.312 ml 
dH2O      3.83 ml  1.71 ml 
SDS      99 µl   25 µl 
APS  (10% [w/v])    49 µl   20 µl 
TEMED     20 µl   10 µl 
 
TEMED and freshly prepared APS were added straight before pouring the gels. The 
resolving gel was poured first up to 2 cm below the limit of the plates. It was layered with 
200 µl of isopropanol and left for 10 minutes to polymerize. After polymerization an 
isopropanol layer was removed and the stacking gel was poured to the top of the cassette. A 
comb was inserted and the gel was left for 15 minutes to polymerize. The gels were fitted 
into the gel box at an angle so as to minimize the creation of air bubbles between the buffer 
and the bottom of the gel. The gel box was filled with 1x Running Buffer (section 2.1.3) for 
SDS-PAGE. Prepared samples were loaded into the gel by deposition into the gel wells. 
Typically the gels were run at 60 mA per two gels for 50 min or until the dyefront reached 
the end of the gel. Then the gels were immersed in Coomassie Blue stain (section 2.1.3) for 
SDS-PAGE and stained for 30 minutes with constant agitation at room temperature. 
Subsequently the gels were washed with dH2O and immersed in Destain Solution for SDS-
PAGE (section 2.1.3) for 1 h. The last step was repeated twice and the gels were placed 
between two sheets of acetate, scanned and saved in a suitable electronic format. 
 
• Sample preparation for SDS-PAGE 
Soluble proteins or soluble cellular extracts were prepared by mixing 20 µl of the sample 
with 5 µl of 5x Sample Buffer for SDS-PAGE. Then the samples were boiled for 5 minutes 
in a water bath, chilled at room temperature and applied on the gel. 
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Insoluble cell debris from 1ml of liquid culture after sonication and centrifugation were 
mixed with 60 µl of Sample Buffer and boiled for 10 minutes in a water bath. Typically a 5 
µl aliquot of the boiled mixture was applied on the gel after cooling down at room 
temperature. 
 
• Silver Staining of SDS-PAGE Gels (Merril et al., 1981) 
Silver staining methods are significantly more sensitive than various Coomassie Blue 
staining techniques (Rabilloud et al., 1994). Consequently, they are the method of choice 
when very low amounts of protein have to be detected on electrophoresis gels. After SDS-
PAGE the gel was stained and destained using Coomassie Blue stain in order to maximise 
sensitivity. The gel was then subjected to the fixation process – 1 h in 100 ml of 30% (v/v) 
ethanol and 10% (v/v) acetic acid. Then the gel was washed for 15 min in 100 ml of 20% 
(v/v) ethanol followed by 15 min wash in water. Then sensitization took place that involved 
1 min wash in 100 ml of 0.1% sodium thiosulphate (222 µl of 4.5% (w/v) stock). The gel 
was then rinsed two times with water for 15 s and subjected to silver staining – 30 min 
incubation in 100 ml of 0.1% silver nitrate (1 ml of 10% (w/v) stock) and 70 µl of 37%  
(v/v) formaldehyde. The gel was then rinsed with water twice for 20 s. Then the 
development process took place – incubation in 100ml of 3% (w/v) Sodium Carbonate, 50 
µl of 37% (v/v) formaldehyde and 4 µl of sodium thiosulphate 4.5% (w/v) stock. The 
reaction was stopped when the protein bands were fully stained in dark brown colour using 
100 ml Stop Solution (section 2.1.3). 
 
2.2.17  Western Blotting 
An SDS-PAGE gel was run as described above. Protein samples were loaded along with 
prestain molecular weight marker. Four pieces of filter paper (Whatman) and one piece of 
nitrocellulose membrane were cut to the size of the gel. The pieces of paper and membrane 
were soaked in Transfer Buffer (section 2.1.3) for 10 min. The gel was rinsed with water. 
Two pieces of filter paper followed by the membrane, the gel and another two pieces of 
filter paper were placed on the cathode of the horizontal semi-dry electro-blotter, avoiding 
air bubbles. The stack was covered with anode and the transfer was carried out for 30 min 
at 10 V. As optional verification of successful transfer, the membrane was incubated for 1 
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minute in 0.1% Ponceau S (Sigma), 5% acetic acid staining solution with gentle agitation in 
order to visualize transferred proteins. The membrane was subsequently destained by 
several washes in dH2O. The membrane was then blocked using 50 ml of Blocking Buffer 
(section 2.1.3) for 60 min (or overnight at 4°C) and incubated with 15 ml anti-His HRP-
labeled antibodies [Sigma; 1:5000 in Blocking Buffer (section 2.1.3)] for 60 min. The 
membrane was then washed several times with TBS-Tween (section 2.1.3) and developed 
using 3, 3-diaminobenzidine tetrahydrochloride (DAB, product no. d5637, Sigma) tablets. 
The DAB tablets were applied as a chromogen substrate for horse radish peroxidase and in 
that way they enabled the staining procedure. DAB produces a brown colour during the 
enzymatic reaction catalysed by horse radish peroxidase. The tablet container was removed 
from the refrigerator and allowed to stand at room temperature for about 15 min. Tablets 
were dissolved in 15 ml of dH2O. The solution was then poured on the top of the membrane 
and left to react for 5 min. The membrane was subsequently washed with water and 
photographed. It could also be dried and saved. 
 
2.2.18 Solubilisation of inclusion bodies 
• Urea solubilisation: 
The inclusion bodies from a 100 ml overnight culture of E. coli cells were isolated. The 
inclusion bodies were mixed with 10 ml of 8 M Urea in 50 mM TRIS buffer pH 8.0, shaken 
vigorously for 5 min and split into 3 samples. Each sample was incubated for 1 h under 
mild agitation at different temperatures. The temperatures were respectively 4°C, 22°C and 
37°C. Then, to verify the effectiveness of the solubilisation, the samples were split in two 
and one half was centrifuged for 10 min at 13,000xg. Both the supernatant as a soluble 
fraction, and the uncentrifuged sample as a control of protein presence, were subjected to 
SDS-PAGE analysis and Western blotting. 
General process: HRP + H2O2 Compound I          Compound II          HRP + 2 H2O
DABH+ + DABH+            ((DAB)2H2) n
((DAB)2H2) n = coloured product of oxidation
DABH+ DABH+DABH2DABH2
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• Guanidine Hydrochloride GnHCl solubilisation: 
The inclusion bodies from a 100 ml overnight culture of E. coli cells were isolated. The 
inclusion bodies were mixed with 10 ml of 6 M GnHCl in 50 mM TRIS buffer pH 8.0, 
shaken vigorously for 5 min and split into 3 samples. Each sample was incubated for 1 h 
under mild agitation at different temperatures. The temperatures were respectively 4°C, 
22°C and 37°C. Then, to verify the effectiveness of the solublisation, the samples were split 
in two and one half was centrifuged for 10 min at 13,000xg. Both the supernatant as a 
soluble fraction and the uncentrifuged sample as a control of protein presence were 
subjected to SDS-PAGE analysis and Western blotting. 
 
2.2.19 Protein purification 
Affinity Chromatography was used to purify recombinant proteins containing 6xHis tag 
or/and Strep2 tag. 
• Standard Immobilised Metal Affinity Chromatography (IMAC) procedure 
One ml of nickel-nitrilotriacetic acid agarose resin (Ni-NTA, Qiagen) was poured into a 
column (“5" Polypropylene chromatography column” with a medium [45-90 µm] filter 
[Evergreen Scientific]). Once the resin settled it was washed with 5 ml of distilled water to 
wash off the ethanol and then pre-equilibrated with 5 ml of Lysis Buffer (section 2.1.3). 
Then 10 ml of the protein isolate was applied on the resin and washed with 5 ml of Lysis 
Buffer (section 2.1.3). The resin was subsequently washed with 5 ml of Lysis Buffer 
(section 2.1.3) with 20 mM – 120 mM imidazole (concentration needs to be optimized 
previously for a given protein) and eluted with 250 mM imidazole in Lysis Buffer (section 
2.1.3). Fractions containing purified protein were pooled together and desalted using 
Amicon columns with 10,000 Da cut off point. The column after use was washed with 10 
column volumes of water followed by 10 column volumes of 20% (v/v) ethanol and stored 
filled with 20% (v/v) ethanol at 4°C. 
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• IMAC purification under denaturing conditions 
Proteins solubilised in either urea or guanidine hydrochloride were applied on pre-
equilibrated columns as described above. Purification was performed similarly to the 
standard IMAC purification but denaturant (urea or guanidine hydrochloride) was present 
in the buffers. 
 
• IMAC purification using FPLC 
The purification was performed using HisTrap FF 1ml colum prepacked with precharged 
NiSepharose™ 6 Fast Flow (GE Healthcare). The flow was 0.5 – 1 ml/minute and the 
maximum bar pressure was 0.5 bar. After column attachment according to the 
manufacturer’s instructions it was washed with 5 ml of water to remove the 20% (v/v) 
ethanol used for storage and then washed with 10 ml of Lysis Buffer (section 2.1.3) to 
equilibrate the resin. Then 50 ml of protein isolate were applied from the injection loop. 
The column was washed using buffers A and B (various volumes – in order to achieve 
various concentrations of imidazole) containing Lysis Buffer (section 2.1.3) and 250 mM 
imidazole in Lysis Buffer (section 2.1.3) respectively. The buffers were mixed 
automatically by the pumping and mixing machinery (ÄKTAxpress) in order to achieve 
desired imidazole concentration. The step gradient of imidazole was applied to remove 
unspecifically bound contaminants from the column and subsequently to elute the His-
tagged protein of interest. Protein elutions were monitored at 280 nm and the resulting 
fractions were analyzed by SDS-PAGE. Fractions containing purified protein were pooled 
together and desalted using Amicon columns with 10,000 Da cut off point. After the run the 
column was washed with 10 ml of water followed by 10 ml of 20% ethanol and stored at 
room temperature, filled with 20% (v/v) ethanol. 
 
• Affinity chromatography using StrepTrap column and Strep2 tag 
StrepTrap HP 1 ml columns (GE Healthcare) containing StrepTactin Sepharose™ were 
used for Strep2-tagged protein purification. The purification was done according to the 
manufacturer’s instructions. Briefly, the cell extract of E. coli after protein isolation in a 
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binding buffer was applied on the pre-equilibrated StrepTrap HP 1 ml column and washed 
with binding buffer to remove contaminants. The Strep2-tagged protein of interest was 
eluted using desthiobiotin. The protein was then washed with water using ultrafiltration 
columns (Amicon) with a 10,000 Da cut off point. 
 
2.2.20 Enzyme Linked Lectin Assay (ELLA) 
The assay was performed on NUNC MaxiSorp 96 well plates. Fifty µl of 1-10 µg/ml 
glycoprotein was applied in PBS buffer on the plate and incubated overnight at 4ºC to 
immobilise it. Then an excess of the glycoprotein was removed and 150 µl of 2.5% (w/v) 
BSA in TBST (section 2.1.3) was applied on the plate to block it. After one hour incubation 
at 4ºC 2.5% (w/v) BSA in TBST was removed and the well of the plate was rinsed three 
times with 300 µl of TBST (section 2.1.3). Then 50 µl of 1-10 µg/ml lectin was applied in 
2.5% BSA-TBST and incubated for 1 hour at room temperature. Next the lectin was 
removed and the well of the plate was rinsed three times with 300 µl of TBST (section 
2.1.3). A 50 µl aliquot of 1:10 000 diluted anti-lectin, HRP-linked antibodies in 2.5% BSA-
TBST were applied to react for 1 hour. Then the antibody was removed and the well of the 
plate was rinsed three times with 300 µl of TBST (section 2.1.3). A 100 µl aliquot of TMB 
solution (section 2.1.3) was applied and left for 5 minutes at room temperature and the 
reaction was stopped by addition of 50 µl of 10% (v/v) HCl. The absorbance was read at 
450 nm. Each sample was tested in triplicate. 
 
2.2.21 Mass Spectrometry (MS) 
Protein solutions were desalted (Amicon Ultra-15 Centrifugal Filter, 10,000 Da cut-off), 
reconstituted into MS grade water and diluted with 10 mM ammonium formate (pH 4) to 
obtain appropriate concentrations (5-20 pmol/µl).  Buffered solutions were directly infused 
into the quadrupole time-of-flight QTOF mass spectrometer (Waters QToF Ultima Global) 
using a standard electrospray interface (ESI). The collision gas was Argon.  Spectra were 
manually deconvoluted to obtain the molecular mass of the analytes. The software used for 
data analysis and processing was MassLynx version 4.1. The following parameters were 
used and were found to be critical for the analysis: accelerating voltage 3.25 kV, extraction 
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cone voltage (Vc) 40V declustering potential (DP) 30 V, collision energy (CE) 10 V, Pi 5.2 
mbar, ST 65°C, and desolvation temperature (DT) 65°C. 
 
2.2.22   Surface plasmon resonance using a Biacore biosensor 
Binding analysis of the SiaP protein with Sia was undertaken by surface plasmon resonance 
using a biosensor (Biacore 3000; Biacore). Covalent linkage of the protein of interest to the 
dextran matrix was achieved by amine coupling (Amine Coupling kit, Biacore). Activation 
of the carboxyl groups on the matrix was performed by injection of 70 µl of the 1:1 mixture 
of N-hydroxysuccinimide (NHS, 11.5 mg/ml in deionized water) and ethyl-N-(3-
diethylaminopropyl) carbodiimide (EDC, 75 mg/ml in deionized water) at 10 µl/min to 
form active esters that react spontaneously with amine groups on the protein. The protein of 
interest (usually at concentration of 100 µg/ml) was immobilised onto a CM5 sensor chip in 
10 mM acetic acid. The pH was previously optimized during pre-concentration studies 
where 5 µl of the protein of interest was injected in a range of pH (3.6 - 5.0). All 
subsequent binding experiments were performed in HBS buffer (section 2.1.3). Samples 
were applied to the sensor chip at a flow rate of 10 µl/min. The remaining active esters 
were subsequently deactivated by injection of 80 µl of ethanolamine-HCl (1 M, pH 8.5). 
Unspecifically bound material was removed by regeneration with 10 mM NaOH (three 5 µl 
flushes). All monosaccharides tested were injected in HBS buffer (section 2.1.3). 
 
2.2.23 In silico analysis of DNA and protein sequences 
In silico analysis of DNA and protein was performed using programmes listed in Table 2.4. 
 
 
Table 2.4.  Programs used for DNA and protein analysis. 
 
Name Features Application Source 
Basic Local 
Alignment 
Search Tool 
(BLAST) 
Finds regions of local 
similarity between sequences 
deposited in GenBank. 
Used to compare DNA 
sequences. 
(Altschul et al., 1990); 
available at 
http://blast.ncbi.nlm.nih.gov
/Blast.cgi 
ClustalW 
General purpose multiple 
sequence alignment program 
for DNA or proteins. 
Used to create and 
manipulate multiple 
sequence alignments of 
DNA and proteins. 
(Thompson et al., 1994); 
available at 
http://www.ebi.ac.uk/Tools/
clustalw2/index.html 
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Name Features Application Source 
GeneDoc 
Full Featured Multiple 
Sequence Alignment Editor, 
Analyser and Shading Utility 
Used to edit multiple 
sequence alignments of 
DNA and proteins. 
Karl Nicholas; available at 
http://www.nrbsc.org/gfx/ge
nedoc 
Webcutter 
2.0 Restriction analysis 
Used to perform in silico 
restriction analysis of 
DNA sequences. 
Max Heiman; available at 
http://rna.lundberg.gu.se/cut
ter2/ 
Oligo Calc Oligonucleotide Properties Calculator 
Used during primer 
design. 
(Kibbe, 2007); available at 
http://www.basic.northweste
rn.edu/biotools/oligocalc.ht
ml 
Protein 
Workshop 3D protein structure viewer 
Used to create 3D protein 
images. 
(Moreland et al., 2005); 
available at www.rscb.org 
MassLynx 
version 4.1 
MS data processing and 
analysis. 
The software was used for 
data analysis and 
processing. 
www.waters.com 
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3 Results 
 
3.1 Overview 
The application of Sia-binding proteins in various analytical platforms for Sia detection 
is inevitably dependent on production of such proteins by methods that are reproducible 
with respect to the protein properties, as well as being cost efficient. The utilization of a 
prokaryotic system for protein expression is generally considered to be the most 
effective in terms of both cost and time. Furthermore, the well defined genetics and 
physiology of Escherichia coli makes it the host of choice for protein production and 
also enables relatively easy and fast modifications of the expressed protein to be 
undertaken by application of different vectors, strains and conditions. Additionally, the 
production of functional, non-glycosylated mammalian protein in E. coli would be 
advantageous, resulting in homogenous product, in contrast to protein product obtained 
from mammalian systems (Castilho, 2008). Thus, the activity of the product would not 
be subjected to variations in the glycan component of the glycoprotein, which often 
happens with such proteins like mammalian enzymes. To avoid drawbacks of 
glycosylation and to achieve the benefit of cost and time effectiveness, the E. coli based 
system of expression was applied for production of proteins in this project. 
Subsequently, several analytical platforms were utilized for characterization of the 
produced protein and ultimately the applicability of produced Sia-binding protein was 
tested for Sia detection and quantification.  
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3.2 Production of haemagglutinin protein (HA) from Influenza A 
virus 
The goal of this part of the project was to produce the globular domain (HA1) of the 
haemagglutinin protein (HA) from Influenza A virus in E. coli cells and to characterize 
it.  
 
3.2.1  Initial cloning of the ha1 gene 
The Influenza A virus (A/Sichuan/2/87(H3N2)) gene for haemagglutinin (HA) was 
obtained on a plasmid from Dr. Patricia Johnson (DCU, Ireland). On the basis of the ha 
gene sequence (PubMed accession number D21173, Nerome et al., 1995) primers were 
designed in order to amplify a ha1 sequence for the globular domain of the 
haemagglutinin gene (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
The primer’s sequences (Table 3.1) contained an NcoI restriction site (forward primer) 
and a BglII restriction site (reverse primer) to enable further cloning of the gene into an 
expression vector. The ha1 gene was initially cloned into the pPCR2.1 vector to avail of 
the TA cloning and enable the amplified sequence of the gene to be verified. PCR 
reactions were carried out using RedTaq DNA Polymerase with both HA1F1 and 
CAAAAACTTCCCGGAAATGACAACAGCACAGCAACGCTGTGCCTGGGACATCATGCAGTGCCAAACG
GAACGCTAGTGAAAACAATCACGAATGATCAGATTGAAGTGACTAATGCTACTGAGCTGGTTCAGAG
TTCCTCAACAGGTAGAATATGCGACAGTCCTCACCGAATCCTTGATGGAAAAAACTGCACACTGATA
GATGCTCTATTGGGAGACCCTCATTGTGATGGCTTCCAAAATGAGAAATGGGACCTTTTTGTTGAAC
GCAGCAAAGCTTACAGCAACTGTTACCCTTATGATGTGCCGGATTATGCCTCCCTTAGGTCACTAGT
TGCCTCATCAGGCACCCTGGAGTTTATCAATGAAGACTTCAATTGGATTGGAGTCACTCAGAGTGGG
GGAAGCTGTGCTTGCAAAAGGGGATCTGTTAACAGTTTCTTCAGTAGATTGAATTGGTTGCACAAAT
CAGAATACAAATATCCAGCGCTGAACGTGACTATGCCAAACAATGGCAAATTTGACAAATTGTACAT
TTGGGGGGTTCACCACCCGAGCACGGACAGAGAACAAACCAACCTATATGTTCGAGCATCAGGGAGA
GTCACAGTCTCTACCAAGAGAAGCCGGCAAACTGTAATCCCGAATATCGGGTCTAGACCCTGGGTAA
GGGGTCTGTCCAGTAGAATAAGCATCTATTGGACAATAGTAAAACCGGGAGACATACTGTTGATTAA
TAGCACCGGGAACCTAATTGCTCCTCGGGGTTACTTCAAAATACGCACTGGGAAAAGCTCAATAATG
AGGTCAGATGCACCTATTGGCACCTGCATTTCTGAATGCATCACTCCAAATGGAAGCATTCCCAATG
ACAAACCCTTTCAAAATGTAAACAAGATCACATATGGGGCATGCCCCAGGTATGTTAAGCAAAACAC
TCTGAAATTGGCAACAGGGATGCGGAATGTACCAGAGAAACAAACTAGAGGCATATTCGGCGCAATA
GCAGGTTTCATAGAAAATGGTTGGGAGGGAATGGTAGACGGTTGGTACGGTTTCAGGCATCAAAATT
CTGAGGGCACAGGACAAGCAGCAGATCTTAAAAGCACTCAAGCAGCAATCGACCAAATCAACGGGAA
ACTGAATAGGTTAATCGAGAAAACGAACGAGAAATTCCATCAAATCGAAAAGGAATTCTCAGAAGTA
GAAGGGAGAATTCAGGACCTCGAGAAATATGTTGAAGACACTAAAATAGATCTCTGGTCTTACAACG
CGGAGCTTCTTGTCGCCCTGGAGAACCAACATACAATTGATCTGACTGACTCAGAAATGAACAAACT
GTTTGAAAAAACAAGGAAGCAACTGAGGGAAAATGCTGAGGACATGGGCAATGGTTGCTTCAAGATA
TACCACAAATGTGACAATGCCTGCATAGGGTCACTCAGAAATGGAACTTATGACCATGATGTATACA
GAGACGAAGCATTAAACAACCGGTTCCAGATCAAAGGTGTTGAGCTGAAGTCAGGATACAAAGACTG
GATACTGTGGATTTCCATTGCCATATCATGCTTTTTGCTTTGTGTTGTTTTGCTGGGGTTCATCATG
TGGGCCTGCCAAAAAGGCAACATTAGGTGCAACATTTGCATTA 
 
Figure 3.1. A sequence of the ha gene. The globular domain is underlined and primers for ha1 
amplification marked in red. 
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HA1R1 primers. The optimised annealing temperature was 54°C, annealing time 1 min 
and extension time 2 min. 
 
Table 3.1. PCR primers used in the amplification of the ha1 gene of the Influenza A virus 
(A/Sichuan/2/87(H3N2)). Restrictions sites are highlighted and described 
        NcoI 
         HA1F1:  5′ CC ATG GCA ATG CAA AAA CTT CCC GGA AAT GAC AAC AGC 3′ 
        Ala 
 
                      BglII 
         HA1R1:  5′ AGA TCT AGT TTG TTT CTC TGG TAC ATT CCG C 3′ 
 
 
Products of the PCR reaction were verified by agarose gel electrophoresis. DNA 
fragments of ~ 1kb in size, which correspond to the ha1 gene (990 bp), were gel 
extracted and used for a ligation reaction with a linearized PCR2.1 vector from the TA 
cloning kit (Invitrogen). The ligation mixture was used to transform E. coli XL10-Gold 
competent cells by heat shock. The resulting plasmid was named pPCRHA1 (Figure 
3.2). As the MCS of the PCR2.1 vector is situated inside the lacZα gene the initial 
screening of the transformants was done on the basis of lacZ α-complementation test. 
The insert is flanked on both sides by EcoRI sites in the PCR2.1 vector and there is no 
EcoRI site in the ha1 gene (Nerome et al., 1995). The successful cloning of the gene 
was further confirmed by restriction analysis with EcoR1 enzyme. A 1 kb fragment was 
generated which corresponds to the size of the ha1 gene (Figure 3.2). Subsequently the 
ha1 gene was sequenced (MWG-Biotech Ltd). The results were aligned with the 
expected sequence of the gene (Figure 3.3). 
 
      
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. An EcoRI restriction 
analysis of the pPCRHA1 plasmid 
after an agarose gel electrophoresis. 
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The sequencing confirmed the sequence of the ha1 gene in the TA clone; however few 
mismatches were found. The changes in the gene sequence correspond to changes in the 
amino acid sequence of the HA1 protein. Six alterations were found in the amino acid 
sequence of the TA clone (Figure 3.4). In order to avoid the immune response of the 
host the surface of influenza virus changes rapidly which involve random mutations in 
both haemagglutinin and neuraminidase proteins (Peiris et al., 2007). The difference 
between the expected and the obtained amino acid sequence of the HA1 protein may be 
attributed to such spontaneous changes. As the reading frame as well as amino acids 
involved in ligand binding were unchanged further work was undertaken using the 
pPCRHA1 plasmid. 
 
Figure 3.3. Sequence alignment of ha1 gene (PubMed accession number D21173 = “expected”) and 
the ha1 gene in pPCRHA1 plasmid = “sequenced”. 
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In order to facilitate efficient expression of the ha1 gene in E. coli the gene was 
subcloned into the pLecB3 (Figure 3.5) expression vector (pKK233 derived), replacing 
the lecB gene. To facilitate further purification of the HA1 protein the gene was cloned 
in frame with a vector borne 6x histidine tag. An ampicillin resistance gene encoded on 
the plasmid enabled plasmid selection. The expression of the ha1 gene was facilitated 
by the vector borne Ptac promoter and replication by the ColE1 origin of replication. 
The ha1 gene in the pPCRHA1 plasmid is flanked by NcoI and BglII sites introduced in 
the primer sequences during PCR (Table 3.1). Similarly the lecB gene in the pLecB3 
plasmid is flanked by NcoI and BglII sites. This pPCRHA1 and pLecB3 plasmids were 
restricted with NcoI and BglII enzymes. DNA fragments were separated by agarose gel 
electrophoresis. A 1 kb DNA fragment, corresponding to the ha1 gene, was extracted 
from the gel where the pPCRHA1 plasmid restriction mix was separated and a 4.6 kb 
DNA fragment corresponding to an empty pLecB3 vector was gel extracted from the gel 
where the pLecB3 plasmid restriction mix was separated. Subsequently, the ha1 gene 
and the vector were ligated resulting in formation of the pJS102 plasmid (Figure 3.6). 
pJS102 has a relatively small size (5.6 kb) which promotes successful transformation of 
competent cells (Hanahan, 1983). The sequence of the plasmid was verified by 
restriction analysis and subsequent sequencing (MWG-Biotech Ltd) (not shown). 
 
 
  
 
Figure 3.4. Amino acid sequence alignment of HA1 protein (PubMed accession number D21173 = 
“expected”) and HA1 protein encoded in pPCRHA1 plasmid = “sequenced”. The amino acids involved 
in ligand binding are marked with red rectangles. 
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Figure 3.5. A map of the pLecB3 plasmid 
[Creavin et al (in prep)]. 
Figure 3.6. A map of the pJS102 plasmid. 
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3.2.2 Initial expression of the haemagglutinin globular subunit 
Expression in BL 21 and Rosetta strains of E. coli 
The heterogenic proteins expressed in E. coli cells are often subjected to proteolytic 
degradation by the host proteases, especially if the protein comes from an evolutionarily 
distinct organism. Taking into consideration the fact that the HA1 protein is native for 
mammalian expression systems the initial expression was performed using protease 
deficient strains of E. coli to prevent the possible protein degradation. The BL 21 E. coli 
strain and its derivatives harbour mutations of the protease genes that make them 
protease deficient. It is also widely known that expression of a mammalian protein in a 
prokaryotic system may result in lower yield or even lack of expression caused by 
different codon distribution in bacterial and mammalian genes (Bonekamp et al., 1988). 
The bioinformatics analysis of the ha1 gene sequence revealed 15 rare Arg codons, 5 
rare Leu codons, 7 rare Ile codons and 5 rare Pro codons (Figure 3.7). These rare codons 
in ha1 gene might interfere with expression in E. coli. 
 
 
 
 
atg gca atg caa aaa ctt CCC gga aat gac aac agc aca gca acg ctg tgc ctg gga cat cat 
gca gtg cca aac gga acg CTA gtg aaa aca atc acg aat gat cag att gaa gtg act aat gct 
act gag ctg gtt cag agt tcc tca aca ggt AGA ATA tgc gac agt cct cac CGA atc ctt gat 
gga aaa aac tgc aca ctg ATA gat gct CTA ttg gga gac cct cat tgt gat ggc ttc caa aat 
gag aaa tgg gac ctt ttt gtt gaa cgc agc aaa gct tac agc aac tgt tac cct tat gat gtg 
ccg gat tat gcc tcc ctt AGG tca CTA gtt gcc tca tca ggc acc ctg gag ttt atc aat gaa 
gac ttc aat tgg att gga gtc act cag agt ggg gga agc tgt gct tgc aaa AGG gga tct gtt 
aac agt ttc ttc agt AGA ttg aat tgg ttg cac aaa tca gaa tac aaa tat cca gcg ctg aac 
gtg act atg cca aac aat ggc aaa ttt gac aaa ttg tac att tgg ggg gtt cac cac ccg agc 
acg gac AGA gaa caa acc aac CTA tat gtt CGA gca tca ggg AGA gtc aca gtc tct acc aag 
AGA agc cgg caa act gta atc ccg aat atc ggg tct AGA CCC tgg gta AGG ggt ctg tcc agt 
AGA ATA agc atc tat tgg aca ATA gta aaa ccg gga gac ATA ctg ttg att aat agc acc ggg 
aac CTA att gct cct cgg ggt tac ttc aaa ATA cgc act ggg aaa agc tca ATA atg AGG tca 
gat gca cct att ggc acc tgc att tct gaa tgc atc act cca aat gga agc att CCC aat gac 
aaa CCC ttt caa aat gta aac aag atc aca tat ggg gca tgc CCC AGG tat gtt aag caa aac 
act ctg aaa ttg gca aca ggg atg cgg aat gta cca gag aaa caa act AGA tct cat cac cat 
cac cat cac taa 
Figure 3.7: Bioinformatic analysis of rare codon distribution in ha1 gene by Rare Codon Calculator – 
RaCC. Red = rare Arg codons AGG, AGA, CGA, Green = rare Leu codon CTA, Blue = rare Ile 
codon ATA, Orange = rare Pro codon CCC. 
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Figure 3.8: SDS-PAGE (left) analysis and the corresponding Western blot (right) analysis of the protein 
isolates from BL 21 and Rossetta strains of E. coli used to overexpress the His-tagged HA1 protein. Lanes 
were loaded as follows: (1) - soluble fraction, BL21; (2) - soluble fraction, Rosetta; (3) - insoluble fraction, 
BL21; (4) - insoluble fraction, Rosetta, (L) - Bio-Rad prestained protein ladder. Red arrows indicate His-
tagged HA1 protein detected by Western Blotting using anti-His antibodies. The calculated molecular 
weight of the HA1 protein is 38918.89 Da. Samples were collected after overnight culturing at 37°C in 
100ml LB amp broth.  
The Rosetta strain of E. coli was utilized to express the HA1 protein, as this strain 
contains a pRARE plasmid harbouring tRNAs for mammalian codons that rarely occur 
in E. coli (Novagen). The HA1 protein was successfully expressed in both BL21 and 
Rosetta strains of E. coli (Figure 3.8). However the HA1 protein was found solely in an 
insoluble form (Figure 3.8 lanes 3 and 4). This indicates that the expression of HA1 is 
successful in this system, hovewer it is not optimal. 
Overexpression of the proteins often leads to deposition of extensively produced protein 
in the form of inclusion bodies (Vallejo et al., 2004). One of the possible ways to 
prevent aggregation of the product is to lower the expression rate of the protein. 
Reduced rate of expression promotes correct folding of the protein and thus promotes its 
solubility (Dyson et al., 2004). A widely applied method to slow down the expression is 
to lower the concentration of inducing agent (Winograd et al., 1993).  
As the initial expression of the HA1 protein was performed in BL21 and Rossetta, 
which offer no induction regulation, other strains of E. coli were used. 
 
Expression in XL10 Gold strain of E. coli 
In order to obtain control over protein expression the XL10-Gold strain of E. coli was 
used. The lacIq mutation is responsible for overproduction of the lac repressor protein 
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(LacI) in this strain which facilitates efficient control over the expression of the genes 
that are under lac (or lac derived) promoter in the absence of the IPTG. The HA1 
protein was successfully expressed in XL10-Gold and the expression was tightly 
regulated as there was no expression of the HA1 protein in uninduced cultures (Figure 
3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression conditions optimization 
Utilization of the XL 10 Gold strain enabled controlled expression of the HA1 protein; 
however, the HA1 protein was exclusively expressed in the inclusion bodies. In order to 
down-regulate the expression of HA1 protein, and thus promote its solubility, lower 
concentrations of IPTG were used for induction. To investigate the influence of IPTG 
level on the expression of a soluble HA1 protein the XL10-Gold pJS102 cultures were 
induced with different concentrations of IPTG. The IPTG concentrations applied were 
as follows: 0.5 µM, 1 µM, 5 µM, 50 µM, 100 µM, 250 µM, 500 µM and 1000 µM. SDS-
PAGE and Western blotting were used to analyse the samples. The HA1 protein was not 
Figure 3.9. SDS-PAGE (left) analysis and the corresponding Western blot (right) analysis of the 
protein isolates from XL 10 Gold strain of E. coli used to overexpress the His-tagged HA1protein. 
Lanes were loaded as follows: (1) soluble fraction, uninduced culture, (2) soluble fraction, 
induced culture, (3) insoluble fraction, uninduced culture, (4) insoluble fraction, induced culture, 
(L) Bio-Rad prestained protein ladder. Cultures were induced with 50 µM IPTG at OD=0.6. 
Samples were collected after overnight culturing at 37°C in 100ml LB amp broth. The Western 
Blot was probed with anti-His antibodies 
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detected in the soluble fraction of the cells which indicates that the application of the 
lower concentrations of IPTG was not a successful method for soluble HA1 expression 
(Figure 3.10). The expression of an insoluble form of HA1 protein (Figure 3.11 A lane 5 
and Figure 3.11 B lanes 1-5) indicates correct culturing conditions and successful 
induction with IPTG. The minimum level of IPTG required to induce the HA1 protein 
expression was 50 µM (lane 5 Figure 3.11 A).  
 
Figure 3.10. Expression of soluble HA1 protein using various concentrations of IPTG. SDS-PAGE analysis 
(bottom part of the images) and the corresponding Western blot analysis (top part of the images) of the 
soluble protein isolates. Cultures were induced with different concentration of IPTG at OD=0.6. The 
Western Blot was probed with anti-His antibodies. The concentration of IPTG used for induction was as 
follows: 
A: 
1 – 0 
2 - 0.5 µM 
3 -  1 µM 
4 -  5 µM 
5 -  50 µM  
L -  Bio-Rad prestained protein ladder. 
C – positive control (insoluble fraction with HA1 
protein) 
B: 
C – positive control (insoluble fraction with HA1  
protein) 
1 - 50 µM 
2 - 100 µM 
3 -  250 µM 
4 -  500 µM 
5 -  1000 µM  
L -  Bio-Rad prestained protein ladder 
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Figure 3.11. Expression of insoluble HA1 protein using various concentrations of IPTG.. SDS-PAGE 
analysis (bottom part of the images) and the corresponding Western blot analysis (top part of the images) of 
the insoluble protein isolates. Cultures were induced with different concentrations of IPTG at OD=0.6. The 
Western Blot was probed with anti-His antibodies. The concentrations of IPTG used for induction were as 
follows: 
A:       B: 
1 – 0       1 - 50 µM 
2 - 0.5 µM      2 - 100 µM 
3 -  1 µM      3 -  250 µM 
4 -  5 µM      4 -  500 µM 
5 -  50 µM      5 -  1000 µM 
L -  Bio-Rad prestained protein ladder.   L -  Bio-Rad prestained protein ladder. 
  
 
 
As the optimisation of IPTG concentration aimed at slowing down expression and 
promote soluble HA1 production failed, another method of expression down regulation 
was applied. Aggregation of heterologous proteins in recombinant systems is often 
minimized through the reduction of the growth temperature (Sørensen et al., 2005) . In 
order to investigate the impact of lowered temperature on soluble HA1 expression the 
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cells were grown up to the density of OD = 0.6 at 37°C. Then, after 15 min adaptation 
period at 30°C, the expression was induced with 50 µM IPTG. The expression of HA1 
protein at 30°C was monitored over a period of 5 hours. It has been found that the 
expression of HA1 is clearly detectable in all samples. There was no HA1 protein 
detected in the soluble fraction of the cells (Figure 3.12, part A); however, the HA1 
protein was only present in the insoluble fraction of the cells (Figure 3.12, part B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12.  SDS-PAGE analysis and the corresponding Western blot analysis of the soluble (A) 
and insoluble (B) protein isolates from cultures grown at 30°C. Samples were collected over the 
period of 5 hours in one hour intervals. Hourly collected samples are presented in lanes 1-5. 
Number of the lane corresponds to the number of the hour after which the sample was collected. 
(L) Bio-Rad prestained protein ladder. (C) positive control (insoluble fraction with HA1 protein). 
The red arrow indicates the HA1 protein. Cultures were grown in 100ml LB amp broth. The 
Western Blot was probed with anti-His antibodies. 
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3.2.3 Two approaches to produce soluble HA1 protein 
As the initial expression resulted in insoluble protein production, two separate 
approaches for the solubilisation of the expressed protein were undertaken. The first 
approach focused on cloning the ha1 gene into various expression vectors in order to 
achieve the expression of the soluble HA1 protein. The second approach was aimed at 
extraction of the HA1 protein from the inclusion bodies, its further solubilisation by 
various denaturing agents followed by purification and finally, the refolding of the 
active HA1 protein. 
 
3.2.3.1 Expression of the soluble HA1 protein in E. coli 
There are several widely applied methods that facilitate expression of soluble 
heterologous proteins in E. coli (reviewed in Sørensen et al., 2005). Several of them 
involve modification of the expression conditions such as the coexpression with 
molecular chaperones or the periplasmic targeting of the polypeptide (reviewed in 
Jonasson et al., 2002). There are also methods that are aimed at the post- or co-
translational alteration of the expressed protein, whereby the solubility is increased by 
fusion to another more soluble protein domain such as maltose binding protein (MBP), 
thioredoxin (Trx) and glutathione-S-transferase (GST) (Dyson et al., 2004). 
 
Periplasmic targeting of the HA1 protein 
Secretion of heterologous proteins expressed in E. coli into the periplasm is a widely 
applied practice in molecular biology as it has several advantages over cytoplasmic 
expression (Soares et al., 2003; Harvey et al., 2004; Takayama and Akutsu, 2007). The 
most important feature of this periplasmic compartment, in terms of mammalian protein 
production, is its more oxidative environment that promotes disulphide bond formation 
and facilitates correct heterologous protein folding (Gasser et al., 2008). Furthermore, 
due to the fact that the concentration of other proteins in the periplasm is much lower 
than that in the cytosol, the purification of overexpressed protein is simplified. There are 
three major pathways for the translocation of polypeptides across the cytoplasmic 
membrane into the periplasm of Gram-negative bacteria: (i) the Sec pathway (Fekkes et 
al., 1999), (ii) the signal recognition particle (SRP) pathway (Koch et al., 2003) and (iii) 
the Tat pathway (Fisher et al., 2004). The Sec and SRP translocation systems are 
responsible for transmembrane transport of unfolded proteins whereas the Tat system is 
  87 
used by folded proteins. The translocation of the protein through the inner membrane of 
E. coli cell can be either post-translational (Sec) or cotranslational (SRP) (Fekkes et al., 
1999; Koch et al., 2003). Recognition of the protein targets by the Sec, SRP or Tat 
translocation system is facilitated by the specific N-terminal signal sequence of the 
nascently produced polypeptide (Fisher et al., 2004). Whether a signal targets its protein 
to SRP or to SecA depends on the relative degree of hydrophobicity of the core region 
of the signal rather than its amino acid sequence (Steiner et al., 2006). While the more 
hydrophobic protein signals associate with the SRP pathway, the less hydrophobic 
signals of secretory proteins utilize the SecA pathway (Fekkes et al., 1999; Steiner et 
al., 2006). 
 
Utilization of the Sec systems for HA1 expression 
The Sec based system was chosen to target the nascently produced, unfolded HA1 
protein into the periplasmic space of E. coli cells. As the aggregation of HA1 protein 
expressed in E. coli is most likely caused by its misfolding, the periplasmic targeting 
has been applied in order to potentially produce the soluble, correctly folded HA1 
protein. The ha1 gene was cloned into the pQE-60-PelB expression vector in frame with 
an N-terminal PelB signal sequence (PelBss) recognized by the Sec system (Steiner et 
al., 2006). The ha1 gene was amplified by PCR. The primer’s sequences contained a 
NotI restriction site (forward primer) and a BglII restriction site (reverse primer) to 
enable further directional cloning of the PCR product into the expression vector (Figure 
3.13). Additional nucleotides were included at the 5’ end of both primers to facilitate 
PCR product restriction with respective enzymes. 
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PCR reactions were optimized for the ha1 gene amplification with F1HA1NotI and 
R1HA1BglII primers 
 
Table 3.2) using Phusion DNA Polymerase. The optimised PCR annealing temperature 
was 60°C, annealing time 15 s and extension time 45 s. 
 
 
Table 3.2. PCR primers used in the cloning of the ha1 gene of the Influenza A virus 
A/Sichuan/2/87(H3N2)) into the pQE60-PelB vector. Restriction sites are highlighted. 
 
The 3518 bp pQE60-PelB expression vector is derived from pQE-60 (Qiagen) which 
had been engineered to incorporate the PelB leader sequence (Figure 3.14) that directs 
expressed protein to the periplasm via the Sec system. The ha1 gene was NotI and BglII 
restricted and ligated into the pQE60-PelB vector. To facilitate further purification of the 
HA1 protein the gene was cloned in frame with a vector borne 6x histidine tag. The 
selection of plasmids was facilitated by the β-lactamase gene and their replication by the 
ColE1 origin of replication. Protein expression was driven by the IPTG inducible T5 
promoter. Ligation of the ha1 gene with the pQE60-PelB vector resulted in formation of 
pJS103 plasmid (Figure 3.15). The sequence of the plasmid was verified by restriction 
                     NotI 
         F1HA1NotI: 5′ ATCG GCG GCC GCC ATG CAA AAA CTT CCC GGA AAT GAC           
 AAC AGC 3′ 
 
                            BglII 
         R1HA1BglII: 5′ GAAGA TCT AGT TTG TTT CTC TGG TAC ATT CCG C 3′ 
 
Figure 3.13. Ligation of ha1 gene with the pQE-60-PelB plasmid. Relevant restriction sites 
are marked. 
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analysis and subsequent sequencing (MWG-Biotech Ltd) (not shown). Competent cells 
(E. coli XL10-Gold) were transformed with ligation mix and used to propagate the 
pJS103 plasmid which was subsequently isolated and verified by restriction analysis 
(not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. A map of the pJS103 plasmid. 
Figure 3.14.  A map of the pQE60-PelB 
plasmid (Ryan Ph.D Thesis). 
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Expression of the HA1 protein with the PelB signal sequence 
The XL10-Gold strain of E. coli was chosen as a host for the HA1 protein expression, 
with the PelB signal sequence. The samples of both soluble and insoluble fractions 
isolated from the cells were analysed by SDS-PAGE and Western blotting (Figure 3.16 
andFigure 3.17). No HA1 protein was detected in the soluble fraction of the cells 
(Figure 3.16 lane 2). However the PelB-HA1 fusion protein was detected in the 
insoluble fraction of the cells (Figure 3.17 lane 2). The shift in the position of PelB-
HA1 fusion protein versus the control HA1 protein in the acrylamide gel can be 
attributed to the difference in calculated molecular weights of these two proteins: HA1 
protein with PelB signal sequence - 40076.6 Da (although appears to be about 50 kDa 
on SDS-PAGE gels – Figure 3.17), HA1 without signal sequence - 38918.9 Da 
(although appears to be about 45 kDa on SDS-PAGE gels – Figure 3.17). This indicates 
that the HA1 protein was successfully expressed with a desired signal sequence. 
However it does not promote solubility of the protein. 
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Figure 3.16. Soluble PelB-HA1 expression. SDS-PAGE analysis and (left) the corresponding Western 
blot analysis (right) of the soluble protein isolates. Lanes were loaded as follows: (1) – PelB-HA1 
protein, uninduced culture; (2) – PelB-HA1 protein, induced culture; (C1) – control – HA1 protein 
from insoluble fraction; (L) Bio-Rad prestained protein ladder. Cultures were grown at 37°C in 100ml 
LB amp broth. Samples were collected after overnight culturing following induction with 50 µM IPTG. 
The Western Blot was probed with anti-His antibodies. 
Figure 3.17. Insoluble PelB-HA1 expression. SDS-PAGE analysis (left) and the corresponding Western 
blot analysis (right) of the insoluble protein isolates. Lanes were loaded as follows: (1) – PelB-HA1 
protein, uninduced culture; (2) – PelB-HA1 protein, induced culture; (C1) – control – HA1 protein from 
insoluble fraction; (L) Bio-Rad prestained protein ladder. Cultures were grown at 37°C in 100ml LB amp 
broth. Samples were collected after overnight culturing following induction with 50 µM IPTG. The Western 
Blot was probed with anti-His antibodies. 
 
          L   1    2   C1 
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Utilization of the fusion proteins to enhance HA1 solubility 
The application of fusion proteins for heterologous protein offers several advantages 
including simplified and efficient purification, increased expression rates and increased 
solubility of the product (Pryor et al., 1997; Dyson et al., 2004 ). Therefore, another 
approach for soluble HA1 protein expression represented co-expression with maltose 
binding protein (MBP). The tagging promotes solubility by the intrinsic soluble 
properties of the MBP. Furthermore, as the MBP is at the N-terminus of the construct it 
undergoes translation and correct folding before the HA1 protein is translated and thus 
additionally promotes proper folding of the HA1 fusion partner. Maltose binding protein 
was chosen as a fusion partner for the HA1 protein as it has consistently proven to be 
the most efficient solubility promoting tag for mammalian protein expression in E. coli 
(Dyson et al., 2004). 
 
Cloning of the HA1 gene into the pMALp2e expression vector 
In order to express the MBP-fused HA1 protein, the ha1 gene was cloned in frame with 
malE gene encoding MBP in the pMALp2E expression vector from NEB (Figure 3.18). 
The above vector was selected as it contains the malE gene and, furthermore, upstream 
from the malE gene there is a signal sequence encoded to direct the polypeptide to the 
periplasm. An ampicillin resistance gene encoded on the plasmid enables plasmid 
selection. The expression is facilitated by the vector-borne Ptac promoter.  The 
replication of the vector is driven by the ColE1 origin of replication. 
 
 
 
 
 
 
 
 
Figure 3.18. A map of the pMALp2E plasmid 
(NEB). 
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        KpnI 
HA1KpnIF1: 5' GA CAG GTA CCG ATG CAA AAA CTT CCC GGA AAT GAC AAC AGC 3' 
 
   BamHI 
HA1BamHIR1: 5' ACT GGA TCC TTA AGT TTG TTT CTC TGG TAC ATT CCG C 3'  
 
Figure 3.19. PCR primers for the amplification of ha1 gene with KpnI and BamHI restriction sites. 
Restriction sites are highlighted and overhangs required by restriction enzymes are underlined. 
 
To clone the HA1 gene into the pMALp2E vector KpnI and BamHI sites were used. 
Primers that were used to amplify the ha1 gene with KpnI and BamHI sites are 
presented in Figure 3.19. The PCR amplification with HA1KpnIF1 and HA1BamHIR1 
primers and pJS102 as a template. The optimised annealing temperature was 65°C, 
annealing time 15 s and extension time 45 s. 
 
 
 
The PCR product was extracted from the reaction mix and restricted with KpnI and 
BamHI enzymes. The pMALp2E vector was also restricted with KpnI and BamH1. The 
restricted fragments of the ha1 gene and the vector were purified and subjected to 
overnight ligation. The ligation mix was later used to transform competent cells (E. coli 
XL10-Gold). No colonies were found on the plate where the transformation mix was 
spread which indicates that either ligation or transformation was unsuccessful. The 
experiment was repeated twice with same relt. Problems with ligation may be attributed 
to the distance between the KpnI site and the BamHI site in the pMALp2E vector which 
is only 7 bp and this may hamper the double restriction using these enzymes (Figure 
3.20). 
 
 
 
 
 
 
 
 
Figure 3.20. A fragment of pMALp2E (NEB) sequence containing the polylinker. Restriction sites are 
marked as well as an enterokinase site for further fusion tag cleavage. 
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Modification of the pMALp2E plasmid to facilitate KpnI/BglII double restriction 
In order to facilitate successful restriction of the pMALp2E plasmid by both KpnI and 
BamHI enzymes the distance between KpnI and BamHI sites was increased by insertion 
of a DNA fragment in between them. The EcoRI site which is between KpnI and 
BamHI sites (Figure 3.20) was utilized. An EcoRI restricted random ~1kb DNA 
fragment was incorporated in the EcoRI site of the pMALp2E plasmid. The ligation mix 
was used to transform competent cells (E. coli XL10-Gold). The plasmid was 
subsequently isolated, verified by restriction analysis (results not shown) and named 
pMALp2Ef. 
 
Cloning of the ha1 gene into the modified pMALp2E vector 
The ha1 gene amplified by PCR with KpnI and BamH1 sites introduced in primer 
sequences as presented in Figure 3.19 was KpnI and BamH1 cloned into the pMALp2Ef 
vector. The DNA fragments of ha1 gene and the vector were subjected to an overnight 
ligation and the ligation mix was used to transform competent cells (E. coli XL10-
Gold). The plasmid was then isolated, verified by restriction analysis and sequencing 
(MWG) (results not shown) and named pJS104 (Figure 3.21). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. A map of the pJS104 plasmid. 
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Once the clone was confirmed by sequencing the expression was performed in the 
XL10-Gold strain of E. coli (using LB broth, induced with 0.1 mM IPTG). Samples of 
both soluble and insoluble fractions isolated from the cells were analysed by SDS-
PAGE (Figure 3.22). Over-expression of the MBP-HA1 protein was not detected as 
there was no distinct band found on the SDS-PAGE in the lane representing induced 
culture at the expected hight of 60 kDa – 80 kDa (Figure 3.22 A lane 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. SDS PAGE analysis of the soluble (A) and insoluble (B) fractions of protein isolates from  
E. coli XL10-Gold pJS104 cultures.  Lanes were loaded as follows: (L) – Wide Range Protein Marker 
(Sigma); (1) – uninduced culture; (2) – induced culture. Cultures were grown at 37°C in 100ml LB amp 
broth. Samples were collected after overnight culturing following induction with 50 µM IPTG. 
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3.2.3.2 Solublisation of the HA1 protein produced in the form of inclusion 
bodies 
It was observed previously that the host cell had a great influence on the quality and 
quantity of the produced recombinant protein (reviewed in Vallejo et al. [2004]). The 
yields of soluble, active, mammalian (non-native) proteins expressed in E. coli are often 
highly affected by the lack of required post-translational modifications. Under such 
circumstances the protein of interest is often produced in the form of inclusion bodies. 
There are several advantages of inclusion bodies formation. Proteins that are normally 
toxic for bacterial cell; can be expressed and stored in an inactive form. Inclusion bodies 
deposition is also a way to avoid or reduce the rate of proteolytic degradation of the 
heterologous proteins. Furthermore, the concentration of an overexpressed protein in 
inclusion bodies exceeds significantly the concentration of protein that can be 
overexpressed in the cytosol. Finally, if it is possible to ultimately obtain an active 
product, the application of a prokaryotic expression system is much more cost effective 
as the microbial media are much cheaper than mammalian cell culture media, the time 
and equipment requirements are lower, and the volumetric yields are greatly higher 
(Vallejo et al., 2004). However, the additional processing that is required to render such 
protein soluble and active is a drawback if the protein is produced in inclusion bodies. 
Nevertheless, successful solubilisation and refolding of such protein aggregates has 
been reported (Carrio and Villaverde, 2001). The initial step in inclusion bodies 
processing is solubilisation of the protein aggregates by use of chaotropic agents such as 
urea and guanidine HCl. 
 
Urea treatment of inclusion bodies 
The HA1 protein aggregates were treated with urea as this chaotropic agent is one of the 
most effective (Vallejo et al., 2004) and is relatively cheap and available. The inclusion 
bodies from 100 ml culture of E. coli XL10-Gold pJS102 cells were isolated, washed, 
split into 3 samples and subjected to 8 M urea treatment for protein solubilisation (for 
one hour). Three different incubation temperatures were used, namely 4°C, 22°C and 
37°C. The samples were then analysed by SDS-PAGE and Western blotting (Figure ). 
The HA1 protein was detected after 8 M urea treatment using Western blotting (lanes 1, 
3 and 5 in Figure ). The position of the HA1 protein on the Western blot and the fact 
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that no fragmented proteins were detected indicates that the primary structure of the 
HA1 protein was intact during the urea treatment. However, the HA1 protein was not 
detected in the soluble fraction (Figure 3.23 lanes 2, 4 and 6). This indicates that 
solubilisation of HA1 with 8M urea under the applied conditions was unsuccessful. 
 
 
 
 
Guanidine hydrochloride treatment of inclusion bodies 
Following the unsuccessful solubilisation of the HA1 protein aggregates with urea, a 
more potent denaturant was applied. Although more expensive, guanidine hydrochloride 
(GnHCl) is superior to urea in terms of its chaotropic properties (Vallejo et al., 2004). 
The inclusion bodies from 100 ml culture of pJS102 XL10-Gold culture of E. coli cells 
were isolated, washed and treated with 6 M GnHCl (for one hour). This concentration is 
the most widely used in such experiments (Vallejo et al., 2004). Three different 
temperatures of incubation were used, namely 4°C, 22°C and 37°C. The samples were 
then analysed by SDS-PAGE and Western blotting (Figure 3.24). Although it was 
possible to detect the HA1 protein on the SDS-PAGE and Western blot (single bands on 
the gel indicates that the primary structure of the protein was intact and not trunkated) 
(Figure 3.24 lanes 1, 3 and 5) the HA1 protein was not detected in the soluble fraction 
(Figure 3.24 lanes 2, 4 and 6). This indicates that solubilisation of HA1 with 6 M 
GnHCl under the applied conditions was unsuccessful. 
Figure 3.23. SDS-PAGE Commassie Blue stained (A) and corresponding Western blot (B) analysis of the 
HA1 protein samples subjected to solubilisation with 8 M urea at different temperatures. Lanes are as 
follows: (L) Bio-Rad prestained protein ladder; (1) - proteins incubated at 4°C, not centrifuged; (2) - 
soluble proteins after incubation at 4°C and centrifugation; (3) - proteins incubated at 22°C, not 
centrifuged; (4) - soluble proteins after incubation at 22°C and centrifugation; (5) - proteins incubated at 
37°C, not centrifuged; (6) - soluble proteins after incubation at 37°C and centrifugation. The red arrow 
indicates the HA1 protein. The Western Blot was probed with anti-His antibodies. 
A B 
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In order to solubilise the HA1 protein a higher concentration of GnHCl was used, 
namely 8 M. After utilization of 8 M GnHCl the HA1 protein was detected by Western-
blotting and SDS-PAGE Commassie Blue stained gel in the soluble fraction (Figure 
3.25 lane 2). 
 
 
 
 
 
 
 
 
 
Figure 3.24. SDS-PAGE (left) and corresponding Western (right) blot analysis of the HA1 samples 
subjected to solubilisation with 6 M GnHCl at different temperatures. Lanes are as follows: (L) Bio-Rad 
prestained protein ladder; (1) - proteins incubated at 4°C, not centrifuged; (2) - soluble proteins after 
incubation at 4°C and centrifugation; (3) - proteins incubated at 22°C, not centrifuged; (4) - soluble 
proteins after incubation at 22°C and centrifugation;(5) - proteins incubated at 37°C, not centrifuged; 
(6) - soluble proteins after incubation at 37°C and centrifugation. The Western Blot was probed with 
anti-His antibodies. 
 
Figure 3.25. SDS-PAGE (left) and Westen-blot (right) analysis of the HA1 protein samples subjected to 
solubilisation with 8 M GnHCl at different temperatures. Lanes are as follows: (L) Bio-Rad prestained 
protein ladder;s (1) - protein sample not centrifuged; (2) - protein sample centrifuged. The Western Blot 
was probed with anti-His antibodies. 
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3.2.4 Purification of the HA1 protein under denaturing conditions 
The ultimate goal of the utilization of inclusion bodies for protein production is to 
obtain a soluble and active final product. The protein aggregates are firstly solubilised 
and the protein of interest is finally refolded. However, it is essential that prior to the 
refolding process the polypeptide of interest is pure, as any contaminatants present in 
the sample often hamper proper protein folding (Middelberg, 2002). The HA1 protein 
(after solubilisation with 8 M GnHCl) was subjected to IMAC purification under 
denaturing conditions (8 M GnHCl). There was no HA1 protein detected in both wash 
and elution fractions which indicates that the HA1 protein did not bind the resin (Figure 
3.26 lanes 3 and 4). It was concluded that the result of the HA1 protein purification 
under denaturing conditions (8 M GnHCl) does not work, which may be attributed to 
the fact that such a high concentration of GnHCl is not compatibile with the Ni-NTA 
resin (Qiagen). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26. SDS-PAGE (left) and corresponding Western blotting (right) analysis of the HA1 sample 
subjected to purification under denaturing conditions (8 M GnHCl) at room temperature. Lanes were 
loaded as follows: (L) - Prestained Protein Marker, Broad Range (NEB); (1) – solubilised HA1 in 8 M 
GnHCl before application on the column; (2) – flow through; (3) – wash with 8 M GnHCl buffer; (4) – 
elution with 8 M GnHCl buffer containing 300 mM imidazole. Each sample comes from 10 ml fraction. 
The Western Blot was probed with anti-His antibodies. 
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3.3 Production, characterisation and application of SiaP protein for 
Sia detection and quantification 
The goal of this section of the project was to produce the SiaP protein from H. 
influenzae utilizing an E. coli-based expression system and characterize the product 
with regards to molecular weight, purity and homogeneity. Results described in this 
section include also testing of the SiaP protein applicability for Sia detection and 
quantification. 
 
3.3.1 Cloning of the siaP gene with a His-tag 
The siaP gene was obtained on a plasmid from Dr. Emmanuele Severi (University of 
York, UK). The pET21b derived pGTY3 plasmid (Figure 3.27), has a STOP codon 
directly downstream from the siaP gene (Severi et al., 2005) and a vector-borne STOP 
codon following the His-tag coding sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
To facilitate further purification of the expressed SiaP protein the pGTY3 plamid was 
modified in order to utilize the 6xHis tag. The siaP native STOP codon was removed. 
Originally the siaP gene, including the signal sequence, was cloned into the pGTY3 
vector using XhoI and NdeI restriction sites. Hence, to remove the STOP codon from 
the end of the siaP gene, this gene was PCR amplified without the STOP codon. 
Forward and reverse primers for PCR, containing NdeI and XhoI sites, respectively, are 
presented in Figure 3.28. The PCR amplification was performed using Phusion DNA 
Figure 3.27. A map of the pGTY3 plasmid. 
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     NdeI 
F1SiaPNdeI:  5′ GGGAATTCCATATGATGAAATTGACAAAACTTTTCC 3′ 
 
    XhoI 
R1SiaPXhoI:  5′ CCGCTCGAG TGG ATT GAT TGC TTC AAT TTG TTT TAA AGC 3′ 
 
Figure 3.28. The primers used for PCR amplification of siaP gene with NdeI and XhoI sites. 
Polymerase. The optmised annealing temperature was 65°C, annealing time 15 s, 
extension time 45 s. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After PCR the DNA fragments were extracted from the reaction mix (RBC gel 
extraction kit). Then the PCR products and the pGTY3 plasmid were restricted with 
NdeI and XhoI enzymes. The PCR products were extracted from the reaction mix (RBC 
gel extraction kit) and the vector was separated by gel electrophoresis in SYBR Safe 
agarose. Subsequently, the 5.3 kb DNA fragment corresponding to the empty pGTY3 
vector was extracted from the electrophoresis gel (RBC gel extraction kit). Then the 
PCR products and the plasmid were ligated together. The ligation mix was used to 
transform E. coli XL10 Gold competent cells. Plasmids were then isolated and the 
sequence of the clone was confirmed by restriction analysis (results not shown) and 
sequencing (MWG; Figure 3.29). 
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 The plasmid was named pJS201 (Figure 3.30). The siaP gene was placed in frame, 
directly upstream of the vector-borne His-tag which was followed by a vector borne 
STOP codon. The pJS201 plasmid includes a strong T7 promoter driving the expression 
of the siaP gene. An ampicillin resistance gene encoded on the plasmid enables plasmid 
selection and a pBR322-derived ColE1 origin of replication drives its replication. 
Figure 3.29. Nucleotide sequence alignment of siaP gene from Haemophilus influenzae and the 
siaP gene present in the pJS201 plasmid sequenced by MWG. The sequence encoding the 6His-tag 
and STOP codon are marked in red.
  103 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Cloning of the siaP gene with a Strep2-tag 
In order to facilitate orientated immobilization of the SiaP protein on various surfaces 
using amine coupling a C-terminal 6xLys-tagged derivative of SiaP was engineered. 
The string of six lysines (Figure 3.31) on the C-terminus increases the possibility for 
immobilization of the SiaP protein via lysine’s amine group. C-terminal orientated 
immobilization is advantageous for SiaP application as a Sia sensor because the Sia-
binding site is on the opposite side of the protein which increases the ability of 
immobilised protein to capture the ligand. Similarly, to facilitate further purification 
over streptactin-coated resins and orientated immobilisation of the SiaP protein on 
streptactin and analogous surfaces, a C-terminal Strep2-tagged derivative of SiaP was 
engineered. The Strep2-tag is a string of ten amino acids which shares high homology 
with biotin with regards to its recognition by streptavidin (Cai et al., 2001) (Figure 
3.32). Thus, the tag has high affinity towards streptavidin and other proteins with 
similar specificity. The tag sequence was introduced by PCR amplification of the entire 
pJS201 plasmid using phosphorylated primers. The optimised annealing temperature for 
the PCR was 60°C, annealing time 15 s and extension time 45 s. The primers used are 
presented in Figure 3.31 and Figure 3.32. 
 
 
 
Figure 3.30. A map of the pJS201 plasmid. 
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After PCR the DNA fragments were extracted from the reaction mix (RBC gel 
extraction kit) and subjected to DpnI digestion that cleaves only methylated DNA, and 
thus the original plasmid (pJS201 used as a template) was eliminated. Then the products 
were separated by gel electrophoresis in SYBR Safe agarose, gel extracted and 
subjected to ligation with T4 DNA ligase. Subsequently the ligation mixes were used to 
transform E. coli KRX competent cells. The plasmids were named pJS202 (Figure 3.33) 
and pJS203 (Figure 3.34). Isolated plasmids were confirmed by restriction analysis (not 
shown) and sequencing (MWG; Figure 3.35 and Figure 3.36).  
 
 
 
 
 
 
Figure 3.32. Sequences of a Strep2-tag and primers used to introduce the tag. (A)Amino acid and 
corresponding nucleotide sequences of the Strep2-tag at the C-terminus of the SiaP protein. (B) Primer 
sequences used to amplify the pJS203 plasmid. The part of the Strep2-tag introduced in the forward primer is 
marked in green and the part of the linker introduced in the reverse primer is marked in brown. The sequences 
shown in black are derived from the pJS201 plasmid used as a template. 
A    Strep2-tag: 
        Amino acid sequence:      Ser   Asn  Trp   Ser   His   Pro   Gln   Phe  Glu  Lys 
        Nuceotide sequence:  5’  AGT AAC TGG TCT CAC CCA CAA TTC GAG AAA 3’ 
 
B    Primer sequences: 
       Forward primer (FSiaPCS): 5’ CCACAATTCGAGAAATGAGATCCGGCTGCTAACAAAGCCC 3’ 
       Reverse primer (RSiaPCS): 5’ GTGAGACCAGTTACTGTGGTGGTGGTGGTGGTGCTCGAG 3’ 
 
A    6Lys-tag: 
       Amino acid sequence:       Lys    Lys   Lys   Lys   Lys   Lys 
       Nuceotide sequence:  5’ CTC CTC CTC CTC CTC CTC 3’ 
 
B    Primer sequences: 
       Forward primer (FSiaLYS): 5’ CTCCTCCTCTGAGATCCGGCTGCTAACAAAGCCC 3’ 
       Reverse primer (RSiaPLYS): 5’ GAGGAGGAGGTGGTGGTGGTGGTGGTGCTCGAG 3’ 
Figure 3.31. Sequences of a 6Lys-tag and primers used to introduce the tag. (A)Amino acid and corresponding 
nucleotide sequences of the 6Lys-tag at the C-terminus of the SiaP protein. (B) Primer sequences used to 
amplify the pJS202 plasmid. The part of the 6Lys-tag introduced in the forward primer is marked in green and 
the part of the linker introduced in the reverse primer is marked in brown. The sequences shown in black are 
derived from the pJS201 plasmid used as a template. 
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Figure 3.33. A map of the pJS202 plasmid. 
Figure 3.34. A map of the pJS203 plasmid. 
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Figure 3.35. Nucleotide sequence alignment of the siaP gene from pJS201 plasmid and the siaP 
gene present in the pJS202 plasmid sequenced by MWG. The sequence coding for 6Lys-tag and 
the STOP codon are marked in red. 
Figure 3.36. Nucleotide sequence alignment of the siaP gene from pJS201 plasmid and the siaP 
gene present in the pJS203 plasmid sequenced by MWG. The sequence coding for the Strep2-tag 
and STOP codon are marked in red. 
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3.3.3 Expression of the His-tagged SiaP protein 
The expression of the His-tagged SiaP protein (SiaP 201) was optimized in terms of 
expression time, concentration of inducing agent and culture cell density at the 
induction time. As the transcription of the siaP gene in the pJS201 plasmid is driven by 
the T7 promoter the vector was transformed into the KRX strain of E.coli (Promega). 
The genotype of the KRX strain contains a T7 polymerase gene under the control of a 
rhmnose promoter which prevents “leaky” expression of the target protein (Promega). 
 
Optimisation of the harvesting time and cell concentration at the point of induction 
In order to establish an optimal post-induction harvesting time as well as optimise the 
cell concentration during the induction that leads to highest yield of SiaP protein, the 
cultures of E. coli KRX pJS201 were induced at various stages of growth and sampled 
every hour afterwards.  The cultures were incubated at 37°C and induced with 0.1% 
rhamnose. The optical densities when the induction took place were 0.5 (midlog phase), 
1.0 and 1.2 (staionary phase) respectively. Both soluble (Figure 3.37, 3.38 and 3.39) and 
insoluble (Figure 3.40, 3.41 and 3.42) fractions of the cells were analysed over time. 
Overexpression of the SiaP protein was visualized by SDS-PAGE. The concentration of 
expressed SiaP protein was increasing over time in the soluble fraction and reached its 
maximum after 6 hours following induction when induced at OD600=0.5 (Figure 3.37) 
and after 5 hours following induction when induced at OD600=1.0 and OD600=1.2 
(Figure 3.38 and 3.39 respectively). The concentration of soluble SiaP protein in the 
cells after overnight culturing was lower then after 5 or 6 hours following induction 
(Figure 3.37, 3.38 and 3.39). The concentration of SiaP in insoluble fractions was also 
increasing over time, it was found to be highest in the samples taken after overnight 
culturing regardless of the OD during the induction and did not decrease overnight 
(Figure 3.40, 3.41 and 3.42). The concentration of soluble protein was found to be 
highest when subjected to induction at OD600=1.2 and harvested after 6 hours (Figure 
3.37, 3.38 and 3.39). Conversely, the concentration of insoluble SiaP protein was higher 
in cultures induced in the earlier stage of culturing. The highest concentration of 
insoluble SiaP protein was found in cultures induced at OD600=0.5 and harvested after 6 
hours (Figure 3.40, 3.41 and 3.42). 
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Figure 3.37. SDS-PAGE gels showing soluble fractions from cultures induced at OD=0.5. Samples from 
uninduced (un) cultures presented along with samples from induced  (in) cultures. Samples were 
collected every hour for 6 hours (1h, 2h, … , 6h) and the last sample was collected after an overnight 
culturing. WR-Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.38. SDS-PAGE gels showing soluble fractions from cultures induced at OD=1.0. Samples from 
uninduced (un) cultures presented along with samples from induced  (in) cultures. Samples were 
collected every hour for 5 hours (1h, 2h, … , 5h) and the last sample was collected after an overnight 
culturing. WR-Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.39. SDS-PAGE gels showing soluble fractions from cultures induced at OD=1.2. Samples from 
uninduced (un) cultures presented along with samples from induced  (in) cultures. Samples were 
collected every hour for 5 hours (1h, 2h, … , 5h) and the last sample was collected after an overnight 
culturing. WR-Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 35.5 kDa. 
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Figure 3.40. SDS-PAGE gels showing insoluble fractions from cultures induced at OD=0.5. Samples 
from uninduced (un) cultures presented along with samples from induced  (in) cultures. Samples were 
collected every hour for 6 hours (1h, 2h, … , 6h) and the last sample was collected after an overnight 
culturing. WR-Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.41. SDS-PAGE gels showing insoluble fractions from cultures induced at OD=1.0. Samples 
from uninduced (un) cultures presented along with samples from induced  (in) cultures. Samples were 
collected every hour for 5 hours (1h, 2h, … , 5h) and the last sample was collected after an overnight 
culturing. WR-Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.42. SDS-PAGE gels showing insoluble fractions from cultures induced at OD=1.2. Samples 
from uninduced (un) cultures presented along with samples from induced  (in) cultures. Samples were 
collected every hour for 5 hours (1h, 2h, … , 5h) and the last sample was collected after an overnight 
culturing. WR-Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 35.5 kDa. 
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Investigation of the optimal concentration of the inducing agent 
To investigate the impact of the inducing agent (rhamnose) concentration on the SiaP 
protein expression the cultures were incubated at 37°C and induced at OD=0.5. The 
final concentrations of rhamnose used to induce expression were 0.001%, 0.005%, 
0.01%, 0.05%, 0.1%, 0.2% and 0.5% (w/v) respectively. Both soluble (Figure 3.43 - 
3.48) and insoluble (Figure 3.49 – 3.54) fractions of the cells were analysed over time. 
Higher concentration of rhamnose resulted in similar levels of SiaP concentration as 
0.01% rhamnose in samples taken one and two hours after induction (Figure 3.43 and 
3.44). However, in samples taken in later stages of culturing the concentration of SiaP 
was lower if induced with more than 0.01% rhamnose (Figure 3.45 – 3.48). This 
indicates that the optimal concentration of rhamnose for the induction of soluble 
expression of the SiaP protein is 0.01%. 
In the insoluble fractions the concentration of SiaP protein was constant if induced with 
rhamnose in the concentration range between 0.01% and 0.5% (Figure 3.49 - 3.54). The 
insoluble SiaP protein was also found in samples taken from cultures induced with 
0.001% and 0.005%, albeit, at lower concentrations than in cultures induced with higher 
levels of rhamnose (Figure 3.53). 
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Figure 3.43. SDS-PAGE analysis of soluble protein fraction isolated from samples taken one hour after 
induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% rhamnose; 
0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-culture 
induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced with 0.5% 
rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.44. SDS-PAGE analysis of soluble protein fraction isolated from samples taken two hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% 
rhamnose; 0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 
0.1-culture induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture 
induced with 0.5% rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
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Figure 3.45. SDS-PAGE analysis of soluble protein fraction isolated from samples taken three hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% 
rhamnose; 0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 
0.1-culture induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture 
induced with 0.5% rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.46. SDS-PAGE analysis of soluble protein fraction isolated from samples taken four hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% 
rhamnose; 0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 
0.1-culture induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture 
induced with 0.5% rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
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Figure 3.48. SDS-PAGE analysis of soluble protein fraction isolated from samples taken after 
overnight culturing following induction with different concentrations of rhamnose. WR –Sigma 
Wide Range protein ladder; un – uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- 
culture induced with 0.005% rhamnose; 0.01-culture induced with 0.01% rhamnose; 0.05-culture 
induced with 0.05% rhamnose; 0.1-culture induced with 0.1% rhamnose; 0.2- culture induced with 
0.2% rhamnose; 0.5-culture induced with 0.5% rhamnose. The predicted molecular weight of SiaP is 
35.5 kDa. 
Figure 3.47.  SDS-PAGE analysis of soluble protein fraction isolated from samples taken five hours after 
induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% rhamnose; 
0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-culture 
induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced with 0.5% 
rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
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Figure 3.49. SDS-PAGE analysis of insoluble protein fraction isolated from samples taken one hour 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% 
rhamnose; 0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-
culture induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced 
with 0.5% rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.50. SDS-PAGE analysis of insoluble protein fraction isolated from samples taken two hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% rhamnose; 
0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-culture 
induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced with 0.5% 
rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
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Figure 3.51. SDS-PAGE analysis of insoluble protein fraction isolated from samples taken three hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% rhamnose; 
0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-culture 
induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced with 0.5% 
rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.52. SDS-PAGE analysis of insoluble protein fraction isolated from samples taken four hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% rhamnose; 
0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-culture 
induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced with 0.5% 
rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
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Figure 3.53. SDS-PAGE analysis of insoluble protein fraction isolated from samples taken five hours 
after induction with different rhamnose concentrations. WR –Sigma Wide Range protein ladder; un – 
uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture induced with 0.005% rhamnose; 
0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 0.05% rhamnose; 0.1-culture 
induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 0.5-culture induced with 0.5% 
rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
Figure 3.54 SDS-PAGE analysis of insoluble protein fraction isolated from samples taken after 
overnight culturing following induction with different concentrations of rhamnose. WR –Sigma Wide 
Range protein ladder; un – uninduced; 0.001-culture induced with 0.001% rhamnose; 0.005- culture 
induced with 0.005% rhamnose; 0.01-culture induced with 0.01% rhamnose; 0.05-culture induced with 
0.05% rhamnose; 0.1-culture induced with 0.1% rhamnose; 0.2- culture induced with 0.2% rhamnose; 
0.5-culture induced with 0.5% rhamnose. The predicted molecular weight of SiaP is 35.5 kDa. 
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Initial purification of the His-tagged SiaP protein over Ni-NTA agarose 
Immobilised nitriloacetic acid nickel ion (Ni-NTA) resin was used to purify the 
expressed His-tagged SiaP protein expressed from pJS201. The stringency of imidazole 
washes was optimized. Soluble SiaP protein was isolated from 100 ml overnight culture 
induced with 0.01% (w/v) rhamnose at OD=1.2, grown at 37°C and harvested after six 
hours. The isolated protein was applied on pre equilibrated Ni-NTA column and washed 
with 20 ml of lysis buffer, followed by 4 ml washes with 20 mM, 40 mM, 60 mM, 
80mM, 120mM and 300mM imidazole. Each of the 4 ml washes was collected in 1 ml 
aliquots and analysed by SDS-PAGE and Western blotting (Figure 5.56 -3.59). Most 
contaminants were removed during the washes with lysis buffer and the 20 mM 
imidazole (Figure 3.55). The lowest concentration of imidazole causing elution of the 
SiaP protein was found to be 40 mM (Figure 3.56 and 3.59), which indicates that the 
SiaP protein is not binding strongly to the resin. The most effective elution of the SiaP 
protein (assessed by comparison of lanes in SDS-PAGE gels) was observed after 
application of 60 mM imidazole (visible in Figure 3.56 and Figure 3.59 lane “II 60”). 
The elution of SiaP protein was also observed in 80 mM, 120 mM and 300 mM 
imidazole fractions although the concentration of SiaP protein in these fractions was 
lower (Figure 3.57, 3.58 and 3.59). However, the SiaP protein was also detected by 
Western blotting in the flow through fraction (Figure 3.59) which may indicate low 
affinity of the protein’s His tag towards the Ni-NTA resin. The SiaP protein yield using 
this purification was estimated to be 1.6 mg from 500 ml culture (purification fractions 
40 mM – 300 mM imidazole were pooled together). 
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Figure 3.55. SiaP protein manual IMAC purification, part 1. Coomassie  stained (left) and corresponding 
silver stained (right) SDS-PAGE gel with the samples of the following purification stages of the SiaP 
protein: crude – soluble fraction of the cell extract; flow – flow through; 1st - 10mM imidazole wash 
(lysis buffer); I 20mM – 1st ml of the 4ml fraction of 20mM imidazole wash; II 20mM – 2nd ml of the 
4ml fraction of 20mM imidazole wash; III 20mM – 3rd ml of the 4ml fraction of 20mM imidazole wash; 
IV 20mM – 4th ml of the 4ml fraction of 20mM imidazole wash. L - Sigma Wide Range protein ladder. 
The predicted molecular weight of SiaP is 35.5 kDa 
Figure 3.56. SiaP protein manual IMAC purification, part 2. Coomassie  stained (left) and a 
corresponding silver stained (right) SDS-PAGE gel with the samples of the following purification stages 
of the SiaP protein: I 40mM – 1st ml of the 4ml fraction of 40mM imidazole wash; II 40mM – 2nd ml of 
the 4ml fraction of 40mM imidazole wash; III 40mM – 3rd ml of the 4ml fraction of 40mM imidazole 
wash; IV 40mM – 4th ml of the 4ml fraction of 40mM imidazole wash; I 60mM – 1st ml of the 4ml 
fraction of 60mM imidazole wash; II 60mM – 2nd ml of the 4ml fraction of 60mM imidazole wash; III 
60mM – 3rd ml of the 4ml fraction of 60mM imidazole wash; IV 60mM – 4th ml of the 4ml fraction of 
60mM imidazole wash. L - Sigma Wide Range protein ladder. The predicted molecular weight of SiaP is 
35.5 kDa 
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Figure 3.57. SiaP protein manual IMAC purification part 3. Coomassie  stained (left) and a 
corresponding silver stained (right) SDS-PAGE gel with the samples of the following purification stages 
of the SiaP protein: I 80mM – 1st ml of the 4ml fraction of 80mM imidazole wash; II 80mM – 2nd ml of 
the 4ml fraction of 80mM imidazole wash; III 80mM - 3rd ml of the 4ml fraction of 80mM imidazole 
wash; IV 80mM – 4th ml of the 4ml fraction of 80mM imidazole wash; I 120mM – 1st ml of the 4ml 
fraction of 120mM imidazole wash; II 120mM – 2nd ml of the 4ml fraction of 120mM imidazole wash; 
III 120mM – 3rd ml of the 4ml fraction of 120mM imidazole wash; IV 120mM – 4th ml of the 4ml 
fraction of 120mM imidazole wash. L - Sigma Wide Range protein ladder. The predicted molecular 
weight of SiaP is 35.5 kDa 
Figure 3.58. SiaP protein manual IMAC purification part 4. Coomassie stained (left) and a corresponding 
silver stained (right) SDS-PAGE gel with the samples of the following purification stages of the SiaP 
protein: I 300mM – 1st ml of the 4ml fraction of 300mM imidazole wash; II 300mM – 2nd ml of the 4ml 
fraction of 300mM imidazole wash; III 300mM – 3rd ml of the 4ml fraction of 300mM imidazole wash; IV 
300mM – 4th ml of the 4ml fraction of 300mM imidazole wash. L - Sigma Wide Range protein ladder. The 
predicted molecular weight of SiaP is 35.5 kDa. 
  120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.59. SiaP protein manual IMAC purification, summary. SDS-PAGE coomassie blue stained (left) 
and corresponding Western blot (right) analysis of the samples of the following purification stages of the 
SiaP protein: C – crude, soluble cell extract; F - flow through; 20 – 2nd ml of the 4ml fraction of 20 mM 
imidazole wash; 40 – 2nd ml of the 4ml fraction of 40 mM imidazole wash; 60 – 2nd ml of the 4ml 
fraction of 60 mM imidazole wash; 80 – 2nd ml of the 4ml fraction of 80 mM imidazole wash; 120 – 2nd 
ml of the 4ml fraction of 120 mM imidazole wash; 300 – 2nd ml of the 4ml fraction of 300 mM imidazole 
wash. L – NEB Prestained Protein Marker, Broad Range. The predicted molecular weight of SiaP is 35.5 
kDa. 
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Linker introduction 
The inefficient binding of the His-tagged SiaP protein expressed from pJS201 to the Ni-
NTA resin (as the protein is present in a flow through fraction) may be attributed to low 
accessibility of the tag. In order to increase the accessibility of the tag the SiaP protein 
was modified. An eight amino acid linker was introduced to separate the protein and the 
6His-tag. The (Gly Gly Gly Ser)2 linker is a straight flexible string of amino acids that 
extends the His tag from the protein and thus makes the His-tag more accessible. The 
linker sequence (Figure A) was introduced by PCR amplification of the entire pJS201 
plasmid using phosphorylated primers. The optimised PCR annealing temperature was 
60°C, annealing time was 15 s and extension time 45 s.The primers containing liker 
sequence are presented in Figure 3.60.  
 
 
 
 
 
 
 
 
 
After PCR the DNA fragments were extracted from the reaction mix (RBC gel 
extraction kit) and subjected to DpnI digestion that cleaves only methylated DNA 
(NEB) and thus the original plasmid (pJS201 used as a template) was eliminated. Then 
the product was separated by gel electrophoresis in SYBR Safe agarose, gel extracted 
and subjected to ligation with T4 DNA Ligase. Subsequently the ligation mix was used 
to transform E. coli KRX competent cells. The plasmid was isolated, analysed by 
restriction and sequencing (Figure 3.61) and named pJS2011 (Figure 3.62). 
Figure 3.60. Primers for linker introduction into the SiaP protein. (A)Amino acid and corresponding 
nucleotide sequences of the linker introduced to separate the SiaP protein and the His tag. (B) primer 
sequences used to amplify the pJS2011 plasmid. The part of the linker introduced in  the forward primer 
is marked in brown and the part of the linker introduced in the reverse primer is marked in green. The 
sequences in black correspond to the pJS201 plasmid used as a template. In order to avoid secondary 
structures formation of the primers various alternative codons for Gly were used: GGT, GGC and GGA. 
A   linker sequence: 
      Amino acid sequence:  Gly   Gly   Gly   Ser   Gly     Gly    Gly    Ser  
     Nucleotide sequence:  GGT GGC GGA AGT GGC GGA  GGA  AGT 
 
B   primer sequences: 
      forward primer (JS2011F): 5' GGCGGAGGA AGTCTCGAGCACCACCACCACCACCAC 3' 
 
      reverse primer (JS2012R): 5' ACTTCCGCCACCTGGATTGATTGCTTCAATTTGTTTTA 3' 
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Figure 3.61. Nucleotide sequence alignment of siaP gene from pJS201 plasmid and siaP gene present 
in the pJS2011 plasmid sequenced by MWG. The sequence coding for the linker is marked in red. 
Figure 3.62. A map of the pJS2011 plasmid. 
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A similar procedure for linker introduction was applied for pJS202 and pJS203 
plasmids. The linker was introduced between the protein and the His-tag using JS2011F 
and JS2011R primers (Figure 3.60). The PCR conditions as well as further cloning steps 
were identical to these described above with the exception of the template used. 
Plasmids pJS202 and pJS203 were used as templates in the PCR step. The sequences of 
newly created plasmids were confirmed by restriction analysis and sequencing (MWG) 
(data not shown) and the plasmids were named pJS2021 (Figure 3.63) and pJS2031 
(Figure 3.64). 
The nomenclature for modified SiaP proteins in subsequent sections is as follows: 
• SiaP 201 – SiaP-6His, expressed from pJS201, 
• SiaP 202 – SiaP-6Lys, expressed from pJS202, 
• SiaP 203 – SiaP-Strep2, expressed from pJS203, 
• SiaP 2011 – SiaP-linker-6His, expressed from pJS2011, 
• SiaP 2021 – SiaP-linker-6His-6Lys, expressed from pJS2021, 
• SiaP 2031 – SiaP-linker-6His-Strep2, expressed from pJS2031. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.63. A map of the pJS2021 plasmid. 
Figure 3.64. A  map of the pJS2031 plasmid. 
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Purification of the His-tagged SiaP protein with the linker 
The His-tagged SiaP protein with the linker (SiaP 2011) was expressed in the KRX 
strain of E. coli and purified over immobilised nitriloacetic acid nickel ion resin. The 
stringency of imidazole washes was optimized. Soluble SiaP 2011 was isolated from 
100 ml overnight culture induced with 0.01% (w/v) rhamnose at OD=1.2 (stationary 
phase), grown at 37°C and harvested after six hours. The isolated protein was applied on 
pre equilibrated Ni-NTA column and purified in the same way as previously described 
for the SiaP 201 protein. It was found that in converse to the SiaP 201 protein the SiaP 
2011 was not present in the flow through fraction (Figure ) which sugests that 
introduction of the linker altered the behaviour of the protein increasing its affinity 
towards the Ni-NTA resin. Furthermore, the SiaP 2011 protein was not detected in the 
40 mM imidazole wash (Figure 3.65), as the linker free SiaP had been (Figure 3.59), 
and the lowest concentration causing SiaP 2011 elution was 60 mM. The SiaP 2011 
protein yield using this purification was estimated to be 6 mg/500 ml culture, which also 
indicates higher efficiency of the procedure (same as before). 
 
  
 
 
 
 
 
Figure 3.65 SDS-PAGE and corresponding Western blot analysis with the samples of SiaP 2011 protein 
purification stages. C – crude, soluble cell extract; F - flow through; W – wash with lysis buffer; 20 – 2nd 
ml of the 4ml fraction of 20mM imidazole wash; 40 – 2nd ml of the 4ml fraction of 40mM imidazole 
wash; 60 – 2nd ml of the 4ml fraction of 60mM imidazole wash;  L – NEB Prestained Protein Marker, 
Broad Range. The predicted molecular weight of SiaP is 35.5 kDa. 
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Purification of SiaP 201 and SiaP 2011 proteins using IMAC on FPLC 
The His-tagged proteins, both with the linker and without the linker, were purified by 
IMAC using FPLC.  Step gradient of imidazole in the range between 10 mM (lysis 
buffer) and 250 mM was used for purification, 0.5 ml samples were collected and 
analysed by SDS-PAGE. During the purification of SiaP 201 protein a minor increase in 
absorbance at 280 nm was observed which correlated with the change (increase) in the 
imidazole concentration. The wash with 20 mM imidazole resulted in a slight, flat peak 
which may be attributed to contaminant elution from the column but also a SiaP elution 
as the protein was detected in this fraction by SDS-PAGE analysis (Figure 3.66 C lane 
“20”). This indicates that SiaP 201 binding to the resin is weak and this result supports 
the findings from the manual IMAC purification described in sections above. The peak 
at 40 mM imidazole may be a result of both contaminants and SiaP elution as both of 
them can be found in Figure 3.66 C lane “40”. The sharpest peak was observed after 85 
mM imidazole application and may be attributed solely to SiaP protein elution as no 
contaminants were detected in lane “85” in Figure 3.66 C. The second band on the SDS-
PAGE gel visualisation of this fraction may be attributed to the SiaP protein with a 
partially degraded N-terminus; hovewer this was not investigated. The 250 mM 
imidazole application resulted in an increase in absorbance but no peak was formed 
which indicates lack or very low amounts of protein contribution in this fraction. Low 
amounts of SiaP 2011 protein present in the 250 mM fraction were confirmed by SDS-
PAGE analysis (lane “250” in Figure 3.66 C). 
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Figure 3.66. SiaP 201 protein purification by IMAC using FPLC. (A) – A280 reading of the overall 
purification including the initial sample injection and lysis buffer wash.  (B) – A280 reading of the 20 
mM – 250 mM imidazole washes. (C) – SDS-PAGE analysis of the SiaP 201 purification fractions. 
Lanes were loaded as follows: L – Prestained Protein Ladder, Broad Range (NEB); C – crude cell 
extract; F – flow through; W – wash with lysis buffer; 20 – 20 mM imidazole wash; 40 – 40 mM 
imidazole wash; 85 – 85 mM imidazole wash; 250 – 250 mM imidazole wash. The predicted molecular 
weight of SiaP is 35.5 kDa. 
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Similarly, during the IMAC FPLC purification of SiaP 2011 protein a minor increase in 
absorbance at 280 nm was observed which correlated with the change (increase) of the 
imidazole concentration (Figure 3.67). The 20 mM imidazole wash resulted in a slight, 
flat peak which may be attributed to contaminant elution from the column. The 
contaminants present in the 20 mM imidazole fraction are observed by SDS-PAGE 
analysis (Figure 3.67 C lane “20”). No SiaP was detected in this fraction by SDS-PAGE 
analysis which indicates that the modified version of the protein with the linker interacts 
with the resin with higher affinity. This result is also in concert with findings from 
manual IMAC purification studies of these two proteins. The peak at 40 mM imidazole 
may be a result of both contaminant and SiaP elution as both of them can be found in 
Figure 3.67 C lane “40”.  Similarly to the SiaP 201, the sharpest peak was observed 
after 85 mM imidazole application and may be attributed solely to SiaP protein elution 
as no contaminants were detected in Figure 3.67 C lane “85”. The 250 mM imidazole 
application resulted in an increase of absorbance but no peak was formed which 
indicates lack or very low amounts of protein in this fraction. Lack of any protein in this 
fraction was also confirmed by SDS-PAGE analysis (Figure 3.67 C lane “250”). 
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Figure 3.67.  SiaP 2011 protein purification by IMAC using FPLC. (A) – A280 reading of the overall 
purification including the initial sample injection and lysis buffer wash.  (B) – A280 reading of the 20 
mM – 250 mM imidazole washes. (C) – SDS-PAGE analysis of the SiaP 2011 purification fractions. 
Lanes were loaded as follows: L – Prestained Protein Ladder, Broad Range (NEB); C – crude cell 
extract; F – flow through; W – wash with lysis buffer; 20 – 20 mM imidazole wash; 40 – 40 mM 
imidazole wash; 85 – 85 mM imidazole wash; 250 – 250 mM imidazole wash. The predicted 
molecular weight of SiaP is 35.5 kDa. 
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Purification of the Strep2-tagged SiaP protein using StrepTactin sepharose 
StrepTactin is a modified version of straptavidin offering high affinity and high 
specificity binding to the Strep2-tag. The competitive elution of the target Strep2-tagged 
protein with desthiobiotin (reversibly binding biotin analogue) adds additional 
specificity to the system. In order to confirm the functionality of the introduced C-
terminal, Strep2-tag the StrepTactin sepharose columns were used to purify the SiaP 
protein. Additionally, to study the impact of the linker addition on the protein features, 
two derivatives of Strep2-tag SiaP proteins were analysed, namely SiaP 203 (Strep2-
tagged without the linker) and SiaP 2031 (Strep2-tagged with the linker). Both proteins 
were found in the elution fractions (Figure  and Figure ), which indicates that the 
Strep2-tag in these proteins is functional. The introduction of the linker was found to 
influence the protein affinity for the StrepTactin resin. The SiaP 203 protein, in converse 
to the SiaP 2031 protein, was detected in the wash fraction (Figure ), which indicates 
low affinity of the protein for the resin. The lack of SiaP 2031 in the wash fraction 
(Figure ) indicates that the linker introduction increased the affinity of the Strep2-tagged 
SiaP protein for the StrepTactin resin used in the purification protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.68. Purification of the Strep2-tagged SiaP 2031 protein over StrepTrap HP column. SDS-
PAGE analysis (left) and corresponding Western blot (right) analysis. Samples colected in 1 ml 
fractions. Lanes: L – Prestained Protein Marker, NEB; C – Crude cell extract; F – flow through; W – 
wash; 1 – elution fraction, first ml; 2 – elution… The Western Blot was probed with anti-His 
antibodies. The predicted molecular weight of SiaP is 35.5 kDa 
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Figure 3.69. SDS-PAGE (left) analysis and corresponding Western blot (right) analysis of 
the purification of the Strep2-tagged SiaP 2031 protein over StrepTrap HP column. 
Samples colected in 1 ml fractions. Lanes: L – Prestained Protein Marker, NEB; C – 
Crude cell extract; F – flow through; W – wash; E - elution fraction. The Western Blot was 
probed with anti-His antibodies. 
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3.3.4 Characterisation of the SiaP protein expressed in E. coli 
Determination of molecular weight and homogeneity of the His-tagged SiaP 
protein using MS 
The homogeneity and molecular weight of the His-tagged SiaP 201 protein expressed in 
E. coli was determined using electrospray ionization (EI) mass spectrometry. The 
sample was prepared and analysed using standard protocol (see section 2.23).  Two 
protein components were identified during this analysis. The revealed molecular mass 
of the major component was 35238.41 ± 0.66 which is almost identical to the predicted 
(35229.97) of the mature protein after cleavage of the 23 amino acid signal sequence 
(Figure 3.70). The revealed molecular weight of the second component was 35538.41 ± 
2.35 which corresponds to the 35539.67 predicted mass of the mature protein 
substituted with Neu5Ac. 
 
 
 
Figure 3.70. The EI-MS analysis of the His-tagged SiaP 201 protein expressed in E. coli. The molecular 
masses corresponding to peaks 2711.59, 2937.50 and 3204.44 corresponds to unsubstituted SiaP proteins 
ions (molecular mass 35238.41 ± 0.66 Da) and peaks 2735.38, 2953.28 and 3232.58 corresponds to 
substituted SiaP ions (molecular mass 35538.41 ± 2.35). The concentration of the SiaP in the injected 
sample was 285 nM. 
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3.3.5 Production of the sialic acid free form of SiaP 
The application of the SiaP protein as an analytical tool in various platforms requires a 
diverse, in-depth functional analysis.  As presented in previous sections of this thesis the 
isolated and purified SiaP protein from E. coli cells was partially saturated with Sia 
which would limit further studies of the protein properties. Therefore, a production 
method of Sia-free SiaP protein had to be developed. In order to produce Sia-free SiaP 
protein two separate approaches were undertaken. 
 
3.3.5.1   Post-induction culturing time extension 
The first approach to produce Sia-free SiaP was based on the fact that E.coli cells 
metabolize Sia and are able to use it a sole source of carbon (Vimr and Troy, 1985). 
Culture of E. coli KRX pJS201 were induced at OD=0.5 (midlog phase) with rhamnose 
0.01% (w/v). Post induction culturing time was extended in order to allow cells to 
metabolize Sia present in the expression medium (LB) that would otherwise be bound 
by the SiaP protein. The cultures were grown at 37°C for 4 and 24 hours after inductio.  
Isolated proteins from both cultures were analysed by MS. There were both Sia bound 
and Sia free fractions of SiaP detected in the sample isolated from the culture after 4 
hours post induction (Figure 3.71). The SiaP sample isolated 24 hours after induction 
was composed solely of Sia free molecules (Figure 3.72). This indicates that production 
of Sia free SiaP protein is possible by extension of culturing time. 
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Figure 3.71. MS analysis of the SiaP protein isolated from E. coli KRX 4 hours following induction. The 
peaks corresponding to both Sia free and Sia bound forms of SiaP are marked. The concentration of the 
SiaP in the injected sample was  285 nM. 
Figure 3.72. MS analysis of the SiaP protein isolated from E. coli KRX 24 hours following induction. 
The peak corresponding to Sia free SiaP is marked. The concentration of the SiaP in the injected sample 
was  285 nM. 
  134 
3.3.5.2     Sialic acid removal by SiaP protein denaturation 
In order to produce the Sia-free form of SiaP, the protein was immobilised on a NiNTA 
agarose column and subjected to strong chaotropic agents (urea or GnHCl) and after 
denaturation the Sia was washed off. As the native three-dimensional structure of 
ligand-binding pocket of the protein is required for Sia binding, the denaturation of the 
protein leads to Sia release. Initially, SiaP (2mg/ml = 567.7 µM in lysis buffer) was 
saturated with Neu5Ac (1135.4 µM) and after 10 min incubation the free Sia was 
removed by washing with molecular grade water (using 10 kDa cut off point Amicon 
columns). The saturation of SiaP with Sia was confirmed by MS analysis (Figure 3.73 
A). Then the SiaP protein was immobilised via the His-tag on Ni-NTA agarose beads 
and the column was washed with 10 ml of 8 M urea or 6 M GnHCl (in lysis buffer) to 
remove the Sia. The protein was then washed with 2 ml of lysis buffer to remove the 
denaturants, eluted with 3 ml of 300 mM imidazole buffer and washed with water. The 
SiaP protein after denaturation was analysed by MS to confirm the effectiveness of the 
procedure. There was no Sia bound SiaP detected in samples treated with either GnHCl 
or urea (Figure 3.73 B and C respectively) which indicates that the Sia was removed 
from the protein during the denaturation step. In order to confirm that the removal of 
Sia is due to denaturant application, and not the impact of the wash, the control sample 
of SiaP was treated with lysis buffer instead of denaturant. After the procedure the SiaP 
protein was still saturated with Sia (Figure 3.74) which indicates that it was not 
removed by the lysis buffer wash. 
The efficient removal of Sia from the SiaP protein binding site requires denaturation of 
the protein; conversely the binding of Sia occurs only if the SiaP protein is correctly 
folded. Hence, after Sia removal by denaturant application it is crucial to make certain 
that the protein refolds and regains its native conformation in order to be fully active. 
After denaturation the SiaP protein immobilised on the Ni-NTA resin was washed with 
lysis buffer to remove urea or GnHCl. To verify the activity of the SiaP protein the 
sample was re-saturated with Sia and analysed with MS. It was found that only Sia 
bound molecules were present (Figure 3.73 D) which indicates full activity of the 
protein. 
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Figure 3.73. MS analysis of Sia elution from SiaP using GnHCl and urea. The concentration of SiaP in 
all samples was 285 nM. SiaP samples before (A) the process, after treatment with respectively GnHCl 
(B) and urea (C) and a control sample (washed with lysis buffer) (D) are presented. Both ligand bound 
and ligand free SiaP fractions are marked. 
Figure 3.74. MS analysisof the SiaP activity after 8 M Urea treatment. 
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Investigation of SiaP protein specificity using ELLA 
The specificity of the SiaP protein for sialylated glycans was investigated using the 
ELLA. Immobilised glycoproteins carrying terminal Sia were used as targets for SiaP 
and two commercially available Sia binders, wheat germ agglutinin (WGA) and 
Sambuccus nigra agglutinin (SNA) used as positive controls. Sialylated glycoproteins 
fetuin and transferin, along with asialofetuin used as a negative control, were probed 
with 6His-tagged SiaP protein and biotinylated WGA and SNA. It was found that SiaP 
did not bind to either of the sialylated glycoproteins tested (Figure 3.75). The presence 
of glycoproteins on the surface of the well was confirmed by positive results of WGA 
and SNA tests. The His-tagged SiaP immobilised directly on the surface as a positive 
control for anti-His antibodies gave a positive result in the test (anti-His Abs positive 
control, Figure 3.75) which confirms that SiaP can be detected in a given concentration 
(5µg/ml). The negative controls for both anti-His and anti-biotin antibodies were tested 
negatively which confirms the antibodies’ specificities.  
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Figure 3.75.  ELLA analysis of the SiaP specificity for sialylated glycoproteins. SiaP protein at two 
different concentrations was tested against Fetuin, Asialofetuin and Transferin immobilised directly on the 
plate. The PBS buffer was used as a negative control for Sia-binding proteins.  The negative controls for 
antibodies consisted of glycoproteins (or PBS) untreated with Sia-binding proteins. The positive control 
for anti-His antibodies was a SiaP protein [5 µg/ml] immobilised directly on the plate. As controls two 
other Sia-binding proteins were tested: WGA and SNA. 
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The negative result of SiaP protein in the ELLA assay with glycoproteins may be 
attributed to either inability of the protein to bind the terminal Sia of the glycoprotein or 
inability to bind Sia in any conjugate. It is possible that the lack of interaction of SiaP 
with glycoproteins is due to steric constraints as the SiaPs conformational change 
during ligand accommodation may be prohibited by the glycan structure to which the 
Sia is attached. 
The SiaP’s deep binding pocket may limit the range of possible ligands to free Sia or 
Sia coupled with much less complex structure than a glycan tree. The ability of the SiaP 
protein to bind such structures was tested using a biotinylated form of Sia. A flexible 
linker (polyacrylamide [PAA]) between Sia and biotin should decrease the steric 
constraints and allow ligand accommodation. Immobilisation of various concentrations 
of biotinylated Sia was achieved by utilization of the biotin-specific neutravidin protein 
which was initially immobilised on NUNC MaxiSorp 96 well plates. Subsequently, the 
surface was incubated with 0.5 mM biotin to cap unsaturated neutravidin binding sites 
and finally tested with SiaP protein and commercial lectins (WGA and SNA). The result 
of this test for the SiaP protein was negative which indicates that SiaP does not bind to 
biotinylated Sia (Figure 3.76). No signal increase was also detected for WGA and SNA 
when applied on the surface treated with 1 µg/ml biotinylated Sia (Sia-biot [1 µg/ml] in 
Figure 3.76). The signal for WGA and SNA doubled in comparison to the negative 
control (PBS) when applied on the surface treated with 10 µg/ml biotinylated Sia. 
However, the same surface tested with anti-biotin antibodies yielded also twice as much 
signal as a reference surface (PBS). This indicates that the biotinylated Sia at the 
concentration of 10 µg/ml was successfully immobilised on the surface; however, SiaP 
showed no specificity for this conjugate. The results of ELLA experiments suggest that 
SiaP protein does not bind to conjugated Sia, neither terminal Sia of glycans nor PAA-
linked Sia. 
 
 
 
 
 
 
  138 
0
0,5
1
1,5
2
2,5
3
PBS Sia-biot [1
µg/ml]
Sia-biot [10
µg/ml]
positive control
for anti-biotin
antibodies
positive control
for anti-His
antibodies
A
bs
o
rb
a
n
c
e
 
a
t 4
50
 
n
m SiaP [10 µg/ml]
WGA [5 µg/ml]
SNA [1 µg/ml]
negative for anti-biotin Abs
negative for anti-His Abs
SiaP [5 µg/ml]
WGA [5 µg/ml]
Figure 3.76. ELLA analysis of the SiaP specificity for sialylated conjugates. SiaP protein was tested 
against biotinylated Neu5Ac immobilised on the plate via neutravidin. The PBS buffer was used as a 
negative control for Sia binding proteins.  The negative controls for antibodies consisted of 
neutravidin/biot-Neu5Ac (or PBS) untreated with Sia binding proteins. The positive controls for anti-His 
and anti-biotin antibodies were SiaP protein [5 µg/ml] and WGA [5 µg/ml] respectively immobilised 
directly on the plate. As controls, two other Sia binding proteins were tested: WGA and SNA. 
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3.3.6 Utilization of SiaP protein for sialic acid determination 
In order to utilize the SiaP protein for detection and quantification of free Sia, the 
activity of the protein was tested with various analytical platforms. Results described in 
this section involve experiments performed using Mass Spectrometry and surface 
plasmon resonance. 
 
3.3.6.1   Mass Spectrometry based free sialic acid quantification using SiaP 
It was previously found (section 3.3.4) that the molecular mass of the SiaP protein can 
be precisely measured using MS. The Sia-free and Sia-bound species of SiaP can be 
distinguished on the basis of their mass to charge ratios. It was also found that after 
addition of the free Sia to the SiaP sample, the only species detected was the ligand-
bound SiaP (Figure 3.75). The aim of this section of the study was to find a range of Sia 
concentrations in which the changes of Sia concentration linearly correlates with 
changes of ligand-free and ligand-bound concentrations of SiaP. This would 
subsequently lead to the development of Sia quantification method based on MS and 
SiaP protein. 
The sample of SiaP was incubated with different concentrations of Sia and as the 
concentration of Sia was gradually increasing the decrease of Sia-free SiaP was 
observed using MS (Figure 3.77). At the same time the Sia-bound SiaP fraction was 
increasing.  
 
Figure 3.77. MS analysis of SiaP samples perincubated with different levels of Neu5Ac. The 
concentration of SiaP was the same in all samples (285 nM) and the concentration of Neu5Ac was as 
follows: A – 0, B – 10 nM , C – 100 nM, D – 285 nM, E- 400 nM, F - 1000 nM. 
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It was found that although the decrease in the amount of the ligand free protein and 
increase in the ligand bound protein correlates with the increase in the Neu5As 
concentration, the correlation is not linear. The concentration of SiaP in all samples was 
285nM. The control sample with no external Sia added was composed of mostly Sia 
free SiaP protein. In the sample with a 10 nM concentration of Sia a significant drop in 
Sia free SiaP and increase in Sia bound SiaP was observed (Figure 3.77 B) in 
comparison to the control sample with no additional Sia added (Figure 3.77 A). 
However, in the sample with a ten times higher concentration of Sia no further changes 
were observed (Figure 3.77 C). The addition of an equimolar amount of Sia to the SiaP 
sample caused larger changes in Sia free and Sia bound fractions of SiaP; nonetheless, 
the Sia free compounds were still detectable. Further addition of Sia caused only slight 
changes to the ratio of ligandfree and ligand-bound SiaP protein concentrations. The 
lack of linearity in the SiaP response to various Sia levels may be attributed to the 
intrinsic features of the protein. The SiaP protein solution may interact in a non-linear 
way with increasing level of Sia. It is also possible that the insufficient resolution of the 
available MS equipment influenced the results as the difference in m/z values between 
unsubstituted and substituted forms of SiaP is minute (2937 and 2953 respecively – see 
Figure 3.70).  
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3.3.6.2   Surface plasmon resonance-based free sialic acid quantification   
using SiaP 
Neutravidin and biotinylated sialic acid tests 
In order to test usability of a surface plasmon resonance for free Sia detection and 
quantification using the SiaP protein various formats were used initially. One approach 
involved immobilisation of neutravidin, addition of biotinylated Sia and probing with 
SiaP (Figure 3.78). The SiaP protein was shown in above ELLA experiments not to bind 
conjugated Sia; hovewer, in the below presented tests a different analytical platform is 
used (surface plasmon resonance). This test was designed for development of a 
competitive assay for free Sia where the SiaP would be mixed with Sia and then applied 
on the chip. As the SiaP has a relatively large mass (35.5 kDa) its interaction with the 
surface would be clearly detectable, increasing the sensitivity of the assay. 
 
 
 
 
 
 
The immobilisation of neutravidin on the CM5 biacore chip was optimised. 
Preconcentration of 50 µg/ml protein was performed using a standard procedure (see 
section 2.24 above). It was found that the optimal pH of the sodium acetate buffer was 
pH 4.4, as the response indicating protein interaction with the dextran surface is the 
highest when sodium acetate buffer at this pH was selected Figure 3.79). 
 
 
 
 
 
 
 
CM5 chip
Neutravidin Strep2 tagged SiaPBiotinylated Sialic Acid    His-tagged SiaP  
Figure 3.78. Immobilisation of biotinylated Sia on CM5 chip via Neutravidin and subsequent treatment 
with SiaP. 
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The neutravidin was then successfully immobilised on a CM5 chip via standard 
EDC/NHS coupling. After application of 200 µl of 50 µg/ml neutravidin the chip was 
capped with ethhanoane and unspecifically bound material was removed by four 
injections of sodium hydroxide. The baseline was found to be stable after NaOH 
injections (Figure 3.80).  
 
 
The neutravidin surface was subsequently used to capture biotinylated Sia. The 
biotinylated Sia was successfully captured on a neutravidin-coated CM5 chip (Figure 
3.78). It was observed that 791 RU of biotinylated Sia were captured on this surface 
Figure 3.79. BIACORE 3000 sensogram representing the preconcentration of neutravidin protein [50 
µg/ml] on the biacore CM5 chip.  The pH of the sodium acetate buffers used for each injection are 
marked over each peak.  
Figure 3.80. BIACORE 3000 sensogram representing neutravidin immobilisation on the CM5 chip. The 
asterisks indicate the beginning and end of injections. The injections of EDC/NHS, neutravidin, 
ethanolamine and NaOH are marked over the areas corresponding to each injection. 
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after 150 µl of 50 µg/ml sample was injected (concentration previously optimised, data 
not shown, Biacore, 2003). Binding was represented by a typical increase in RU, as 
illustrated in Figure 3.81.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, the SiaP protein was passed over the surface. A 50 µl sample of 50 µg/ml was 
selected and the response was monitored on the sensorgram presented in Figure . No 
stable change in response was observed in the sensogram. A rise of response straight 
after the start of the injection was detected but it declined afterwards resulting in overall 
baseline drift of 35 RU (Figure 3.82). The molecular mass of SiaP is 35.5 kDa and, if 
bound to the CM5 chip, it would clearly be detected with the biacore system. Lack of a 
stable signal on the sensorgam indicates that there is no true binding between the 
neutravidin/biot-Neu5Ac CM5 chip and the SiaP.  This eliminates the possibility of 
utilisation of this particular format and confirms earlier ELLA-based analysis, which 
shows that SiaP can only bind to a free (and not conjugated) Sia. 
 
 
 
 
 
Figure 3.81. BIACORE 3000 sensorgram demonstrating binding of biotinylated Sia to a neutravidin 
coated CM5 chip. The asterisks indicate the beginning and end of injection of biot-Neu5Ac (150 µl of 50 
µg/ml). 
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Immobilisation of and Strep2-tagged SiaP protein via neutravidin  
In the subsequently tested formats the SiaP protein was immobilised on CM5 biacore 
chips and used to detect free Sia. Two of the formats applied involved indirect 
immobilisation of SiaP on the biacore CM5 chip via either a deglycosylated version of 
avidin, neutravidin or antibodies. These would benefit from orientated immobilisation 
and enable regeneration of the surface as the neutravidin (or antibody)/SiaP interaction 
is not covalent. In the first format the SiaP 2031 (C-terminally Strep2 tagged with a 
linker) was immobilised on a neutravidin-coated CM5 chip via the Strep2 tag (Figure 
3.83).  Sia was subsequently passed over the sensor surface at varying concentrations 
and the changes in signal were monitored. 
 
 
The neutravidin was successfully immobilised on a CM5 chip via standard 
EDC/NHS coupling. Application of 200 µl of 50 µg/ml neutravidin yielded a stable 
baseline (baseline did not shift ater regeneration with NaOH) at 39.400 response 
units (RU) (Figure 3.84). 
CM5 chip
Neutravidin Strep2 tagged SiaP Sialic Acid
Figure 3.83. Immobilisation of Strep2-tagged SiaP via Neutravidin and subsequent treatment with free Sia. 
Figure 3.82 BIACORE 3000 sensorgram demonstrating injection of the SiaP protein on a 
neutravidin/biot-Neu5Ac-coated CM5 chip. Points 1 and 2 indicate respectively start and stop of the SiaP 
(50 µl of 50 µg/ml) injection. 
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The neutravidin surface was used to immoblise SiaP 2031 protein (Strep2-tagged with a 
linker). The injection of 50 µl of 50 µg/ml of SiaP protein resulted in an increase of 121 
RU of the baseline (Figure 3.85). However, as the baseline was not stable after the 
injection and significant drift was observed, the injection of SiaP was repeated. An 
additional injection of 150 µl of 50 µg/ml of SiaP resulted in an overall increase of 275 
RU. The baseline after SiaP immobilisation was found to be unstable and significant 
baseline drift was observed over time in the absence of any analyte (Figure 3.85).  This 
baseline drift is attributed to the decrease of the mass of the molecules present on the 
surface of the chip. As the neutravidin was covalently linked to the dextran layer of the 
chip the mass change may be attributed to the leaching of the SiaP protein from the chip 
under the flow of the buffer (10 µl/min), which in turns indicates low affinity of the 
SiaP for the neutravidin surface. 
 
Figure 3.84. BIACORE 3000 sensogram representing neutravidin immobilisation on the CM5 chip. The 
astersks indicate the beginning and end of injections. The injections of EDC/NHS, neutravidin, 
ethanolamine and NaOH are marked over the areas corresponding to each injection. 
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Application of various concentrations of Sia over neutravidin-SiaP surface 
In order to test the surface response to Sia, various concentrations of Sia were selected.  
Application of various concentrations of Sia (1 nM – 1 mM) did not result in a 
noticeable increase in RU, or did not stabilise the baseline. The injection of a 5mM Sia 
sample resulted in a temporarily-increased signal (Figure 3.86). This phenomenon is 
caused by change of refractive index (RI) as the buffer injected had a different 
composition (higher Sia concentration in comparison to “pure” HBS buffer used 
between injections). The lack of a stable response after Sia injection may be attributed 
to insufficient quantities of SiaP on the sensor surface. 
 
 
 
 
 
Figure 3.85. BIACORE 3000 sensorgram demonstrating binding of the SiaP protein to a neutravidin-
coated CM5 chip.  The astersks indicate the beginning and end of injections. During the first injection of 
SiaP 50 µl of 50 µg/ml protein was applied; during the second injection of SiaP 150 µl of 50 µg/ml 
protein was applied. The HBS buffer flow was monitored after each protein injection. 
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Immobilisation of the Strep2-tagged SiaP protein via Anti-Strep2 tag antibodies  
In order to increase the SiaP protein concentration on the CM5 biacore chip the protein 
was immobilised via antibodies. Additionally, this format potentially allows for chip 
regeneration as the secondary antibodies could be stripped down. Goat anti-mouse IgG 
was immobilised directly on the CM5 chip and used to capture anti-Strep2 antibody 
(StrepMAB-Immo).  Subsequently, the SiaP protein was immobilised on the chip via its 
Strep2 tag and used to capture free Sia Figure 3.87.  
 
CM5 chip
Goat anti Mouse IgG StrepMAB-Immo
Strep2 tagged SiaP
Sialic Acid
Figure 3.87. Immobilization of Strep2 tagged SiaP via a Goat anti-mouse IgG and a StrepMAB-Immo 
antibody, and subsequent treatment with free Sia. 
Figure 3.86.  BIACORE 3000 sensorgram demonstrating injections of Sia at various concentrations on 
the SiaP coated surface. The astersks indicate the beginning and end of injections. The concentrations 
of Sia used are indicated above the parts of sensogram corresponding to them. Between the Sia 
injections the HBS buffer flow was monitored. 
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The immobilisation of goat anti-mouse antibodies on a CM5 biacore chip was 
optimised. Preconcentration of 50 µg/ml protein (Biacore, 2003) was performed using 
standard procedure. It was found that the optimal pH of the sodium acetate buffer was 
4.6 (Figure 3.88). 
 
 
 
The goat anti-mouse antibody was then successfully immobilised on a CM5 chip via 
standard EDC/NHS coupling. Application of 200 µl of 50 µg/ml of the antibody yielded 
a stable baseline (baseline did not shift after regeneration with NaOH) at 36.400 
response units (RU) (Figure 3.89).  
Figure 3.88. BIACORE 3000 sensogram representing the preconcentration of neutravidin protein [50 
µg/ml] on the biacore CM5 chip.  The pH of the sodium acetate buffer used for each injection is marked 
over each peak. 
Figure 3.89.  BIACORE 3000 sensogram representing goat anti-mouse antibodies immobilisation on the 
CM5 chip. The asterisks indicate the beginning and end of injections. The injections of EDC/NHS, goat 
anti-mouse antibodies, ethanolamine and NaOH are marked over the areas corresponding to each 
injection. 
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The goat anti-mouse antibody surface was used to immobilise mouse anti-Strep2 
antibodies (StrepMAB-Immo). The injection of 200 µl of 50 µg/ml of StrepMAB-Immo 
resulted in an increase of 2391 RU over the baseline (Figure 3.90). 
 
 
Subsequently the SiaP protein was immobilised on the antibody surface. The injection 
of 200 µl of 300 µg/ml of SiaP 2031 protein resulted in an increase of 207 RU in the 
baseline (Figure 3.91). After the injection the baseline was not stable and a drift of the 
baseline was observed; however, the drift was not as sharp as when the SiaP was 
immobilised on the neutravidin surface, indicating that the antibody surface has a higher 
affinity for SiaP than neutravidin. The immediate drift of the baseline after the start of 
injection and sharp rise at the end of the injection is attributed to the buffer composition 
change. The sample of SiaP had a relatively high concentration (300 µg/ml of protein) 
in comparison to the HBS buffer that flows through the flowcell before and after the 
injection. The unstable interaction between SiaP protein and the surface was not optimal 
for the development of a quantitative test; however, the surface was tested with Sia in 
order to investigate the responsiveness of the equipement. 
 
 
 
 
 
 
 
Figure 3.90. BIACORE 3000 sensogram representing mouse anti-Strep2 antibodies immobilisation on 
the goat anti-mouse antibodies coated CM5 chip. The asterisks indicate the beginning and end of 
injections. The injection of mouse anti-Strep2 antibodies is marked over the area corresponding to each 
injection. 
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Application of various concentrations of sialic acid over StrepMAB antibodies-SiaP 
surface 
The antibody/SiaP surface was ultimately tested with Sia. The initial application of 5 
mM Sia was found to cause a stable rise of an overall signal of 432 RU (Figure 3.92). 
The sharp increase of the signal after the start of the Sia injections and drift of the signal 
at the end of the injections were attributed to the change of the refractive index of the 
buffer caused by different buffer compositions during the injections. The active surface 
was subsequently treated with 10mM NaOH (regeneration step). An incline of the signal 
of 512 RU indicates that Sia was washed off the chip as the baseline returned almost to 
the state before Sia application. The sudden drift of the baseline at the beginning of the 
10 mM NaOH application and sharp increase of the signal at the end on the injection 
were attributed to the buffer composition changes. The application of 5 mM Sia was 
repeated two more times. After each Sia application the increase in response units was 
observed which indicates that Sia was captured (Figure 3.92). However, injection of 1 
mM Sia did not yield a stable increase of the signal. This indicates that the lower 
detection limit of this surface for Sia is between 1 mM and 5 mM. More importantly 
this indicates that it is possible to detect Sia using the SiaP protein and Biacore systems. 
Nonetheless, it is crucial for further tests to optimize SiaP immobilisation in order to 
have a stable baseline before Sia injections. 
Figure 3.91. BIACORE 3000 sensogram representing SiaP immobilisation on the antibodies coated CM5 
chip. The asterisks indicate the beginning and end of injections. The injection of SiaP is marked over the 
area corresponding to the injection. 
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Direct immobilisation of the 6xLys tagged SiaP protein on the CM5 chip 
Another format tested in order to maximize the stability of SiaP on the CM5 biacore 
Figure 3.92. BIACORE 3000 sensorgram demonstrating injections of Sia at various concentrations on 
the SiaP coated surface. The asterisks indicate the beginning and end of injections. The concentrations of 
Sia used are indicated above the parts of sensogram corresponding to them. Between the Sia injections 
the HBS buffer flow was monitored. 
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chip surface involved direct immobilisation of the 6Lys-tagged SiaP (SiaP 2021) protein 
on the active surface. This simplified format offers higher stability of the immobilised 
SiaP protein as the protein is covalently immobilised on the dextran surface of the chip. 
The 6Lys-tagged SiaP protein was selected for this process as the C-terminally located 
lysine tag used for EDC/NHS standard amine coupling increases the possibility of 
orientated immobilisation (Allard et al., 2001). Preconcentration of 100 µg/ml protein 
was performed using the standard procedure (see section 2.2.4 above). It was found that 
the SiaP protein unspecifically binds to the surface (Figure 3.93) as the signal was 
gradually increasing after each protein sample injection.  
 
 
 
The preconcentraion procedure was modified by adding a NaOH regeneration step after 
each SiaP injection in order to remove the unspecifically bound SiaP molecules. The 
regeneration involved injection of 5 µl of 10 mM NaOH at 10 µl/min. Using this 
modified preconcentration procedure the immobilisation conditions for SiaP 2021 were 
optimised. It was found that the optimal pH of the sodium acetate buffer was 5.0 (Figure 
3.94). 
Figure 3.93. BIACORE 3000 sensogram representing the preconcentration of SiaP 2021 protein [100 
µg/ml] on the biacore CM5 chip.  The pH values of the sodium acetate buffer used for each injection are 
marked over each peak. 
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The SiaP 2021 protein was then successfully immobilised on a CM5 chip via standard 
EDC/NHS coupling. Application of 200 µl of 100 µg/ml of the protein yielded a stable 
baseline at 24,007 RU (Figure 3.95). After subtraction of the baseline before the process 
only 4657 RU of SiaP was immobilised. 
 
 
Figure 3.94. BIACORE 3000 sensogram representing the modified preconcentration of the SiaP 2021 
protein [100 µg/ml] on the biacore CM5 chip.  The asterisks indicate the beginning and end of injections. 
The pH of the sodium acetate buffer used for each injection are marked over each peak. 
Figure 3.95. BIACORE 3000 sensogram representing SiaP 2021 immobilisation on the CM5 chip. The 
asterisks indicate the beginning and end of injections. The injections of EDC/NHS, SiaP, ethanolamine 
and NaOH are marked over the areas corresponding to each injection. 
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In order to confirm the activity of the immobilised SiaP in this format the chip was 
tested with 5 mM Sia. This concentration of Sia was previously found to be detectable 
with SiaP protein using biacore system (SiaP protein immobilised on StrepMAB 
antibodies). Injection of 5 mM Sia resulted in a drift of 5 RU (Figure 3.96) which 
indicates that there was no true binding between Sia and SiaP on the chip. This may be 
attributed to either the protein being inactive after direct immobilisation or the amount 
of protein immobilised on the chip being too low to detect the Sia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To increase the concentration of SiaP 2021 on the CM5 chip the immobilisation 
procedure was modified. A higher concentration of the protein was used (200 µg/ml) 
and the volume of the injection was increased to 300 µl. It was found that a significantly 
greater amount of SiaP was immobilised using these conditions: 12336 RU (Figure 
3.97). Furthermore the baseline after SiaP immobilisation was stable. This was achieved 
by the application of amine coupling which generates stable covalent bonds between the 
dextran layer and the SiaP protein.  
 
 
 
 
 
 
Figure 3.96. Activity test of SiaP directly immobilised on the CM5 chip with Sia. Points 1 to 2: injection of 
50 µl of 5 mM Sia. 
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In order to confirm the activity of the immobilised SiaP the chip was tested with 5 mM 
Sia. Injection of the Sia resulted in an increase of 81.3 RU (Figure 3.98); however, on 
the reference surface (non activated carboxymethylated dextran) a similar increase of 
79.4 RU (Figure 3.99) was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.97. Immoblilisation of the SiaP protein on the Biacore CM5 chip. Points 1 to 2: surface activation 
with 70 µl of EDC/NHS; points 3 to 4 immobilisation of 300 µl of SiaP [200 µg/ml]; points 5 to 6: 
blocking with 70 µl of ethanolamine-HCl (pH 8.5, 1 M); points 7 to 12: regeneration with three 5 µl 
injections of NaOH [5 mM]. 
Figure 3.98. Activity test of SiaP directly immobilised on the CM5 chip with Sia. Points 1 to 2: injection of 
50 µl of 5 mM Sia. 
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To eliminate the Sia interaction with the reference surface, it was blocked by activation 
followed by capping. The dextran surface was activated by 140 µl injection of 
EDC/NHS followed by capping with 70 µl of ethanolamine and regeneration with 
NaOH (Figure 3.100). 
 
 
 
 
After blocking the reference surface, the activity test with 5 mM Sia was repeated. 
Injection of the Sia resulted in an increase of 203.1 RU (Figure 3.101). On the reference 
Figure 3.99.  Sensorgam representing the injection of 50 µl of 5 mM Sia onto the reference surface 
during the activity test of immobilised SiaP protein. 
Figure 3.100. Blocking of the dextran surface by EDC/NHS activation and ethanolamine capping 
followed by NaOH removal of unspecifically bound material. 
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surface an increase of 50.6 RU (Figure 3.102) was observed. The net increase after 
subtraction of the reference surface was 152.5 RU which indicates that true binding 
between Sia and SiaP immobilised directly on the chip takes place and that the protein is 
active in this format. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.101. Activity test of SiaP directly immobilised on the CM5 chip with Sia. Points 1 to 2: 
injection of 50 µl of 5 mM SA. 
Figure 3.102. Sensorgam presenting the injection of 50 µl of 5 mM Sia onto the blocked reference 
surface during the activity test of immobilised SiaP protein. 
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Detection of various concentrations of sialic acid using SiaP on the Biacore chip 
The response of SiaP directly immobilised on the CM5 chip was studied using various 
concentrations of Sia (in triplicates). Initially a range of Sia concentrations from 1 mM 
to 8 mM was studied. It was found that increasing concentrations of Sia resulted in the 
increasing response of the active surface. The injection of HBS buffer yielded 3 RU 
(Figure 3.103 and Appendix), 1mM Sia yielded 17 RU, 3 mM – 20 RU, 5 mM – 24 RU, 
7 mM – 34 RU, 8 mM – 40 RU. The injection of 10 mM galactose used as a specificity 
control yielded 7 RU. Furthermore the response in a given range was close to linear (R2 
= 0,9283) (Figure 3.103 and Appendix). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to test the upper detection limit of the system higher concentrations of Sia were 
tested (in triplicates) and the results are plotted in Figure 3.104. It was found that the 
injection of 10 mM Sia yielded 166 RU (Appendix) which is unproportionally high in 
comparison to 8 mM result of 40 RU. The subsequent injection of 15 mM – resulted in 
135 RU, which is a decline in comparison to 10 mM 166 RU. The result of injection of 
20 mM was again lower than previous – 49 RU. The active surface was ultimately 
tested with 8 mM Sia to verifiy its activity. It was found that injection of 8 mM Sia 
resulted in 40 RU (Appendix), which is in concert with the first 8 mM test. This 
indicates that the active surface was fully functional. The specificity of the method was 
Correlation between sialic acid concentration and SiaP response on 
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Figure 3.103. Correlation between Sia concentration in the range of 0 mM to 8 mM and SiaP protein 
response on the biacore chip.  
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tested with 10 mM galactose. It was found that the galactose injection resulted in the 
increase of the baseline of 7 RU (Appendix), which is similar to the HBS buffer value 
and thus indicates no interaction with the surface of the chip. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation between sialic acid concentration and SiaP response on 
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Figure 3.104. Correlation between Sia concentration in the range of 0 mM to 20 mM and SiaP protein 
response on the biacore chip. 
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4 Discussion 
 
As the ultimate goal of the project was to apply Sia binding lectins as an analytical tool 
the goal of this section was to produce active HA1 protein expressed in E. coli. The ha1 
gene was initially cloned into the pKK233 derived pLecB3 expression vector containing 
an additional Ribosome Binding Site and His-tag sequence to facilitate efficient 
expression and convenient further purification of the HA1 protein. Another 
advantageous feature of the pLecB3 vector is the strong IPTG inducible Ptac promoter 
which allows for regulated expression of the ha1 gene. 
E. coli BL21 and Rosetta strains were initially chosen as hosts for expression. These are 
protease deficient strains that should limit heterologous protein degradation. 
Furthermore the Rosetta strain contains an additional plasmid with tRNAs for 
mammalian codons that rarely occur in E. coli. The initial expression of the HA1 
protein in E. coli from the pJS102 plasmid confirmed the successful use of the 
expression system utilized. However, the successfully expressed HA1 protein was 
exclusively produced in an insoluble form in inclusion bodies. Expression of the protein 
in a number of E. coli strains was undertaken under a variety of expression conditions. 
However, the results of these experiments were not fully successful, regretfully, with 
respect to the production of a soluble HA1 protein. Furthermore, there was no control 
over the induction process caused by “leaky” expression at a substantial level. The 
“leaky” expression in the E. coli Bl21 strain is in accordance with previous reports 
(Gosse et al., 1993; Tougu et al., 1996). Therefore, the XL10-Gold strain was utilized to 
lower the pace of expression by regulated induction of the ha1 gene. It is a common 
practice in protein expression studies to promote solubility by lowering the growth 
temperature and concentration of inducing agent (Sørensen et al., 2005).  The culturing 
conditions were optimized in order to slow down expression and thus enable correct 
folding of the HA1 protein that would increase its solubility. Such factors as culturing 
temperature and concentration of IPTG used for induction were tested. However, the 
HA1 protein was expressed exclusively in an insoluble form. 
In order to produce the HA1 protein in soluble form two separate approaches were 
undertaken. One was based on alteration of the expression system in order to obtain a 
soluble protein. The second approach was focused on solubilisation of the initially 
expressed aggregates of HA1 protein. 
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As previously reported, the solubility of heterologous proteins expressed in E. coli is 
often increased by targeting to the periplasmic space as well as by fusion protein 
utilization (Pryor et al., 1997; Dyson et al., 2004). Both of the above strategies were 
used to promote solubility of the HA1 protein. The Sec translocation system was 
initially utilized for HA1 targeting into the periplasmic space. Although successfully 
expressed with a signal sequence the HA1 protein was insoluble. This may be attributed 
to the mechanism of transloaction by the Sec system which is a posttranslational system 
(Fekkes et al., 1999). Thus, nascently produced polypeptide is translocated in this case 
after being fully synthesized. The aggregation that possibly occurred before the 
termination of   the translation process might have prevented subsequent translocation.  
Fusion proteins are often used for heterologous protein expression in E. coli offering 
several advantages like increased expression rates or simplified and efficient 
purification and also, most importantly for this study, increased solubility of the product 
(Pryor et al., 1997; Dyson et al., 2004). The maltose binding protein (MBP) was found 
to be the most effective fusion partner for promoting solubility (Dyson et al., 2004). 
Thus the ha1 gene was successfully cloned in frame with the malE gene encoding MBP 
in pMALp2E vector. The expression of MBP fused HA1 was unsuccessful as the 
overexpression of the MBP-HA1 was not detected by SDS-PAGE analysis neither in the 
soluble nor in the insoluble fractions of the cells. The lack of HA1 protein may be 
explained by the protease activity, which is present in the XL10-Gold strain of E. coli 
(Stratagene). However, the HA1 protein was successfully expressed in this strain before. 
The addition of MBP as a fusion partner seems to hamper the production of the protein. 
It is possible that the large size of the transcript which is 2235 bp corresponding to 745 
amino acids (including the signal sequence) impairs or even makes the production of 
such a polypeptide impossible. Such results of HA1 expression in E.coli are in concert 
with previous reports where the entire influenza virus hemagglutinin protein was 
expressed with β-galactosidase as a fusion partner in a soluble form but in a very low 
quantity (Davis et al., 1981). 
Production of soluble mammalian proteins in E. coli by solubilisation and refolding of 
polypeptides expressed in the form of inclusion bodies is another widely applied 
practice (Vallejo et al., 2004). Such a strategy was applied in parallel with previously 
discussed expression alterations as the results of this part of the study would be 
beneficial in two ways with regards to the ultimate goal of the project. Firstly, optimized 
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solubilization conditions would enable efficient HA1 purification and, as a result, 
promote refolding of the soluble active product (Fekkes et al., 1999). Secondly, 
effective denaturation followed by successful refolding may be utilized for ligand 
release to regenerate the ligand free form of the protein. Concentrated solutions of urea 
as well as guanidine hydrochloride, respectively, were used in this study as they are 
reported to be the most potent chaotropic agents for solubilisation of protein aggregates 
(Vallejo et al., 2004). The solubilisation of the HA1 protein using urea at various 
temperatures of incubation was unsuccessful. It is possible that urea is not a strong 
enough chaotropic agent to solubilise this particular protein. The unsuccessful 
solubilisation may also be attributed to the reported impact of the pH on the 
solubilisation process using urea, as urea at various pH values influences the 
solubilisation of a given protein differently (Estapé et al., 1996). 
The application of guanidine hydrochloride as a denaturant was initially unsuccessful 
with the concentration of the chaotropic agent of 6 M, which is the most widely used 
concentration reported (Vallejo et al., 2004). As the unsuccessful solubilisation of HA1 
protein by 6 M GnHCl may be attributed to the denaturant being still too weak to break 
the protein aggregates down, a higher concentration of GnHCl was applied. The 
solubilisation of HA1 protein by 8 M GnHCl was successful and soluble polypeptide 
was obtained. 
In order to purify the solubilised HA1 protein, which would promote efficient refolding 
of the polypeptide, Immobilised Metal Affinity Chromatography (IMAC) was used. 
However, the solubilised HA1 protein was found not to bind to the preequilibrated resin 
of Ni-NTA agarose (Qiagen). The lack of binding may be attributed to the high 
concentration of GnHCl (8 M) during the procedure.  Such a high concentration may be 
incompatible with the resin, as the manufacturer suggests using a 6 M concentration of 
GnHCl at most; nevertheless, a lower concentration of GnHCl was found to be 
ineffective for HA1 protein solubilisation. Application of other resins (Westburg, 
Invitrogen) might be more successful. However, at this point in the project it was 
concluded that HA1 protein is not readily amenable to production for the purpose of the 
project and it was decided to use another sialic acid binding protein. 
The Sia-binding protein, SiaP, of H. influenzae was modified, produced, characterized 
and applied for sialic acid detection. The siaP gene was initially cloned into a pET-21b 
derived expression vector. Efficient expression of the gene was driven by the strong T7 
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promoter. The C-terminal 6His-tag was utilized to facilitate further efficient purification 
and immobilisation of the SiaP protein. Additionally C-terminal Strep2 and 6Lys tags 
were introduced which were subsequently utilized for immobilisation on the biacore 
chips.  
As an expression host E. coli KRX (Promega) cells were chosen. The T7 polymerase 
encoded in the genome of KRX cells is under control of the rhamnose 
promoter/operator. This results in not only high but also regulated protein expression 
(Guzman et al., 1995). Furthermore the ompT- and ompP- mutations eliminate 
proteolysis of the overexpressed proteins, whereas a lack of the most common nuclease 
that copurifies with plasmid DNA, achieved by endA- mutation, is an advantage during 
cloning steps (Promega). 
The expression of the SiaP protein was optimized with regards to expression time, 
concentration of inducing agent and culture cell density at the induction time. The 
decreased concentration of soluble SiaP protein in cultures induced with a higher than 
optimal level of rhamnose and/or in cultures after prolonged (overnight) expression time 
was observed. This can be attributed to the deposition of SiaP in inclusion bodies which 
is a common phenomenon of overexpressed proteins in E. coli (Vallejo and Rinas, 
2004). This reasoning is supported by the findings of the increased concentration of the 
SiaP protein present in the insoluble fractions of the respective cultures. 
The optimal conditions were applied for expression of the soluble SiaP protein that was 
later purified using affinity chromatography. During the initial manual IMAC 
purification using NiNTA agarose columns it was found that the 6His-tagged SiaP 201 
protein has low affinity for the resin and was not efficiently captured by the resin. This 
may be attributed to the low accessibility of the 6His-tag to the environment as it is 
directly at the C-terminus of the 35.5 kDa globular protein and the steric contraction 
may block it from interaction with nickel ions of the resin. In order to increase the 
accessibility of the 6His-tag the SiaP protein was engineered by introduction of the (Gly 
Gly Gly Ser)2 linker/spacer between the globular protein and the tag. The introduction 
of a flexible peptide linker composed of Gly and Ser was previously reported to 
improve immunoreactivity of a fusion peptide by increasing the distance between 
domains of the polypeptide (Hu et al., 2004). Extending the tag from the globular part 
of the SiaP protein by the utilization of the linker did indeed improve the purification 
efficiency by both nickel and StrepTactin affinity chromatography. The StrepTactin is a 
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streptavidin derivative protein with a high affinity for the biotin mimicking Strep2-tag 
(Skerra et al., 2000). Purification over the StrepTactin coated resin also verifed the 
functionality of the C-terminal Strep2-tag. 
Subsequently the molecular weight of the purified SiaP protein was accurately 
determined using MS. The results of these studies were in concert with the in silico 
predicted values. Interestingly, the SiaP protein analysed, which was isolated from a 
total cellular fraction, corresponded in size to the mature protein after cleavage of the 
initial 23-amino acid leader sequence directing the polypeptide to the periplasm. No 
larger polypeptides, containing leader sequence, were detected and thus further isolation 
of the SiaP was based on the total cell extracts, as there was no requirement for more 
complicated and time consuming periplasmic protein isolation. The highly precise MS 
method facilitated the distinction between molecules with similar molecular masses; 
hence, it was found that two - sialic acid-free and sialic acid-bound species of SiaP 
protein were present in the analysed material. The slight deviation of the analysed 
molecules from the predicted molecular masses may be attributed to the adducts of both 
water and ammonium formate. The presence of two forms of sialic acid binding SiaP 
protein is a result of the complex medium (LB) containing sialic acid utilized for 
expression. The impact of sialic acid present in the media on the SiaP protein was 
reported previously (Severi et al., 2005). It was found that SiaP protein expressed by 
cells grown in LB medium was saturated with Sia. 
SiaP with sialic acid bound is undesired for further application and in order to eliminate 
it the production process for the SiaP protein was modified. Two separate approaches 
were undertaken to obtain a homogenous, sialic acid free population of SiaP. The first 
was based on the fact that E. coli cells metabolise sialic acid and utilize it as a sole 
source of carbon (Vimr et al., 1985). Post-induction expression time was extended in 
order to allow cells to metabolize sialic acid present in the expression media (LB) which 
would otherwise be bound by SiaP protein (Severi et al., 2005). The methodology 
involving extension of the culturing time was found to be effective for sialic acid free 
production of the SiaP protein. In the second-developed method for sialic acid-free 
production of the SiaP protein the ligand was washed off from the protein by 
denaturation using chemical denaturants. The SiaP protein after immobilisation on the 
NiNTA agarose was denatured with urea or GnHCl. As the native three dimensional 
structure of the ligand binding pocket of the protein is required for sialic acid binding 
  166 
the denaturation of the protein leads to sialic acid release. The efficiency of this method 
was verified by MS. It was found that application of this protocol leads to complete 
removal of the sialic acid from sialic acid-saturated SiaP sample. The activity of the 
sialic acid free molecule was also positively verified by MS. As the SiaP protein was 
found to refold spontaneously in lysis buffer, there was no requirement for application 
of special refolding methods or conditions, which may be time consuming and not 
always succesfull (Middleberg, 2002; Vallejo and Rinas, 2004; Katoh and Kaoh, 2000). 
This suggested the possibility of regeneration of sialic acid-free protein could be reused 
in analytical devices after diagnostic tests. Both of the developed methods for sialic 
acid-free SiaP protein production were found to be successful. The clear advantage of 
the first method is its simplicity, as no additional preparation steps are required. 
However, a limiting factor may be the changeable composition of the complex medium 
with regards to sialic acid content if provided by different manufacturers or when 
different lots of the media are utilised. Elevated levels of sialic acid in the medium may 
lead to decreased efficiency of this method.  The second method of sialic acid free SiaP 
production based on the utilisation of chaotropic agents requires an additional step of 
protein denaturation. This method, however, offers reduced production time as the post-
expression time is 19 hours shorter in comparison to the alternativ method (5 and 24 
hours, respectively). Furthermore, the second protocol is much less prone to be affected 
by changeable free sialic acid content in the expression medium. In large scale 
production, the cost effectiveness of relatively cheap urea addition in the second method 
would most probably exceed the cost effectiveness of much longer expression time in 
the first method of the sialic acid free SiaP generation. It is also possible to utilise 
minimal medium for the protein expression and thus eliminate the sialic acid 
contamination (Severi et al., 2005); however, the time and cost effectiveness of such 
protocols would be limiting factors. Thus, the denaturation method is suggested if high 
amounts of the SiaP protein are required. 
Subsequently, the specificity of the SiaP protein for terminal sialic acid of 
glycoconjugates was tested using ELLA. The sialylation of the glycoproteins used in the 
tests was confirmed by positive results of the tests with commercial lectins (WGA and 
SNA).  It was found that the His-tagged SiaP protein can be readily detected using 
HRP-conjugated anti-His antibodies when immobilised on the surface of the plate used 
in the tests. Hence, the negative results of the protein tested against sialylated 
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glycoprotein can be attributed to the lack of SiaP-glycan interaction and not to the 
detection problems. It was reported previously that the SiaP protein during the ligand 
accommodation drastically changes its conformation, burying the ligand deep into the 
binding pocket (Johnston et al., 2007). Therefore, it is possible that steric constrains 
limit the binding of terminal sialic acid of the complex glycans by the SiaP, as the ligand 
is not accessible for the internally situated binding site. In order to test the SiaP 
specificity for less complex sialic acid conjugates the biotinylated sialic acid was used. 
The polyacrylamide linker connecting the two components is a much less complex 
structure than a glycan chain and thus should interfere less with the SiaP at the binding 
site. The negative results of ELLA experiments supported by similar findings using 
surface plasmon resonance, indicates lack of interaction between the SiaP protein and 
sialic acid conjugates. It is possible that the structure and mechanism of ligand 
accommodation of the SiaP protein limit the scope of the ligand to free entities and not 
conjugated ones. The elevated signal for WGA and SNA lectins observed in the same 
experiment may indicate that the biotinylated sialic acid was successfully immobilised 
using neutravidin coated surface. The increased signal was also found in the negative 
control for the anti-biotin antibodies.  This also suggests successful immobilisation of 
the biotinylated sialic acid on the surface. However, this finding makes it unclear 
whether SNA and WGA lectins bound specifically to the sialic acid or underwent an 
unspecific interaction. The SNA and WGA were previously, successfully applied for 
detection of Sia in glycoconjugates using Biacore system (Kelly et al., 2007). In order 
to investigate the specificity of SNA and WGA for biotinylated sialic acid a surface 
plasmon resonance analysis with immobilised target compound is suggested. 
Nonetheless, the biotinylated sialic acid was not captured by the SiaP protein and the 
interaction with other sialic acid binders is in question. 
As it was found that the SiaP protein in the above described tests expressed exclusive 
specificity to free sialic acid, further experiments were focused on application of the 
protein for free sialic acid detection. The MS platform was found to efficiently detect 
various concentrations of sialic acid. The detection was based on the fact that sialic acid 
saturated SiaP has a higher molecular mass than the sialic acid free SiaP. As it is 
possible to distinguish between these two species using MS, it was found that addition 
of sialic acid to the analysed SiaP protein caused relative increase of the concentration 
of sialic acid saturated species in comparison to the sialic acid-free species in the 
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sample. By monitoring the relative increase of one species and the concomitant decrease 
of the second, different responses of SiaP are observed for different concentrations of 
sialic acid.  Although detection of sialic acid was found to be possible using SiaP on the 
MS platform, the efforts to quantify the ligand were unsuccessful as the correlation 
between sialic acid concentration and the response was not linear. The creation of a 
standard curve for sialic acid quantification was impossible due to the lack of linear 
response. This may be attributed to either intrinsic features of the SiaP protein and its 
mechanism of binding or to the equipment imperfections. As the resolution of the MS is 
limited the precise differentiation between two molecules with very similar m/z values 
may occure difficult. Future advances in MS technology would certainly improve the 
resolution essential for this type of assay and therefore further tests with more advanced 
MS devices are suggested. 
Further application of the SiaP protein for free sialic acid detection and quantification 
involved utilization of the surface plasmon resonance (SRP) analysis. The SRP platform 
has been previously applied for various assay development such as telomerase activity 
assay (Maesawa et al., 2003), DNA-gyrase assay (Maxwell et al., 2006), immunoassay 
for nut protein presence (Bremer et al., 2009) and the assay to test coliphages 
contamination as a fecal pollution in water (Garcia-Aljaro et al., 2008). Both indirect, 
with immobilised biotinylated sialic acid, and direct assays for free sialic acid detection 
were tested and different formats were employed. For the indirect assay development 
neutravidin was immobilised on the CM5 biacore chip and was used to capture 
biotinylated sialic acid. Subsequently, the SiaP protein was injected in order to capture 
the immobilised ligand. The pre-incubation of the SiaP protein with the sample 
containing free sialic acid would decrease the amount of SiaP protein able to bind to the 
surface of the chip. This was designed to lead to the development of the competitive 
assay for free sialic acid. Furthermore, the relatively large molecular mass of the SiaP 
would increase the precision of the assay as any changes in the amount of such a large 
compound are clearly detectable using the Biacore system. The increased signal 
baseline after biotinylated sialic acid injection indicates successful immobilisation of 
the conjugate on the neutravidin coated surface of the chip. However, subsequent testing 
with the SiaP protein injection yielded no stable increase of the signal. This indicates 
that the SiaP protein was not binding to the surface.  The baseline drift of 35 RU 
observed during the SiaP injection can be attributed to the unspecifically bound 
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biotinylated compound leaching off the surface.  These findings are in concert with the 
previously discussed results of ELLA experiments where no interaction between SiaP 
and sialylated conjugates was observed.  
In the subsequently-tested formats for direct sialic acid detection, the SiaP protein was 
immobilised on the CM5 chip and used to capture the analyte. For the immobilisation of 
the SiaP protein on the CM5 chip three different approaches were utilized: 
immobilisation via Strep2-tag and Strep2-tag-specific neutravidin, immobilisation via 
Strep2-tag and Strep2-tag-specific antibodies and immobilisation via 6Lys-tag directly 
on the dextran surface of the CM5 chip. The immobilisation of ligands on the Biacore 
chip surfaces using streptavidin-biotin interaction as well as via monoclonal antibodies 
has been previously reported ( Kazemier et al., 1996; Jensen et al., 1997). This type of 
immobilisation offers milder conditions and reduce the probability of negative effects of 
the immobilisation process on the ligand (L\rofas S., et al., 1995). The immobilizations 
of the ligand via 6xHis or 10xHis tag and iminodiacetic acid or nitrilotriacetic acid were 
also reported; however, the moderate affinity of the chelate–Ni2+–histidine ternary 
interaction means that there is sometimes considerable decay in the level of 
immobilised ligand (Nieba et al., 1997; Cooper M., 2002). 
The immobilisation via neutravidin or antibodies was selected, as these would also offer 
the possibility of the regeneration of the detection device after the diagnostic test. In 
these formats the SiaP protein, degraded over time or irreversibly saturated, would be 
replaced with a fresh batch of the protein, hence regenerating the surface. Regeneration 
of the Strep2-tag specific StrepTactin, which as neutravidin, is a streptavidin derivative 
can be achieved by the cycle of desthiobiotin and sodium hydroxide washes which was 
reported previously (Schmidt et al., 2007). The immobilisation of SiaP protein via anti-
Strep2-tag antibodies (StrepMAB-Immo) is irreversible in physiological conditions. 
However, the regeneration of the surface may be achieved by utilization of primary 
goat/rabbit anti-mouse antibodies as a support for mouse StrepMAB-Immo. As the 
primary/secondary antibody binding is pH dependent it is possible to recharge the 
surface with StrepMAB-Immo antibodies and subsequently with SiaP. 
Initial tests with a neutravidin coated CM5 chip suggested the possibility of the Strep2-
tagged SiaP immobilisation. The C-terminal tag was used to promote the orientated 
immobilisation of the SiaP protein as the C-terminus of the protein is located directly 
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opposite the binding site of the globular protein. Such orientation would be preferred for 
further analyte capture on the surface of the chip. However, unstable baseline in the 
form of significant drift after the SiaP protein injection on the neutravidin coated surface 
was observed. This can be attributed to the insufficient affinity of neutravidin for the 
Step2-tag of the SiaP protein in the conditions applied and thus under the flow of the 
HBS buffer (10 µl/min) the captured SiaP protein was leaching off the surface of the 
chip. The subsequent injections of sialic acid at various concentrations did not render a 
stable increase in the signal which indicated that for further development of this type of 
assay an efficient immobilisation of SiaP protein is crucial. 
In order to increase the affinity of the CM5 biacore chip surface for the SiaP protein 
primary goat anti-mouse and secondary mouse anti-Strep2-tag antibodies were utilized. 
The initial immobilisation of Strep2-tagged SiaP protein on the StrepMAB-Immo coated 
surface resulted in an increase in the baseline. It was observed that the baseline was 
more stable than the previously tested neutravidin surface; however, a drift of the 
baseline was still observed. This indicates that the antibody surface has higher affinity 
for Strep2-tagged SiaP than neutravidin, which is in concert with previous reports 
(Schmidt et al., 2007), where it was found that monoclonal antidobies are a preferential 
surface for Biacore application when targeting Strep2-tagged proteins. Subsequently, 
injection of 5 mM sialic acid resulted in a stable increase in the signal which was the 
first indication that it is possible to detect sialic acid using this methodology. The 
possibility of chip regeneration was also tested by NaOH utilization which is commonly 
used for analyte removal (Biacore; Karlsson et al., 2004). The regeneration scouting 
process is commonly used in Biacore application in order to regenerate the active 
surface. The concentration of sodium hydroxide (or other chemicals) needs to be 
optimised. In this study the regeneration of the chip may be attributed to the removal of 
only sialic acid from the surface, as after the regeneration with NaOH the baseline 
returned to the level close to the one before sialic acid injection. This indicates that only 
sialic acid was removed and the SiaP protein stayed on the surface of the chip. The 
possibility of sialic acid removal by SiaP protein denaturation was previously discussed 
and is in concert with this result. The removal of sialic acid was facilitated by the flow 
of the NaOH containing HBS buffer that denatures/relaxes the SiaP protein. The 
subsequent repeated injection of an equal sample of sialic acid rendered a similar effect, 
which may indicate that the SiaP protein spontaneously refolds in HBS buffer and 
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regains its activity after sialic acid removal by NaOH. In order to test different 
concentrations of sialic acid a 1 mM sample was analysed; however, the result was 
negative as no stable increase in the baseline was observed. The subsequent tests were 
continued with 5 mM sialic acid to verify the reproducibility of the results. As the 
subsequent injection resulted in gradually decreasing values of RU it was concluded 
that, using this format, it would be difficult to obtain reproducible results. Furthermore, 
after a sequence of analyte and NaOH injection an overall drift of the baseline was 
observed.  This may be attributed to the surface degradation although it is not clear if 
the SiaP protein elution off the chip, the elution of one of the antibodies or maybe the 
elution of all of the protein off the chip was responsible for this effect. 
The utilization of indirect immobilisation of the SiaP protein on the CM5 biacore chip 
using neutravidin/antibodies would offer the potential for advantageous regeneration; 
however, this approach was found to be unsuccessful due to the problems with protein 
stability on the surface. In order to immobilise the SiaP protein on the CM5 biacore chip 
surface and maximise the stability of the binding, the SiaP protein was directly 
immobilised on the dextran surface. 6Lys-tag SiaP protein was covalently bound to the 
dextran layer of the chip by primary amine chemistry. The poly lysine tag was selected 
as the lysine residue contains a primary amine group in its side chain. Primary amine 
groups were utilized in the immobilisation chemistry (EDC/NHS coupling). Therefore, 
a string of six lysine residues at the C-terminus of the SiaP protein would increase the 
possibility of the desired, orientated immobilisation. Otherwise the protein would be 
immobilised using any of the available primary amines on the surface. The utilization of 
a poly-lysine tag was previously shown to be an effective method of orientated 
immobilisation in comparison to the untagged proteins. The studies with modified HIV 
proteins demonstrated that an increase of the charge and amine density in the tag 
enhances the coupling yield, the most efficient tag being a six lysine one (Allard et al., 
2001). Furthermore, it was found to be an effective method for increasing the protein 
concentration on the surface. It previous studies under modified HIV proteins 
(Ladaviere et al., 1998) it was found that the maximum loading capacity of the polymer, 
on which the protein was immobilized, depended on whether the protein bore the lysine 
tag or not. It was demonstrated that 6xLys tag increased the effectiveness of 
immobilisation, which would also be advantageous in this project. 
The EDC/NHS chemistry was selected as a method of choice as it is the most 
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widespread method of direct immobilisation on CM5 chips (Biacore); however, 
immobilisation using dimethyl pimelimidate dihydrochloride was found to be more 
efficient (Catimel B., et al, 1997). 
The application of this format generated the most stable baseline for sialic acid testing 
among all of the utilized formats. The activity of the SiaP protein was confirmed and the 
surface was tested with various concentrations of sialic acid. Injections of sialic acid in 
the range of concentrations from 1 mM to 8 mM generated an almost linear response. 
This proves that it may be possible to quantify free sialic acid using this method; 
however, the protocol has to be modified to optimise detection of possibly lower 
concentrations and also extend the operational range of the assay. The subsequent 
studies aimed at identification of the upper detection limit of the system generated 
unusual results for 10 mM sialic acid. The unexpectedly high signal generated by the 10 
mM sialic acid sample may indicate that at some concentration of the ligand the transfer 
of flowing molecules over the chip becomes easier and that the ligand becomes more 
accessible for the immobilised protein. The subsequent injections of higher 
concentrations of sialic acid resulted in lower than 10 mM signal. This can indicate the 
saturation of the surface or the gradual degradation of the SiaP protein. However, the 
ultimate injection of 8 mM sialic acid generated an identical result to the previous test 
with the same concentration, which indicates that the response of the surface did not 
change. 
The specificity of the method was tested with 10 mM galactose. It was found that the 10 
mM galactose injection generates a similar response to the HBS buffer, which is the first 
indication of the specificity of the used methodology. This result is in concert with 
previous reports (Severi et al., 2005; Muller et al., 2006), where the SiaP protein was 
found to be highly specific for Neu5Ac, with Kd value of 120 nM in comparison to 
Neu5Gc (Kd=280nM) and α(2→3)sialyl lactose (Kd=18µM). Unspecific interactions of 
other monosaccharides are highly improbable as no such findings have been previously 
reported. However, further, in-depth, investigation of this matter using various sugars as 
well as other substances is needed. 
The specificity of the SiaP protein and thus the potential specificity of the SiaP-based 
assay for sialic acid, in conjunction with the short analysis time, create the possibility 
for this method to outclass the existing methods (Warren, 1959; Svennerholm, 1956, 
1957; Sugahara, 1980; Teshima et al., 1988; Marzouk et al., 2007). The SiaP-based 
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assay, because of the intrinsic features of the SiaP protein, would be more specific for 
Neu5Ac than widely applied colorimetric methods for sialic acid quantification which 
suffer from interference from other members of the sialic acid family (Romero et al., 
1997). With regards to relatively expensive enzymatic methods (Sugahara, 1980; 
Teshima et al., 1988), the assay with immobilised SiaP protein which is capable of 
regeneration, and thus multiple use, would be competitive, especially where the cost is 
an issue, such as would be the case for multiple sample analysis in medical diagnostics. 
The clear advantage of the SiaP-based method over the HPLC method (Morimoto et al., 
2001) for sialic acid quantification is the time required. The SiaP based assay requires 
only five minutes and it may be possible to reduce this time.  
The lower detection limit of the sialic acid concentration (1 mM) of the SiaP protein 
using Biacore technology is unexpectedly high. As the affinity of the SiaP protein for 
Neu5Ac is high (Kd = 28 nM (Johnston et al., 2007)) the detection limit was expected to 
also be in the nano or micro molar range. The relatively high lower detection limit may 
be attributed to the SiaP protein behaviour being altered once immobilised in 
comparison to the molecule in the solution. This would be consistent with the literature 
reports of the altered activity and other features of proteins after immobilization. 
Metapyrocatechase was reported to be only 30% as active following immobilization as 
a free enzyme; however its stability was greatly improved (Iwaki et al., 1982). The 
altered activity following immobilization was reported for rabbit muscle pyruvate 
kinase, where the pH optimum for catalytic activity shifted into a more alkaline 
direction (Simon et al., 1985). Another explanation of the unexpected detection range 
may lie in the concentration of the SiaP protein on the surface of the chip. In the 
experiments with 6Lys-tagged SiaP immobilized directly on the CM5 chip it was found 
that for detection of sialic acid to occur a certain amount of SiaP protein is required on 
the chip (12336 RU was found to be sufficient). Insufficient amount of the protein 
results in no response for sialic acid. These findings suggest the need for investigation 
of the optimal concentration of the SiaP protein on the CM5 surface for precise and 
reliable sialic acid detection and quantification. 
The research presented in this thesis was aimed at development of a sialic acid detection 
and quantification method based on sialic acid-specific proteins. To an extent this was 
successful with the SiaP protein. The SiaP based method for free sialic acid analysis has 
the potential to significantly influence medical diagnostics where the free sialic acid 
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level in samples serves as an important indicator of physiological states and diseases 
(Salvolini et al., 1998; Diamantopoulou et al., 1999; Paszkowska et al., 2000; 
Wongkham et al., 2003; Marzouk et al., 2007). For the pharma industry the implications 
of the SiaP based method may be even greater as the rapid analysis may enable real time 
monitoring of production processes, which is of great importance for biopharmaceutical 
production in cell culture. As the sialylation of glycoproteins significantly improves 
their activity, immunogenetic characteristic and blood retention time, it is highly 
desirable that this process occurs during the cell culture based production process (Egrie 
and Browne, 2001; Fernandes and Gregoriadis, 2001). The decrease in free sialic acid 
level in the medium due to its incorporation in the glycan structures and the subsequent 
sialic acid level rise as a result of product degradation after reaching a certain stage of 
culturing are important indications of the point where harvesting should occur. For this 
the real time, specific and reliable analysis of the free sialic acid in the production 
medium is crucial. Additionally, as presented and discussed above, SiaP is a free sialic 
acid binder. For media monitoring this is a serious advantage, as no interference from 
sialylated structures is possible since the protein does not bind sialylated 
glycoconjugates. 
Furthermore, the SiaP protein application for sialic acid detection may be further 
extended for the purpose of sialylation analysis of various glycoconjugates such as EPO 
(Egrie and Browne, 2001) and asparaginase (Fernandes and Gregoriadis, 2001). The 
significance of sialic acid presence in glycans for human physiology and pathology, 
which were described above (see section 1.1.3), implies a requirement for its in-depth 
analysis. Paradoxically, the free sialic acid-specific SiaP protein has the potential to be 
applied for sialylated structure analyses by utilization of upstream processing of the 
analyte. The sialic acids may be liberated from the glycoprotein by neuraminidase 
treatment and the resulting free sialic acid subsequently captured by SiaP, enabling its 
detection and quantification (Figure 4.1 A).   
Here it is important to emphasise that the linkage between terminal sialic acid and the 
penultimate monosaccharide of human glycans predominantly occurs in two different 
conformations, namely α(2→3) and α(2→6) (Lehmann et al., 2006). The application of 
neuraminidases capable of specific cleavage of one of the linkages would liberate only 
one class of sialic acid (Figure 4.1 B and C). This would enable precise measurement of 
the sialic acid that is linked in a known conformation.  
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Both free sialic acid present in the medium and the liberated sialic acid from sialylated 
glycans would be subjected to analysis by the SiaP protein immobilised on biacore CM5 
chip. The possible methodology would involve sampling and filtering of the production 
culture in order to remove cells. The material could be then directly injected onto the 
SiaP covered chip in order to measure the free sialic acid content in the expression 
medium (Figure 4.1). In order to analyse the sialylation, the product would be purified 
from the medium, sialic acid liberated from the product by neuraminidase treatment and 
Figure 4.1. The schematic representation of the neuraminidase treatment of sialylated glycans. Unspecific 
neuraminidase treatment (A) liberates all terminal sialic acids from the glycans, treatment with α2-3 specific 
neuraminidase (B) liberates α2-3 linked sialic acids and treatment with α2-6 specific neuraminidase (C) 
liberates α2-6 linked sialic acids. The liberated sialic acid is subsequently captured by SiaP and measured. 
As the SiaP is specific for free sialic acid, there is no requirement for separation of the neuraminidase-treated 
products (glycans and sialic acid) as these glycans will not interact with SiaP. 
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Detection of sialic acid by signal 
increase in the sensogram 
the measurement of liberated sialic acid content would indicate the sialylation level of 
the product.  
 
 
The sialic acid concentration may be calculated by comparison of the signal generated 
by the sample on the CM5 chip (in RU) with the standard curve of chip response to 
various sialic acid levels. As presented above, it is possible to remove the sialic acid 
bound to the chip surface, and thus regenerate the surface. This suggests that the chip 
may be reusable, which is advantageous with regards to the cost efficiency of this 
method. 
Figure 4.2. Sample preparation and detection of free sialic acid using the SiaP protein immobilised on a 
biacore CM5 chip. Preparation of sample for measuring the free sialic acid in the medium and 
preparation of the sample for measurement of the glycoprotein sialylation is presented. Both samples can 
be subsequently analysed by injection onto the SiaP coated CM5 chip. The cycle of sialic acid capture by 
SiaP and removal of sialic acid from the surface is presented. 
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The interaction confirmed in this study, between sialic acid and SiaP, as well as 
development of the methodology for monitoring of this interaction, creates the 
possibility for implementation of SiaP based assays exploiting other analytical 
platforms. One of the envisaged applications of the SiaP protein may be a fluorimetric 
assay for sialic acid quantification. This assay could be based on the conformational 
change that SiaP undergoes after sialic acid accommodation. Such a conformational 
change influences the intrinsic fluorescence of the SiaP protein, namely the intensity of 
emission at 310 nm (Muller et al., 2006). The free sialic acid-containing sample would 
be applied on the well of a 96-well plate with pre-immobilised SiaP protein (Figure 4.3). 
The sialic acid would be captured by the protein and the sample subsequently removed. 
The increase of the emission at 310 nm in comparison to the blank sample would be 
used to quantify the sialic acid concentration in the sample. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another approach for sialic acid quantification using SiaP protein would be exploitation 
of the intrinsic features of the ligand. As the sialic acid is highly negatively charged, the 
accommodation of such a ligand changes the net charge of the capturing protein and the 
net charge of the surface covered with this protein. Accurate detection of such changes 
would enable precise quantification of the sialic acid captured by the protein. The 
immobilisation of the SiaP protein on monolithic columns and subsequent capture of 
charged sialic acid would change the electrical characteristics of the column. The 
Application of the free sialic 
acid containing sample on 
the well of 96 well plate with 
immobilised SiaP.
Capture of the free sialic acid 
by SiaP with concomitant 
conformational change of the 
protein.
Sample removal followed by 
fluorescence measurement
Figure 4.3. Fluorescence based quantification of sialic acid using SiaP. 
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increase of the charge of the column by bound sialic acid would positively impact the 
passage of electrons through the column from one electrode fixed on one side of the 
column to the second electrode fixed on the second side of the column. The ability of 
the monolithic column to conduct electrons can be measured using a method called 
capacitively coupled conductivity detection (C4D) (Connolly et al., 2007). The C4D is a 
particular type of conductivity-based detector where the electrodes are not in direct 
contact with the measured solution. Two tubular electrodes placed over the capillary. 
Each of the electrodes forms a capacitor with the buffer solution inside the capillary 
through which the signal can be coupled into and out of the capillary. 
 Thus the injection of a free sialic containing sample onto the monolithic column with 
immobilised SiaP protein would result in ligand capture, change of the column 
conductivity and a rise in the signal. Initial studies aimed at SiaP immobilisation on 
monolithic column have been successful and the signal changes after sialic acid 
application were also detected (O’Shea, Ph.D Thesis, DCU 2009). 
In conclusion, as the aim of this study was to develop a method for sialic acid detection 
and quantification based on sialic acid-specific proteins, the results of this study show 
the possibility for sialic acid detection and quantification based on the SiaP protein 
immobilised on a Biacore chip. The SiaP protein was successfully produced in a 
prokaryotic expression system and its purification was optimised. The secondary goal of 
Sia-free SiaP production was also achieved. The Sia-free SiaP protein was analysed 
using MS, ELLA and surface plasmon resonance. The SPR platform was selected for 
SiaP protein application for Sia detection and quantification. The methodology requires 
further optimisation with regards to specificity, detection range and protein 
concentration on the active surface. There also is a vast potential for application of the 
SiaP protein on other platforms and preliminary results are promising. The successful 
evolution of this assay may contribute to development of similar assays based on 
transport proteins for monosaccharides and other molecules, enabling their detection 
and quantification. 
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Sensogram representing the injection of 50 µl of HBS buffer (0 Sia) onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min.  
Sensogram representing the injection of 50 µl of 1 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
Sensogram representing the injection of 50 µl of 3 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
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Sensogram representing the injection of 50 µl of 5 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
Sensogram representing the injection of 50 µl of 7 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
Sensogram representing the injection of 50 µl of 8 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
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Sensogram representing the injection of 50 µl of 10 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
Sensogram representing the injection of 50 µl of 15 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
 
Sensogram representing the injection of 50 µl of 20 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
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Sensogram representing the injection of 50 µl of 8 mM sialic acid onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
 
Sensogram representing the injection of 50 µl of 10 mM galactose onto the active surface and NaOH [5 
µl of 5 mM] regeneration of the surface. The sample was passed over both the SiaP surface and the 
reference surface (blocked dextran) and the sensogram represents data after reference subtraction. The 
flowrate = 10  µl/min. 
 
